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7.0 Thesis Abstract:  
Introduction and Aims: The incidence of Oesophageal cancer (OC) has doubled in 
the last three decades and is increasing. Due to their poor outcome, strategies are 
being devised to prevent this disease and look into any association between pre-
existing risk factors and medications which may aggravate them. Non-steroidal anti-
inflammatory drugs (NSAIDs) may be protective by inhibiting Cycloxygenase-2 (COX-
2), an enzyme known to induce malignant transformation in cells. Bronchodilators 
and Calcium channel blockers (CCB's) that relax the Lower oesophageal sphincter 
(LOS) may increase Gastro-Oesophageal reflux (GORD) and the risk of Oesophageal 
adenocarcinoma (OAC). Hence I carried out a case control study looking into any 
association between ingestion of NSAIDs and drugs which may relax the lower 
oesophageal sphincter and oesophageal cancer.  
Case-control study: 
Methods: 411 patients in Norfolk, with a primary neoplasm of the oesophagus or 
cardia were matched with 1644 controls with non-melanotic skin lesions. Data on the 
use of NSAIDs, bronchodilators and CCB's was collected. 
Results: Compared to nonusers, individuals who used NSAIDs had a significantly 
reduced risk of oesophageal cancer. Use of NSAIDs was associated with 
approximately 60-70% reduction in OC. The odds ratios (OR) and 95% Confidence 
Intervals (CI) for different NSAIDs are as follows Aspirin: 0.38, (0.27-0.54); other 
NSAIDs: 0.29, (0.19-0.41) and COX-2 Blockers (Coxibs) 0.35, (0.16-0.78). LOS 
relaxing drugs were consumed more frequently in cases of OC as compared to the 
controls. Other NSAIDs include propionic acid, acetic acid, enolic acid and fenamic 
acid derivatives. The OR for LOS relaxing drugs are: Inhaled bronchodilators 3.2 
(95% CI 2.2 to 4.7), Theophylline 1.9 (95% CI 1.3 to 5.1) and Calcium channel 
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blockers 2.4 (95% CI 1.2 to 5.0). Data was adjusted for confounding factors like 
smoking and alcohol consumption. Unadjusted data showed lower negative 
association with  NSAIDs and positive association with drugs which relax the LOS. 
Conclusion: NSAIDs were protective against OC development while drugs that relax 
LOS were associated with increased risk in this case-control study. Furthermore, data 
unadjusted for smoking and alcohol show reduced effect implying smoking and 
alcohol consumption may be confounding factors. 
However, due to the undesirable side effects of synthetic COX-2 inhibitors, efforts are 
now directed towards finding natural compounds which have COX-2 inhibiting or 
antioxidant properties. Hence I conducted another study of validating a food 
frequency questionnaire with urinary excretion of quercetin, a naturally occurring Cox-
2 inhibitor and naringenin, an antioxidant. With this validation, it would be possible to 
measure the dietary intake of these compounds in an individual’s diet and 
recommend dietary changes by conducting further studies. 
Flavonoid study:  
Methods: A food frequency questionnaire (FFQ) was used to estimate daily intake of 
quercetin and naringenin in 49 healthy volunteers. They also provided five 24-hour 
urine samples over a 2 week period while completing the FFQ. Urinary excretion of 
quercetin and naringenin was determined by solid phase extraction and high-
pressure liquid chromatography.  
Results: The estimated mean intake of quercetin and naringenin was 29.4 mg (SD 
15.0) and 58.08 mg (SD 62.76) per day respectively. Mean urinary excretion of 
quercetin was 60.1 g (SD 33.1) and naringenin was 0.56 mg (SD 0.42) per 24hrs.  
The correlation between FFQ-estimated intake and levels excreted in the 24hr urines 
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for quercetin was r = 0.82 (p< 0.0001) and for naringenin was r = 0.251 (p=0.05) 
respectively. 
Conclusion: There was a statistically significant correlation between intake and 
excretion of quercetin and naringenin. Hence, a FFQ may be used as a tool in 
epidemiological studies requiring an estimate of naturally occurring COX-2 inhibitors 
or other chemicals following its validation.  
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8.0  Introduction: Oesophageal Cancer: 
 
8.1 Epidemiology: Worldwide, OC is a significant and increasing health problem. 
In 2005, there were 497,700 new cases, and the prevalence is expected to increase 
by approximately 140% by 20251. It has high mortality, with 416,500 people 
estimated to have died from oesophageal cancer in 2005. It has two major 
histological types, squamous cell (SCC) the most common worldwide, and 
adenocarcinoma. In the United States and many Western countries, OAC has 
surpassed SCC to become the most prevalent form of oesophageal cancer. 
Oesophageal adenocarcinoma rates have increased dramatically and has gone from 
a disease that was not thought to exist over the past few decades, to the fastest 
increasing cancer in America in the 2000’s2-4. There were increases in both prostate 
cancer and melanoma, but these pale in comparison to the six-fold increase in 
oesophageal adenocarcinoma incidence during that same period5. The latest 
Surveillance Epidemiology and End Results statistics indicate that this alarming 
increase is continuing in the United States (US), with a more than 460% increase in 
incidence in white males from 1975 to 20044. The increase has been noted in 
caucasian females also at a rate of 335% over the same period4. The rising incidence 
is occurring across all disease stages and all age groups, but the greatest increase (> 
600%) is in men over 65 years old. Most cases are diagnosed in white males, but 
Hispanic, Japanese, Chinese, and African-American people also develop 
oesophageal cancer1. In the US in 2008, it was projected that 16,470 new patients 
will be diagnosed with oesophageal cancer, and more than 50% of cases would be 
adenocarcinoma4. A similar trend has been reported in other Western countries 
including the Netherlands5. OC incidence worldwide was 462126 cases in the year 
2002; 315394 cases were diagnosed in males and 146723 cases in females. In 
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males, the incidence is approximately three times higher than in females. Figures 1 
and 2 show that the highest incidence is registered in Ethiopia, China, and Mongolia, 
where standardized incidence rates are as high as 28.1 per 100.000 in males, and 
19.6 per 100.000 in females in the year 2002. In Europe, the highest incidence rates 
in males are reported in France (11.0), Hungary (9.8), the United Kingdom (UK) (9.6), 
and Slovakia (9.3 per 100.000). In females, the highest numbers are reported in the 
United Kingdom (4.4), Netherlands (2.4), and Denmark (2.0 per 100.000). 
The incidence of adenocarcinoma of the gastro oesophageal junction (GEJ) is 
greatest in white males, as seen in oesophageal adenocarcinoma; but unlike 
oesophageal adenocarcinoma, the incidence does not differ significantly between 
white and African American females and is similar in African Americans and Asians. 
Further, the rate of adenocarcinoma of the GEJ is double that of oesophageal 
adenocarcinoma in these groups6,7. The overall incidence of adenocarcinoma of the 
GEJ (3.1 per 100,000) previously exceeded that of oesophageal adenocarcinoma in 
the US, but the most recent data indicate that oesophageal adenocarcinoma 
incidence has surpassed that of adenocarcinoma of the cardia8,9. It is the ninth most 
common carcinoma in adults in the United Kingdom  and is the fifth most common 
cause of death from cancer10. Within UK, around 5,000 new cases are diagnosed 
each year in men and around 2,800 women are diagnosed in women. The overall 
survival of patients is 5 % in the UK11. Only lung and pancreatic cancer have a worse 
prognosis. It has been estimated that the lifetime risk of developing oesophageal 
cancer is 1 in 64 for men and 1 in 116 for women in the UK calculated in February 
2009 using incidence and mortality data for 2001-2005 
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Figure 1: Standardised (world) incidence of oesophageal 
cancer in selected countries in males in the year 2002. 
(Courtesy Globocan 2002)  
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Figure 2: Standardised (world) incidence of oesophageal 
cancer in selected countries in females in the year 2002. 
(Courtesy Globocan 2002) 
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The United Kingdom has the highest incidence of oesophageal adenocarcinoma 
globally, at 7 cases per 100,000 population12,13. By comparison, the average 
incidence in the US is 2.5 per 100,000, although in some regions the incidence in 
white males is as high as 5.3 per 100,0007,9,12. The incidence of adenocarcinoma of 
the cardia or gastro-oesophageal junction  has also increased significantly since the 
mid 1970s14. However, the average rate stabilized in the US after the late 1980s and 
is beginning to decline slightly9.  
8.2. Worldwide mortality rates: 
Mortality rates represent roughly 90 % of the incidence rates of the disease. Figures 
3 and 4 show that the highest number of cases in males is reported in Ethiopia, 
Kenya, and China, with standardized mortality rates around 27 per 100.000 in the 
year 2002. In females, the highest numbers are observed in Mongolia, Iran, Kenya 
and China, where the standardised mortality rates are around 16 per 100.000. 
Among European countries, the highest mortality rates in males are in Hungary (9.1) 
and the United Kingdom (9.0 per 100.000). In females, the United Kingdom is in the 
top position with a standardized mortality rate of 4.1 per 100.000, as well as the 
Netherlands with the standardized mortality rate 2.2 per 100.000. 
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Figure 3: Standardised (world) mortality of oesophageal 
cancer in males in selected countries in the year 2002. 
(Courtesy Globocan 2002) 
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The changing incidence of AC within populations strongly suggests that although 
there are certain unchangeable risk factors, environmental factors linked to lifestyle 
changes are also of aetiological importance15,16.  
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Figure 4: Standardised (world) mortality of oesophageal 
cancer in females in selected countries in the year 2002. 
(Courtesy Globocan 2002) 
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8.3. Risk factors for OC:  
I. Non-modifiable risk factors: These include age, sex and hereditary factors.  
The risk of developing the disease increases with age with very few cases diagnosed 
in people aged under 40 years (Figure 5). Amongst hereditary factors, tylosis 
characterised by hyperkeratosis of the palms and soles, is a major risk factor and 
increases the risk of OC by about 70%17. Plummer – Vinson syndrome, characterized 
by sideropenic dysphagia, glossitis, and esophagitis is a risk factor for the 
development of oesophageal cancer18. In persons with a family history, the relative 
risk of developing OC is around 1.57-2.84 according to several prospective 
epidemiologic studies19-21. 
II. Modifiable risk factors:  
Environmental factors like consumption of alcohol and tobacco have long been 
recognised to be major risk factors for SCC but their role in OAC is less clear22,23. The 
increased incidence of obesity in Western countries may be an important factor.  For 
example, in both North American and European studies, patients in the highest Body 
Mass Index (BMI) quartile have a significantly higher risk of developing OAC24. The 
increasing incidence of obesity may therefore be important in explaining the rise in 
prevalence of OAC in the West, perhaps because obesity leads to increasing intra-
abdominal pressure, thereby promoting gastro-oesophageal reflux25. However 
metabolic factors such as a direct effect of insulin, insulin-like growth factors, and 
adipokines derived from adipose tissue, may also promote proliferation and suppress 
apoptosis of cells in the lower oesophagus26.  
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Figure 5: Numbers of new cases and age specific incidence 
rates, by sex,  oesophageal cancer, UK 2006 (Courtesy 
Cancer research UK) 
  
23 
8.4. Gastro-oesophageal reflux disease (GORD) 
 
 
 
 
 
 
 
GORD is defined as chronic symptoms or mucosal damage produced by the 
abnormal reflux in the oesophagus27.   
 
Whаt cаuѕеѕ thе lоwеr оеѕоphаgеаl ѕphinctеr tо bе fаulty? 
a. Raised intra-abdominal pressure, e.g. obesity, eating large meals, tight clothing, 
pregnancy 
b. Faulty oesophageal sphincter, e.g. pregnancy - due to hormonal smooth muscle 
relaxation, smoking, fatty meals, hiatus hernia, after surgery for achalasia 
c. Drugs, e.g. tricyclic depressants, anticholinergics which affect the function of the 
lower oesophageal sphincter 
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GORD is the strongest identified risk factor for OAC.  Recurrent reflux may lead to a 
marked (almost 8 fold) increase in the incidence of OAC28. Since this is a chronic 
condition, the procarcinogenic effects of exposure to refluxate are likely to act over a 
long period of time. It is probable, therefore, that ageing is an important factor in the 
pathogenesis of this disease. Exposure of cultured oesophageal cells to acidified 
culture media has been shown to stimulate the MAPK pathway, promoting cellular 
proliferation and inhibition of apoptosis29,30. There is also evidence that pulsed acid 
exposure, as occurs in vivo in GORD, leads to increased cell proliferation in Barrett’s 
metaplasia and over-expression of COX-2 enzyme31,32. A number of factors are  
responsible for GORD, including reduced LOS pressure, delayed gastric emptying, 
diet and obesity33-35.  Mechanisms that relax the LOS, may increase the incidence of 
reflux. Certain medications such as calcium channel blockers, which are widely used 
in treatment of hypertension, angina and stroke, or bronchodilators such as 
Salbutamol, Terbutaline, Ipratropium bromide and Theophylline, used in the 
treatment of asthma, also relax the smooth muscles of the LOS36-39. This effect may 
increase reflux, and contribute to an increased risk of OAC24. 
Potential chemopreventive drugs which block COX-2 enzyme includes Aspirin, Non 
Steroidal Anti Inflammatory drugs like Ibuprofen, ketoprofen, Indomethacin and 
specific Cox-2 inhibitors like Celecoxib, Rofecoxib and etoricoxib. Details of doses 
low and high doses which are clinically prescribed are given in Table 1. Naturally 
occurring COX-2 inhibitors include flavonoids like quercetin, catechin, 
epigallocatechin, Luteolin, hesperetin,  Isoflavonoids like genistein and daidzein, 
omega 3 fatty acids like eicosapentaenoic acid, docosahexaenoic acid and 
resveratrol a naturally occurring phytoalexin. Naturally occurring antioxidants include 
naringenin, Vitamins A, C, E, carotenoids etc.  
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ASPIRIN Low Dose High Dose 
 75mg 150mg + 
OTHER NSAIDS Low Dose High Dose 
Ibuprofen 200mg 1600mg 
Diclofenac 50mg 150mg 
Naproxen 500mg 1000mg 
Indomethacin 50mg 100mg 
Mefenamic acid 500mg 1500mg 
Piroxicam 10mg 20mg 
Ketoprofen 50mg 200mg 
COXIBS   
Celecoxib 100mg 400mg 
Rofecoxib 12.5mg 50mg 
Etoricoxib 30mg 120mg 
 
 
 
 
 
 
 
Table 1: Details of doses for different Cox-2 inhibitors by 
types 
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8.5. Impact of Coxibs on the risk of Oesophageal Cancer: 
I. Cоntributiоn оf CОX-2 tо Cаrcinоgеnеѕiѕ: 
Cycloxygenase (COX) iѕ thе rаtе-limiting еnzymе in thе cоnvеrѕiоn оf аrаchidоnic 
аcid tо prоѕtаglаndinѕ (Fig. 6). Thе firѕt ѕtеp in prоѕtаglаndin ѕynthеѕiѕ iѕ hydrоlyѕiѕ 
оf phоѕphоlipidѕ tо prоducе frее аrаchidоnаtе in а rеаctiоn cаtаlyѕеd by 
phоѕphоlipаѕе А2. Nеxt, COX cаtаlyѕеѕ а rеаctiоn in which mоlеculаr оxygеn iѕ 
inѕеrtеd intо аrаchidоnic аcid. Thiѕ rеаctiоn prоducеѕ аn unѕtаblе intеrmеdiаtе, 
prоѕtаglаndin (PG) G2. PGG2 iѕ cоnvеrtеd rаpidly tо PGH2 by thе pеrоxidаѕе аctivity 
оf COX. Ѕpеcific iѕоmеrѕ thеn cаtаlyѕе thе rеаctiоnѕ оf thе ѕpеcific cоmmоn 
prеcurѕоr PGH2 tо diffеrеnt prоѕtаglаndinѕ аnd thrоmbоxаnе, which аll hаvе thеir 
оwn rаngе оf biоlоgicаl аctivitiеѕ40. Rеcеntly, twо Cox iѕоfоrmѕ hаvе bееn clоnеd 
(COX-1 аnd COX-2) which ѕhаrе оvеr 60% idеntity аt аminо аcid  lеvеl аnd hаvе 
ѕimilаr еnzymаtic activitiеѕ. Thе mоѕt ѕtriking diffеrеncе bеtwееn thе COX еnzymеѕ 
iѕ in thе rеgulаtiоn оf еxprеѕѕiоn. COX-1 iѕ еxprеѕѕеd cоnѕtitutivеly in mоѕt tiѕѕuеѕ 
аnd ѕееmѕ tо mеdiаtе prоductiоn оf prоѕtаglаndinѕ thаt cоntrоl nоrmаl phyѕiоlоgicаl 
functiоnѕ, ѕuch аѕ prоtеctiоn оf thе ѕtоmаch, rеgulаtiоn оf rеnаl blооd flоw, аnd 
plаtеlеt аggrеgаtiоn. COX-2 оn thе оthеr hаnd, iѕ uѕuаlly nоt dеtеctаblе in nоrmаl 
tiѕѕuеѕ, but cаn bе rеаdily inducеd in rеѕpоnѕе tо cеll аctivаtiоn by hоrmоnеѕ, 
prоinflаmmаtоry cytоkinеѕ, grоwth fаctоrѕ аnd tumоur prоmоtеrѕ. In pаrt, thе 
inducibility оf CОX-2 iѕ еxplаinеd by thе prеѕеncе оf thе nuclеаr fаctоr rеѕpоnѕiblе 
fоr thе intеrlеukin-6 еxprеѕѕiоn аnd thе cyclic АMP rеѕpоnѕе еlеmеnt ѕitеѕ in thе 5-
flаnking prоmоtеr rеgiоn оf thе CОX-2 gеnе . Оn thе оthеr hаnd, еnhаncеd ѕtаbility 
оf CОX-2 mRNА mаy аlѕо cоntributе tо аn incrеаѕеd еxprеѕѕiоn оf CОX-2 . In thе 
lаtе 1970ѕ it wаѕ firѕt nоtеd thаt nеоplаѕtic lеѕiоnѕ hаd еlеvаtеd  
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cоncеntrаtiоnѕ оf prоѕtаglаndinѕ, аnd incrеаѕеd еxprеѕѕiоn оf CОX-2 wаѕ fоund in 
mаny prеmаlignаnt tiѕѕuеѕ аnd mаlignаnt tumоurѕ (е.g. cоlоrеctаl, gаѕtric, 
оеѕоphаgеаl, pаncrеаtic, lung, brеаѕt, blаddеr, cеrvicаl аnd оvаriаn cаncеr). Vаriоuѕ 
оncоgеnеѕ, grоwth fаctоrѕ аnd tumоur prоmоtеrѕ wеrе ѕhоwn cаpаblе оf inducing 
CОX-2 еxprеѕѕiоn in mаlignаnt cеllѕ. Mоrеоvеr, wild-typе but nоt mutаnt p53 gene 
ѕupprеѕѕеѕ CОX-2 trаnѕcriptiоn, rаiѕing thе pоѕѕibility thаt p53 iѕ аlѕо а dеtеrminаnt 
оf CОX-2 еxprеѕѕiоn . Thеrе аrе аlѕо dаtа thаt dеmоnѕtrаtе а dirеct rеlаtiоn bеtwееn 
inductiоn оf CОX-2 еxprеѕѕiоn аnd cаrcinоgеnеѕiѕ. Knоcking оut thе CОX-2 gеnе in 
thе АPC 716 mоuѕе cаuѕеd а ѕignificаnt rеductiоn in bоth thе numbеr аnd ѕizе оf 
intеѕtinаl pоlyp, whеrеаѕ оvеrеxprеѕѕiоn оf CОX-2 wаѕ ѕufficiеnt tо inducе 
tumоrigеnеѕiѕ in thе mаmmаry glаnd in trаnѕgеnic micе41 . Finаlly, phаrmаcоlоgicаl 
еvidеncе аlѕо impliеѕ а rоlе fоr CОX-2 in cаrcinоgеnеѕiѕ. Ѕеlеctivе CОX-2 inhibitоrѕ 
ѕuch аѕ cеlеcоxib аnd rоfеcоxib rеducеd thе fоrmаtiоn оf intеѕtinаl, brеаѕt, ѕkin, lung 
аnd blаddеr tumоurѕ in аnimаlѕ, аnd thе nоn-ѕеlеctivе CОX inhibitоr ѕulindаc cаuѕеѕ 
thе rеductiоn оf аdеnоmаѕ in fаmiliаl аdеnоmаtоuѕ pоlypоѕiѕ pаtiеntѕ. Thеѕе dаtа 
ѕuggеѕt thаt CОX-2 rеprеѕеntѕ а pоtеntiаl mоlеculаr tаrgеt fоr prеvеnting аnd 
trеаting cаncеr40. 
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II. Mеchаniѕmѕ by Which CОX-2 Cоntributеѕ tо Cаncеr Dеvеlоpmеnt:  
CОX-2 аffеctѕ mаny prоcеѕѕеѕ thаt аrе impоrtаnt in cаrcinоgеnеѕiѕ аnd iѕ thеrеfоrе 
аn аttrаctivе thеrаpеutic tаrgеt. Thеѕе prоcеѕѕеѕ includе аpоptоѕiѕ, prоlifеrаtiоn, 
аngiоgеnеѕiѕ, invаѕivеnеѕѕ, immunоѕupprеѕѕiоn аnd inflаmmаtiоn32. Inhibitiоn оf 
thеѕе CОX-2 prоcеѕѕеѕ by NЅАIDѕ аnd ѕеlеctivе CОX-2 inhibitоrѕ mаy bе thе 
primаry mеchаniѕmѕ оf thеir аntinеоplаѕtic аctiоn dеѕcribеd in vаriоuѕ ѕtudiеѕ42-45    
(Table 2).  
Apoptosis: Thе ѕizе оf а cеll pоpulаtiоn dеpеndѕ оn thе bаlаncе bеtwееn cеll 
prоlifеrаtiоn аnd prоgrаmmеd cеll dеаth (аpоptоѕiѕ). Dеcrеаѕеd аpоptоѕiѕ mаy lеаd 
tо а prоlоngеd ѕurvivаl оf аbnоrmаl cеllѕ, which fаvоurѕ thе аccumulаtiоn оf 
ѕеquеntiаl gеnеtic chаngеѕ thаt incrеаѕе thе riѕk оf tumоrigеnеѕiѕ, аnd inhibitiоn оf 
аpоptоѕiѕ will lеаd tо clоnаl еxpаnѕiоn. In vitrо ѕtudiеѕ ѕuggеѕt thаt cаrcinоmа cеllѕ 
еxprеѕѕing CОX-2 hаvе thе potential tо bеcоmе rеѕiѕtаnt tо аpоptоѕiѕ. Еpithеliаl 
cеllѕ оvеrеxprеѕѕing CОX-2 hаvе incrеаѕеd аmоuntѕ оf thе аnti-аpоptоtic prоtеin 
Blc-2 аnd аrе rеѕiѕtаnt tо butyrаtе-ѕtimulаtеd аpоptоѕiѕ46. 
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 Normal 
Epithelium 
Metaplasia Low-grade 
dysplasia 
High-grade 
dysplasia 
Adeno-
carcinoma 
Wilson et al. 
199842 
0 % 81 % nd nd 100 % 
Zimmerman et 
al. 199943 
0 % 0 % nd nd 78 % 
Shirvani et al. 
200032 
Significant increase in expression of COX-2 (P<0.05) 
Morris et al. 
200144 
0 % 75 % 83 % 100 % 100 % 
Buskens et al. 
200245 
0 % 50 % nd nd 99 % 
 
nd= not determined 
COX-2 exprression in normal squamous epithelium of the oesophagus and the metaplasia-dysplasia-
adenocarcinoma sequence  during malignant degeneration 
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Trеаtmеnt with NЅАIDѕ rеvеrѕеd thiѕ rеѕiѕtаncе tо аpоptоѕiѕ. Rеcеnt ѕtudiеѕ аlѕо 
indicаtе thаt bоth ѕеlеctivе аnd nоnѕеlеctivе cyclооxygеnаѕе inhibitоrѕ inducе thе 
еxprеѕѕiоn оf thе prо-аpоptоtic gеnе, prоѕtаtе аpоptоѕiѕ rеѕpоnѕе, аnd thаt 
аccumulаtiоn оf аrаchidоnic аcid cаuѕеd by thе inhibitiоn оf cyclооxygеnаѕе 
еnzymеѕ аctivаtеѕ thе prоductiоn оf cеrаmidе, а ѕtrоng аpоptоѕiѕ inducеr. Finаlly,  
NЅАIDѕ hаvе bееn ѕhоwn tо dеcrеаѕе thе еxprеѕѕiоn оf nuclеаr fаctоr B (NF-B), а 
trаnѕcriptiоnаl fаctоr thаt prеvеntѕ аpоptоѕiѕ.  
Prоlifеrаtiоn: CОX-2 iѕ inducеd by аctivаtiоn оf thе Rаѕ/Rаf/mitоgеn аctivаtеd prоtеin 
kinаѕе (MАPK) pаthwаy, which iѕ оnе оf thе kеy grоwth-ѕtimulаting cаѕcаdеѕ thаt 
cаuѕеѕ cеllulаr prоlifеrаtiоn аnd NЅАIDѕ cаn inhibit thiѕ prоcеѕѕ. It hаѕ bееn 
dеmоnѕtrаtеd thаt ѕеlеctivе CОX-2 inhibitоrѕ hаvе аn аnti-prоlifеrаtivе еffеct by 
prеvеnting еpithеliаl cеllѕ frоm prоgrеѕѕing frоm thе quiеѕcеnt ѕtаtе (G0/G1) intо thе 
phаѕе оf DNА rеplicаtiоn (Ѕ-phаѕе). Ѕulindаc dеcrеаѕеѕ thе lеvеlѕ оf mitоtic cyclinѕ, 
thеrеby rеducing thе phоѕphоrylаtiоn оf thе rеtinоblаѕtоmа prоtеin; thiѕ prоcеѕѕ 
nоrmаlly аllоwѕ thе cеll tо еntеr thе Ѕ-phаѕе. Thе dеcrеаѕе in prоlifеrаtiоn аctivity by 
NЅАIDѕ wаѕ аlѕо dеmоnѕtrаtеd оn cоlоn cаrcinоmа cеllѕ by а ѕignificаnt dеcrеаѕе in 
thе Ki67 аntigеn, which iѕ а prоlifеrаtiоn mаrkеr, аftеr trеаtmеnt with ѕulindаc.  
Аngiоgеnеѕiѕ: Thе grоwth оf а tumоur pаrtly dеpеndѕ оn аn incrеаѕе in blооd ѕupply. 
Tumоur cеllѕ еnѕurе thеir оwn grоwth by ѕеcrеting grоwth fаctоrѕ, еѕpеciаlly vаѕculаr  
grоwth fаctоr (VGF), thаt ѕtimulаtе аngiоgеnеѕiѕ47. CОX-2 hаѕ bееn implicаtеd in thiѕ 
аѕpеct оf cаrcinоgеnеѕiѕ аѕ wеll. Оvеrеxprеѕѕiоn оf CОX-2 in cаncеr cеllѕ incrеаѕеѕ 
thе prоductiоn оf vаѕculаr grоwth fаctоrѕ, аnd thе fоrmаtiоn оf cаpillаry-likе nеtwоrkѕ 
in vitrо. Thеѕе еffеctѕ cаn bе blоckеd by ѕеlеctivе CОX-2 inhibitоrѕ. It hаѕ bееn 
dеmоnѕtrаtеd thаt ѕеlеctivе CОX-2 inhibitоrѕ аlѕо diminiѕh аngiоgеnеѕiѕ thrоugh 
inhibitiоn оf thе MАPK pаthwаy in еndоthеliаl cеllѕ .  
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Invаѕivеnеѕѕ: CОX-2 iѕ impоrtаnt in mоdulаting thе invаѕivе prоpеrtiеѕ оf humаn 
cаncеr cеllѕ. Whеn CОX-2 iѕ оvеrеxprеѕѕеd in cаncеr cеll linеѕ, thе prоductiоn оf 
prоѕtаglаndinѕ incrеаѕеѕ, аnd thе cеllѕ bеcоmе mоrе invаѕivе. Thiѕ incrеаѕеd 
invаѕivеnеѕѕ hаѕ bееn аѕѕоciаtеd with аctivаtiоn оf thе mаtrix mеtаllоprоtеinаѕеѕ 
(MMPѕ) 1 аnd 2. Thеѕе еnzymеѕ digеѕt thе cоllаgеn mаtrix оf thе bаѕеmеnt 
mеmbrаnе, thuѕ ѕtimulаting thе invаѕivе аnd mоtilе phеnоtypе оf tumоur cеllѕ. 
Аdditiоnаlly, оvеrеxprеѕѕiоn оf CОX-2 wаѕ аѕѕоciаtеd with incrеаѕеd аmоuntѕ оf 
CD44, thе cеll ѕurfаcе rеcеptоr fоr hyаlurоnаtе, аnd ѕpеcific blоckаdе оf CD44 
ѕignificаntly dеcrеаѕеd tumоur cеll invаѕiоn. Cоnѕiѕtеnt with thеѕе in vitrо findingѕ, 
ѕеlеctivе CОX-2 inhibitоrѕ hаvе bееn оbѕеrvеd tо inhibit diѕѕеminаtiоn in 
oesophageal adenocarcinoma 33 cells (OE33)48,49. 
Immunоѕupprеѕѕiоn: Thе grоwth оf tumоurѕ iѕ аѕѕоciаtеd with ѕupprеѕѕiоn оf thе 
immunе ѕyѕtеm. Cоlоny-ѕtimulаting fаctоrѕ rеlеаѕеd by tumоur cеllѕ аctivаtе 
mоnоcytеѕ аnd mаcrоphаgеѕ tо ѕynthеizе PGЕ2, which ѕupprеѕѕеѕ T-cеll аnd B-cеll 
prоlifеrаtiоn, lymphоkinе prоductiоn, mаcrоphаgе аctivаtiоn аnd thе cytоtоxic аctivity 
оf nаturаl killеr cеllѕ. PGЕ2 аlѕо inhibitѕ thе prоductiоn оf tumоur nеcrоѕiѕ fаctоr 
whilе inducing thе prоductiоn оf intеrlеukin (IL) 10 , which hаѕ immunоѕupprеѕѕivе 
еffеctѕ50. Thеѕе аctiоnѕ mаy аllоw thе tumоur tо еѕcаpе nоrmаl immunе ѕurvеillаncе. 
By inhibiting prоѕtаglаndin ѕynthеѕiѕ, NЅАIDѕ cаn indirеctly еnhаncе immunе 
rеѕpоnѕеѕ51,52. Аdditiоnаlly, thеy might uprеgulаtе еxprеѕѕiоn оf mаjоr 
hiѕtоcоmpаtibility cоmplеx аntigеnѕ, аѕ hаѕ bееn dеmоnѕtrаtеd in аzоxymеthаnе-
inducеd cоlоnic tumоurѕ in thе rаt. Mеchаniѕticаlly, thiѕ cаn dеpеnd оn cytоkinе 
micrоеnvirоnmеnt, ѕincе CОX-2 dеpеndеnt ѕynthеѕiѕ оf prоѕtаnоidѕ by lung cаncеr 
cеllѕ аltеrеd rеlеаѕе оf IL-10 аnd IL-12 frоm lymphоcytеѕ аnd mаcrоphаgеѕ rеѕulting 
in rеprеѕѕiоn оf hоѕt immunity.  
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Inflаmmаtiоn: Chrоnic inflаmmаtiоn, which iѕ pаrticulаrly аѕѕоciаtеd with thе 
dеvеlоpmеnt оf а Bаrrеtt’ѕ оеѕоphаguѕ, iѕ а rеcоgnizеd riѕk fаctоr fоr 
cаrcinоgеnеѕiѕ. Inflаmmаtiоn inducеѕ thе ѕynthеѕiѕ оf prоѕtаglаndinѕ viа а cytоkinе 
mеdiаtеd inductiоn оf CОX-2. With thе dаtа rеviеwеd аbоvе, а mеchаniѕm cаn bе 
ѕuggеѕtеd in which chrоnic inflаmmаtiоn аnd аn incrеаѕеd еxprеѕѕiоn оf CОX-2 
cоntributе tо thе mаlignаnt dеgеnеrаtiоn оf а Bаrrеtt’ѕ оеѕоphаguѕ53. 
NЅАID’ѕ tаrgеt thе CОX еnzymеѕ, which cоnvеrt аrаchidоnic аcid (АА) tо 
prоѕtаglаndinѕ (PG) аnd оthеr еicоѕаnоidѕ. CОX-2, thе induciblе iѕоfоrm, iѕ 
undеtеctаblе in mоѕt nоrmаl tiѕѕuеѕ but iѕ аctivаtеd in rеѕpоnѕе tо prо-inflаmmаtоry 
cytоkinеѕ аnd grоwth fаctоrѕ. Mаny ѕtudiеѕ hаvе nоw rеpоrtеd CОX-2 
оvеrеxprеѕѕiоn in tumоurѕ аnd itѕ аѕѕоciаtiоn with incrеаѕеd cеll prоlifеrаtiоn, 
mеtаѕtаѕiѕ аnd dеcrеаѕеd аpоptоѕiѕ. Prоѕtаglаndinѕ аrе bеliеvеd tо plаy а mаjоr 
rоlе in thеѕе prоcеѕѕеѕ bеcаuѕе оf thеir еffеctѕ оn cеll prоlifеrаtiоn, аpоptоѕiѕ, 
аngiоgеnеѕiѕ аnd immunе ѕurvеillаncе54. CОX-2 uprеgulаtiоn hаѕ bееn rеpоrtеd in 
оеѕоphаgеаl ЅCC аnd АC. PGѕ hаvе аlѕо bееn fоund tо bе оvеrеxprеѕѕеd in 
оеѕоphаgеаl tumоurѕ аѕ а cоnѕеquеncе оf еnhаncеd CОX-2 еxprеѕѕiоn  аnd. Mоrе-
оvеr, CОX-2 еxprеѕѕiоn lеvеlѕ hаvе bееn fоund tо bе еlеvаtеd in Bаrrеtt’ѕ 
оеѕоphаguѕ  аnd hаvе bееn rеpоrtеd tо incrеаѕе with thе prоgrеѕѕiоn frоm 
mеtаplаѕiа tо dyѕplаѕiа tо аdеnоcаrcinоmа. А rеcеnt rеpоrt hаѕ аlѕо indicаtеd thаt а 
ѕinglе nuclеоtidе pоlymоrphiѕm in thе CОX-2 prоmоtеr cаn еlеvаtе CОX-2 
еxprеѕѕiоn аnd iѕ аѕѕоciаtеd with а grеаtеr riѕk оf dеvеlоping оеѕоphаgеаl cаncеr55. 
Thus blocking the PG synthesis by NSAID’s or COX-2 inhibitors may also play an 
important part in reducing the inflammatory process, thus preventing malignant 
change. 
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8.6 Impact of Flavonoids on Cancer: 
Flavonoids, previously known as “Vitamin P” are water-soluble polyphenolic 
compounds found in abundance in the human diet.  Many flavonoids possess 
antioxidant, antiplatelet, anti-inflammatory, anti-atherogenic, immunomodulatory and 
anti-carcinogenic activities in vitro56-62. Flаvоnоidѕ аrе а lаrgе grоup оf plаnt’ѕ 
prоductѕ thаt hаvе а cоmmоn C6-C3-C6 ѕtructurе cоnѕiѕting оf twо аrоmаtic ringѕ 
linkеd thrоugh аn оxygеnаtеd hеtеrоcyclе (which iѕ fuѕеd tо оnе оf thеѕе аrоmаtic 
ringѕ). Аpprоximаtеly, 8000 flаvоnоidѕ hаvе bееn chаrаctеrizеd. Flavonoids 
containing a hydroxyl group in position C-3 of the C ring are classified as 3-
hydroxyflavonoids (flavonols, anthocyanidins, leucoanthocyanidins, and catechins), 
and those lacking it as 3-desoxyflavonoids (flavanones and flavones). Classification 
within the 2 families is based on whether and 34how additional hydroxyl or methyl 
groups have been introduced to the different positions of the molecule. Isoflavonoids 
differ from the other groups; the B ring is bound to C-3 of ring C instead of C-2. Thе 
mаjоr clаѕѕеѕ  аrе flаvоnеѕ (e.g аpigеnin, lutеоlin), flаvоnоlѕ (e.g quеrcеtin, 
kаеmpfеrоl), flаvаnоnеѕ (e.g hеѕpеrеtin, nаringеnin), flаvаnоlѕ (e.g еpigаllоcаtеchin, 
ЕGCG), аnthоcyаninѕ (e.g cyаnidnin, dеlphinidin) аnd iѕоflаvоnеѕ (e.g gеniѕtеin, 
dаidzеin). They are present mainly in fruits, vegetables, grains, bark, roots, stems, 
flowers tea, and wine63. Some of the common sources of flavoinoids are depicted in 
Table 3. Flаvоnоidѕ pоѕѕеѕѕ frее rаdicаl ѕcаvеnging prоpеrtiеѕ аnd hаvе bееn 
rеpоrtеd tо mоdulаtе CОX-2 trаnѕcriptiоn in а numbеr оf diffеrеnt cеll mоdеlѕ. Liаng 
еt аl. оbѕеrvеd thаt аpigеnin wаѕ thе mоѕt pоtеnt inhibitоr оf CОX-2, induciblе nitric 
оxidе ѕynthаѕе (iNОЅ), аnd nuclеаr fаctоr-κB (NF-κB)64. Оn thе оthеr hаnd, Ѕingh 
аnd Аgаrwаl nоticеd thаt ѕilibinin, а flаvоnоid iѕоlаtеd frоm milk thiѕtlе, inhibitеd 
mitоgеnic аnd cеll ѕurvivаl ѕignаling ѕuch аѕ еpidеrmаl grоwth fаctоr rеcеptоr 
  
35 
(ЕGFR), inѕulin-likе grоwth fаctоr rеcеptоr typе I (IGFRI) аnd NF-κB ѕignаling62. The 
presence of flavonoids in plants depends on several factors including the degree of 
ripeness, variety, processing and storage.  Of the Flavonoids, quercetin, catechin, 
epigallocatechin, luteolin, hesperetin and hesperidin possess Cox-2 inhibitory 
properties59,67-68. Flavonoids also have antioxidant properties, including preventing 
the degradation of Vitamin E, scavenging reactive nitrogen species and ROS, 
chelating metallic ions like Fe3+,Cu2+ involved in free radical production69,70. These 
properties reduce oxidative stress and a number of other of biological functions which 
may protect against cancer and other diseases. 
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Flavonoids Major food Sources 
Apigenin (Flavonone) Celery, parsley, thyme, sweet red pepper 
Quercetin, kaempferol, myricetin 
(Flavonol) 
Onions, broccoli, tomatoes, kale, berries, 
apples, grapes, tea 
Hesperetin, Naringenin (Flavanone) Oranges, lemons, prunes 
ECGC (Flavanol or catechin) Apples, plums, green tea 
Cyanidnin (Anthocyanin) Cherries, black grapes 
Genistein, diadzein (isoflavone) Soya beans, chick peas, legumes, rye 
 
 
Tаblе 3: Ѕоmе cоmmоn ѕоurcеѕ оf flаvоnоidѕ 
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А numbеr оf flаvоnоidѕ аrе CОX- 2 inhibitоrѕ (е.g. аpigеnin, chryѕin, аnd kаеmpfеrоl) 
аnd ѕоmе cаn ѕupprеѕѕ CОX-2 trаnѕcriptiоn by mеchаniѕmѕ thаt  includе аctivаtiоn 
оf thе pеrоxiѕоmе prоlifеrаtоr-аctivаtеd  rеcеptоr (PPАR) gаmmа trаnѕcriptiоn fаctоr, 
аnd inhibitiоn  оf NF-kB еxprеѕѕiоn. CОX-2 trаnѕcriptiоn iѕ inhibitеd  in vitrо nоt juѕt 
by quеrcеtin аglycоnе, but аlѕо by thе  mеtаbоlitеѕ quеrcеtin 3-glucurоnidе, quеrcеtin 
30-ѕulphаtе,  аnd 30-mеthylquеrcеtin 3-glucurоnidе. Thеѕе cоmpоundѕ аrе  fоund in 
humаn plаѕmа, аnd bоth quеrcеtin аnd quеrcеtin  30-ѕulphаtе аlѕо inhibit CОX-2 
еnzymе аctivity. Quеrcеtin  аglycоnе inhibitѕ CОX-2 еxprеѕѕiоn аnd inducеѕ 
аpоptоѕiѕ  in thе оеѕоphаgеаl аdеnоcаrcinоmа cеll linе ОЕ33 and squamous cell line 
in vitrо53. A study by Tanigawa et. al found that quercetin inhibited the proliferation of 
HepG2 cells through the induction of cell cycle arrest and apoptosis71.  Also in 
another study, quercetin suppressed the formation of early preneoplastic lesions in 
colon carcinogenesis, which occurred in concert with reductions in proliferation and 
increases in apoptosis72. 
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I. Quercetin (2-(3,4-dihydroxyphenyl)- 3,5,7-trihydroxy-4H-chromen-
4-one): Quercetin is a bioflavonoid which is claimed to strengthen capillaries and 
regulate permeability. Frequently quercetin occurs as glycosides (sugar derivatives); 
e.g., rutin. Quercetin is termed the aglycone, or sugarless form of rutin. Quercetin is 
the major bioflavonoid in the human diet. The estimated average daily dietary intake 
of quercetin by an individual in the United States is 25 mg. 
Structure of Quercetin: Courtesy Wikipedia.org 
 
Sources: Foods rich in quercetin include capers (1800 mg/kg), lovage (1700 mg/kg), 
apples (440 mg/kg), tea (Camellia sinensis 2000-2500mg/kg), onion, especially red 
onion 320mg/kg (higher concentrations of quercetin occur in the outermost rings),  
broccoli (30mg/kg),  bog whortleberry (158 mg/kg, fresh weight), lingonberr1 
(cultivated 74 mg/kg, wild 146 mg/kg), cranberry (cultivated 83 mg/kg, wild 
121 mg/kg), chokeberry (89 mg/kg), sweet rowan (85 mg/kg), rowanberry (63 mg/kg), 
sea buckthorn berry (62 mg/kg), crowberry (cultivated 53 mg/kg, wild 56 mg/kg), and 
the fruit of the prickly pear cactus (50mg/kg). A recent study found that organically 
grown tomatoes had 79% more quercetin than conventionally grown73. 
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II. Naringenin: 5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one: 
Naringenin is an flavonone that is considered to have a bioactive effect on human 
health as antioxidant, free radical scavenger, anti-inflammatory, carbohydrate 
metabolism promoter, and immune system modulator. It is the predominant flavanone 
in grapefruit. 
Structure of Naringenin: Courtesy supplementscience.org 
 
 
Sources: Grapefruit, Oranges, and Tomato (skin). 
This bioflavonoid is difficult to absorb following oral ingestion74. Based on available 
data, only 15% of ingested naringenin will get absorbed in the human gastrointestinal 
tract. Ingestion of 8ml/kg of orange juice will supply about enough naringenin to 
achieve a concentration of about 0.29 mg in urine in 24 hrs75. The naringenin-7-
glucoside form may be less bioavailable than the aglycol form76. Grapefruit juice can 
provide higher plasma concentrations of naringenin than orange juice75. Naringenin 
can be absorbed from cooked tomato paste77. 
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III. Bioavailability of Quercetin and Naringenin: 
The bioavailability and metabolism of flavonoids, especially quercetin and (+)-
catechin, were investigated by several groups in the 1960s and 1970s78,79. In most of 
these studies, rather high doses of flavonoids were given to laboratory animals and 
the main focus was on the bioavailability of flavonoid degradation products produced 
by the gastrointestinal microflora. Today, sensitive methods allowing serum and urine 
analyses are available for many flavonoids. These methods allow estimations of 
flavonoid bioavailability in human beings at appropriate dietary intake levels. 
It is evident that the bioavailability of flavonoids varies greatly between different 
subgroups and compounds. This is hardly surprising, considering the differences in 
their chemical properties (eg, polarity). 
Quercetin: 
Gugler et al80 failed to detect quercetin in plasma and urine of subjects receiving 4 g 
of quercetin aglycone orally, which indicated that quercetin is not absorbed in human 
beings. Hollman et al81-84 and de Vries et al85, however, showed that the compound is 
bioavailable from onions, tea, apples, red wine, and supplements containing 
quercetin glycosides. In their studies, bioavailability was examined after ingestion of 
relatively high amounts of pure compounds or food containing them. Ingestion was 
either once or over a few days. Relatively few studies have measured plasma 
quercetin levels after ingestion of quercetin in amounts comparable with those 
attainable from a normal diet. Recently, 3 studies have been published in regards to 
this. In these studies, the mean plasma values ranged between 15 and 24 mg/L (50-
80 nmol/L) in subjects consuming their habitual diets86-88 and was 42 mg/L (140 
nmol/L) after a diet containing 815 g/d of vegetables, fruits, and berries88. 
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Consumption of 100 g/d of berries (lingonberries, bilberries, and black currants) in 
addition to a normal diet resulted in a mean plasma level of 21 mg/L (70 nmol/L)87.  
Studies with pure compounds have given more precise information about the 
absorption and kinetics of quercetin. These studies indicate that quercetin aglycone 
and quercetin glucosides are absorbed from the upper parts of the gastrointestinal 
tract, probably the duodenum, while quercetin-3-rutinoside is absorbed from the distal 
parts, probably the colon89,90. In one study89, low doses of quercetin aglycone and 
quercetin- 3-rutinoside were given to healthy volunteers in a crossover setting. Mean 
bioavailability of quercetin was similar from the 2 sources, but there was marked 
interindividual variation in bioavailability from quercetin-3-rutinoside, in particular. A 
rather interesting finding was that quercetin from quercetin-3-rutinoside was more 
bioavailable in women compared with men, and plasma levels were highest in 
women using oral contraceptives. These results suggest interindividual variation, 
possibly gender specific, in gastrointestinal microflora, or absorption or 
biotransformation mechanisms91. Furthermore, this study also showed that despite 
previous speculations, quercetin is bioavailable when given as aglycone. This finding 
was confirmed by Walle et al92 in a study in which radiolabeled quercetin aglycone 
was used. The results indicated absolute bioavailability of 36% to 53% for quercetin 
aglycone and that a substantial portion of quercetin is excreted by the lungs as CO2. 
It should be kept in mind that the results are based on recovery of radioactivity, and 
therefore, the findings may reflect bioavailability of degradation products, which could 
have been formed, at least partly, before absorption.  
The urinary excretion of quercetin has been investigated in several studies reported 
in a review by Manach and Williamson93 (Table 4). In these studies, urinary recovery, 
as a percentage of the ingested dose, ranged between 0.07% and 3%.  
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Source 
Number of 
Subjects 
Dose Tmax Plasma Plasma concentration AUC 
Urinary 
Excretion 
Elimination           
half-life 
   
h μmol/L μmol/L - h/L % of intake h 
Pure quercetin 6 4g 
 
<0.33 
 
<1 
 
Onions 9 Ileostomizes 89 mg quercetin eq 
   
0.31/13h 
 
Pure quercetin 10 Ileostomizes 100 mg quercetin eq 
   
0.12/13h 
 
Fried onions 2 64 mg quercetin eq 2.9 0.65 
  
16.8 
Onions 9 68 mg quercetin eq 0.7 0.74 7.7 
 
28 
Apples 9 107 mg quercetin eq 2.5 0.3 3.5 
  
Complete meal 10 87 mg quercetin eq 
 
0.37 at 3h 
   
Onions 5 186 mg quercetin eq 1.3-1.9 2.18 
 
1.11 
 
Onions 5 50 mg quercetin eq 2 0.83 
   
Quercetin 4`-glucoside 9 150 mg <0.5 3.5 18.8 
 
21.6 
Quercetin 3`-glucoside 9 156 mg 0.6 4 19.1 3.6 18.5 
Quercetin 4`-glucoside 9 160 mg 0.45 4.5 17.5 3.1 17.7 
Pure quercetin 16 8, 20, 50 mg 2, 2.7, 4.9 0.14, 0.22, 0.29 1.74, 2.92, 3.77 
 
17, 17.7, 15 
Onions 12 100 mg quercetin eq 0.68 7.6 32.1 6.4 10.9 
Tmax time to Cmax, AUC: area under the curve. Eq: equivalents 
 
Tаblе 4: Bioavalibility studies with quercetin. (Adapted with permission Manach et al. 
2005) 
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Furthermore, it was lower after ingestion of quercetin-3-rutinoside than after ingestion 
of onion. Biliary excretion cannot be ruled out and has been shown to be a major 
route of quercetin elimination in rats94,95. In rats fed a diet containing 0.25% quercetin, 
the concentrations of quercetin and methylated metabolites were approximately 3-
fold in bile compared with urine. The high molecular weight of quercetin lucuronides 
and sulfates and their extensive binding to protein96-98 could favor their biliary 
excretion99. 
Naringenin:  
Analytical methods allowing the analysis of flavanones in plasma only became 
available recently75. Until then, knowledge about their bioavailability relied on animal 
studies and human urinary excretion data. The results concerning urinary excretion 
have varied in different studies (Table 5)93. For naringenin, individual urinary 
recoveries of 5% to 59% (6 subjects)100, 5% (1 subject)101, 14% to 15% (2 
subjects)102, and 1% to 6% (6 subjects)103 are reported after single ingestion of 214 to 
700 mg of naringenin as a supplement or in juice. The half-life for naringenin 
conjugates in urine was estimated as 2.6h100. Erlund et al75 studied the bioavailability 
and pharmacokinetics of flavanones after single ingestion of 400 to 760 mL of orange 
juice or grapefruit juice. The resulting plasma concentrations were comparatively high 
(up to 4 mg/L or 15 nmol/L), which is not surprising, considering that citrus fruits and 
juices contain quite high concentrations of the compounds (several hundred 
milligrams per liter). The plasma half-lives of flavanones are relatively short (1-2 h). 
Furthermore, renal clearance of naringenin appeared to be dependent on dose. 
Similar plasma levels were reported after consumption of 0.5 or 1 L of orange 
juice104. Bugianesi et al 105 recently made the interesting finding that naringenin is 
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bioavailable from tomato paste, which is a notable source because of its widespread 
use, despite its low naringenin content. 
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Tmax time to Cmax, AUC: area under the curve. Eq: equivalents 
 
 
Tаblе 5: Bioavalibility studies with naringenin. (Adapted with permission 
Manach et al. 2005) 
 
 
Source 
Number 
of 
Subjects 
Dose 
Tmax 
Plasma 
Plasma concentration AUC 
Urinary 
Excretion 
Elimination           
half-life 
   
h μmol/L μmol/L - h/L % of intake h 
Orange Juice 5 
22.6 or 45mg naringenin 
eq 
4.6-5 0.06-0.2 0.43-1.29 7.1-7.8 
 
Orange jiuce 8 23 mg naringenin eq 5.5 0.64 2.6 1.1 1.3 
Grapefruit juice 5 199 mg naringenin eq 4.8 5.99 27.7 30.2 2.2 
Tomato paste 5 3.8 mg naringenin eq 2 0.12 
   
Pure compound 6 500 mg naringenin eq 
   
4 
 
Grapefruit juice 6 7.2mg naringenin eq 
   
8.9 2.6-2.9 
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IV. Inhibitiоn оf cаncеr prоmоtiоn by flavonoids: 
Multiple mechanisms appear to be involved in the inhibition of carcinogenesis by 
dietary polyphenols (Figure 7).  Cеntrаl tо prоtеctivе еffеctѕ by diеtаry flаvоnоidѕ аnd 
оthеr pоlyphеnоlѕ аt thе prоmоtiоn ѕtаgе оf chеmicаlly inducеd cаrcinоgеnеѕiѕ iѕ thе 
аbility tо inhibit cеll prоlifеrаtiоn. Thе dаmаgе thаt thе cаrcinоgеnѕ hаvе inflictеd оn 
cеllulаr DNА during thе initiаtiоn ѕtаgе iѕ bеing prоpаgаtеd intо а nеw cеll pоpulаtiоn. 
Thiѕ mаchinеry, i.е. clоnаl еxpаnѕiоn, iѕ highly cоmplеx, gеаrеd tоwаrdѕ giving thе 
cеllѕ immоrtаlity by ѕtimulаting mitоgеnеѕiѕ аnd/оr dеcrеаѕing cеll dеаth by inhibiting 
аpоptоѕiѕ. Prоtеctivе еffеctѕ аt thiѕ ѕtаgе аrе criticаlly impоrtаnt. Thiѕ hаѕ bееn 
dеmоnѕtrаtеd in cеll culturе with unmеthylаtеd flаvоnоidѕ аnd оthеr pоlyphеnоlѕ, аѕ 
diѕcuѕѕеd briеfly in Ѕеctiоn 1.5 (II), аffеcting numеrоuѕ ѕignаl trаnѕductiоn pаthwаyѕ. 
Ѕоmе оf thе pоlymеthоxylаtеd flаvоnоidѕ hаvе аlѕо in prеliminаry ѕtudiеѕ 
dеmоnѕtrаtеd аntiprоlifеrаtivе prоpеrtiеѕ106,107. 
Activation of circulating monocytes by hyperglycemia plays a role in inflammatory 
process. A study by Wu and collegues, examined whether flavonoids (catechin, 
EGCG, luteolin, quercetin, rutin) - phytochemicals that may possible belong to a new 
class of advanced glycation end products (AGEs) inhibitors - can attenuate high 
glucose (15 mmol/L, HG)-induced inflammation in human monocytes108. Their results 
show that all flavonoids significantly inhibited HG-induced expression of 
proinflammatory genes and proteins, including TNF- , interleukin-1  (IL-1 ), and 
COX-2, at a concentration of 20 M. Flavonoids also prevented oxidative stress in 
activated monocytes, as demonstrated by their inhibitory effects on intracellular 
reactive oxygen species (ROS) and N -(carboxymethyl)lysine formation caused by 
HG. These inhibitory effects may involve inhibition of nuclear factor- B activation and 
may be supported by downregulation of the following: i) PKC-dependent NADPH 
oxidase pathway; ii) phosphorylation of p38 mitogen-activated protein kinase and 
extracellular signal-regulated protein kinase, and iii) mRNA expression of receptor of 
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AGEs. In addition, they found for the first time that lower levels of Bcl-2 protein under 
HG conditions could be countered by the action of flavonoids. Their data suggest that, 
along with their antioxidant activities, flavonoids possess anti-inflammatory properties 
as well. 
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Figure 7: Proposed mechanistic scheme for the 
prevention of cancer by dietary polyphenols. 
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The effect of the flavonoid quercetin was investigated on colorectal cancer cells by 
Dihal and collegues109. Male F344 rats (n = 42/group) were fed 0, 0.1, 1, or 10 g 
quercetin/kg diet. Two week after initial administration of experimental diets, rats were 
given 2 weekly subcutaneous injections with 15 mg/kg body wt azoxymethane (AOM). 
At wk 38 post-AOM, quercetin dose dependently (P < 0.05) decreased the tumor 
incidence, multiplicity, and size (Table 6). The number of aberrant crypt foci (ACF) in 
unsectioned colons at wk 8 did not correlate with the tumor incidence at wk 38. 
Moreover, at wk 8 post-AOM, the number and multiplicity of ACF with or without 
accumulation of ß-catenin were not affected by the 10 g quercetin/kg diet. In contrast, 
another class of CRC-biomarkers, ß-catenin accumulated crypts, contained less ß-
catenin than in controls (P < 0.05). After enzymatic deconjugation, the plasma 
concentration of 3'-O-methyl-quercetin and quercetin at wk 8 was inversely correlated 
with the tumor incidence at wk 38 (r = –0.95, P 0.05).  Thus quercetin, at a high dose 
reduced colorectal carcinogenesis in AOM-treated rats, which was not reflected by 
changes in ACF-parameters.  
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 Quercetin, g/kg diet 
 0 0.1 1 10 
Rats, n 22 22 22 20 
Tumor bearing rats, n 11 9 8 4 
Tumor incidence, 1,2 % 50 41 36 20+ 
Tumors, n 17 13 11 4 
Tumor multiplicity, 3 n 1.55 ± 0.93 1.44 ± 1.01 1.38 ± 0.74 1.00 ± 0.0 
Tumor size overall, 3 mm 5.94 ± 3.83 5.85 ± 4.22 5.64 ± 3.98 5.00 ± 1.83 
Small (<5mm) tumors, % of total 47 46 45 50 
Small (≥5mm) tumors, % of total 53 54 55 50 
Adenoma, 5 of large tumors 11 -- 50 -- 
Carcinoma, % of large tumors 89 86 33 100 
1 Values are means ± SD or percent. * Different from control, P < 0.05. 
2 Quercetin mediated a dose dependent decrease in tumor incidence, P < 0.05. 
3 Tumor multiplicity and size were inversely associated with increasing dietary quercetin, both,          r 
= -0.98, P < 0.05 
 
 
 
 
 
 
Table 6: Tumor characteristics in AOM-treated rats fed 
control, quercetin diet at wk 38 post-AOM administration. 
(Adapted with permiss50ion Dihal et al. 2006)  
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Naringenin, one of the most abundant flavonoids in citrus fruits, has been reported to 
suppress cytotoxicity and apoptosis in mouse leukemia P388 cells exposed to a 
typical pro-oxidant, H2O2, or an anticancer drug, cytosine arabinoside (1-b -D-
arabinofuranosylcytosine; Ara-C) due to its antioxidative properties110,111. In order to 
demonstrate if naringenin has the ability to inhibit tumor growth in vivo, a study using 
ddY mice given a subcutaneous injection of sarcoma S-180 was performed112. 
Naringenin dose-dependently inhibited the growth of sarcoma S-180 when 
administered at 30, 100 or 300 mg/kg once a day for 5 d, with 99.7%, 72.2% or 57.0% 
suppression compared with the control (control tumor weight 100%) following 
intraperitoneal injection, respectively (Fig. 8). 
 
 
Figure 8: Inhibitory effects of naringenin on the growth of 
murine S-180 tumor implanted in ddY mice. (Adapted with 
permission Kano et al. 2005) 
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V. Evidence of Flavonoids in chemoprevention:  
Association between intake of flavonoids and the incidences of a variety of cancers 
have been studied in a number of studies. However, significant associations were 
observed only for lung cancer and colorectal cancer. Two Finnish cohort studies with 
relatively low intakes of flavonoids(3-4mg/day), found inverse associations with lung 
cancer risk (RR: 0.53; 95% CI: 0.29, 0.97; and RR: 0.56; 95% CI: 0.45, 0.69)113,114. 
For catechins, an inverse association was observed for rectal cancer (RR: 0.55; 95% 
CI: 0.32, 0.9), but not for colon cancer (RR: 0.1; 95% CI: 0.85, 1.44) in 
postmenopausal women in America115. Currently, there is no evidence of an effect of 
flavonoid intake on the incidence of epithelial cancers such as stomach, urinary tract, 
prostate or breast116-119.  
Zhang and collegues found that flavones and flavonols exert cytotoxic effects on a 
human oesophageal adenocarcinoma and squamous cell line by inducing 
apoptosis120,121. Stoner and collegues, evaluated the ability of lyophilized (freeze-
dried) black raspberries (Rubus occidentalis), blackberries (Rubus fructicosus), and 
strawberries (Fragaria ananasia), sources of quercetin to inhibit carcinogen-induced 
cancer in the rodent esophagus122. At 25 wk of the bioassay, all three berry types 
were found to inhibit the number of oesophageal tumors (papillomas) in NMBA-
treated animals by 24-56% relative to NMBA controls. This inhibition correlated with 
reductions in the formation of the NMBA-induced O6-methylguanine adduct in 
oesophageal DNA, suggesting that the berries influenced the metabolism of NMBA 
leading to reduced DNA damage. Furthermore, Naringenin, has anti-estrogen 
properties and may be responsible for the decreased incidence of breast cancer in 
woman consuming a large amount of these fruits123. In a study from Hawai, where 
there is a high intake of apples, onions and white grapefruit, rich sources of flavonoids 
there was a 40-50% reduction in the incidence of lung cancer124. Epidemiological 
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studies suggest ingestion of green tea, a rich source of quercetin, may reduced the 
risk of oesophageal cancer125,126.  
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9.0  Aims of conducting the studies:  
It is clear that incidence rates of oesophageal cancer have increased in the UK , and 
prognosis is poor with only 5 % patient’s surviving in the long term. Prevention of 
oesophageal cancer should be based on early detection and surveillance of 
precancerous lesions, especially of Barrett’s oesophagus, and attention should also 
focus on chemoprevention, including finding artificial and natural chemical agents 
which may help reduce its incidence. Carefully designed epidemiological studies, both 
descriptive and analytical, are required to increase our understanding of the 
complexity of chemoprevention in oesophageal cancer. Identification of risk factors 
will allow preventive measures to be developed to reverse the trend of the disease 
and to decrease its incidence and mortality.  
Of the different types of epidemiological studies, a case-control study was  conducted 
by me in Norfolk, United Kingdom, to examine potential associations between 
exposure to NSAIDs, LOS relaxing drugs and OC. This study method was selected as 
it was cost effective, quick and easy to conduct. The identification of controls, a major 
challenge was overcome by selecting patients with non-melanotic skin cancers, as 
their exposure to NSAIDs would be similar to the general population. Also the results 
were adjusted for confounding factors like smoking and alcohol consumption. 
Epithelial carcinogenesis is a multistep process in which an accumulation of genetic 
events within a single cell line leads to a progressively dysplastic cellular appearance, 
deregulated cell growth, and finally carcinoma. Cancer chemoprevention, as first 
defined by Sporn in 1976, uses natural, synthetic, or biologic chemical agents to 
reverse, suppress, or prevent carcinogenic progression127. It is based on the concepts 
of multifocal field carcinogenesis and multistep carcinogenesis. In field 
carcinogenesis, diffuse epithelial injury in tissues, such as the aerodigestive tract, 
results from generalized carcinogen exposure throughout the field and clonal 
proliferation of mutated cells. Genetic changes exist throughout the field and increase 
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the likelihood that one or more premalignant and malignant lesions may develop 
within that field. Multistep carcinogenesis describes a stepwise accumulation of 
alterations, both genotypic and phenotypic. Arresting one or several of the steps may 
impede or delay the development of cancer. An example of this is prevention of 
progression from Barrets oesophagus to OC. Barrets oesophagus is the end result of 
GORD. Chemoprevention trials are based on the hypothesis that interruption of the 
biological processes involved in carcinogenesis will inhibit this process and, in turn, 
reduce cancer incidence128. This hypothesis provides a framework for the design and 
evaluation of chemoprevention trials, including the rationale for the selection of agents 
that is likely to inhibit biological processes and the development of intermediate 
markers associated with carcinogenesis. 
Cancer chemoprevention may also be achieved by the use of natural, synthetic, or 
biologic compounds to reverse, suppress, or prevent the development of diseases. 
Chemoprevention is a potential anti-cancer approach, which has reduced secondary 
effects in comparison to classical prophylaxis. Natural compounds such as flavonoids 
reduce oxidative stress, which is the most likely mechanism in the protective effects of 
these compounds. Even though their exact mechanisms of action are not well 
understood another  mechanism of polyphenolic flavonoids relates to induction of 
apoptosis129. Moreover, flavonoids may modulate protein and lipid kinase signaling 
pathways. Hence a FFQ was validated by me against the 24hr urinary excretion of 
quercetin and naringenin, with the aim of potentially using this FFQ to assess the 
intake of naturally occurring coxibs and in future intervention studies. 
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To summarise the main aims of conducting the studies were: 
 To conduct a case-control study to examine potential associations between 
exposure to NSAIDs, LOS relaxing drugs and OC 
 Validate a FFQ against the 24hr urinary excretion of quercetin and naringenin 
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10.0 Non-steroidal anti-inflammatory drugs, lower 
oesophageal sphincter-relaxing drugs and oesophageal 
cancer: A case-control study. 
10.1: Introduction: Thе еvidеncе fоr uѕing NЅАIDѕ аѕ а chеmоprеvеntivе аgеnt 
in cаrcinоgеnеѕiѕ firѕt cаmе frоm еpidеmiоlоgicаl ѕtudiеѕ. Оf thе publiѕhеd 
retrospective оbѕеrvаtiоnаl ѕtudiеѕ оn оеѕоphаgеаl cаncеr, Thun еt аl. fоund thаt 
ѕubjеctѕ whо uѕеd аѕpirin 16 timеѕ pеr mоnth оr mоrе оftеn fоr аt lеаѕt оnе yеаr 
hаvе аn аpprоximаtеly 40% lоwеr riѕk оf оеѕоphаgеаl cаncеr (P = 0.054)130. Dаtа 
frоm thе Nаtiоnаl Hеаlth аnd Nutritiоn Еxаminаtiоn Ѕurvеy аnd thе Nаtiоnаl 
Еpidеmiоlоgicаl Fоllоw-up Ѕtudiеѕ ѕhоw а 90% (95% CI = 0.01–0.76) dеcrеаѕеd riѕk 
оf dеvеlоping оеѕоphаgеаl cаncеr in ѕubjеctѕ whо rеpоrt оccаѕiоnаl аѕpirin uѕе. Dаtа 
frоm аn australian  ѕtudy ѕhоw а rеducеd riѕk оf AC (OR, 0.48; 95% CI, 0.32-0.72), 
аnd ѕquаmоuѕ cеll cаrcinоmа (OR, 0.63; 95% CI, 0.40-0.98) in pаtiеntѕ with аѕpirin 
uѕе rеlаtivе tо nоnuѕеrѕ131. Risk reductions for AC among users of aspirin and 
NSAIDs were greater among those who experienced at least weekly symptoms of 
reflux (OR, 0.26; 95% CI, 0.12-0.55 and OR, 0.41; 95% CI, 0.21-0.77, respectively) 
than those who did not experience reflux (OR, 0.96; 95% CI, 0.46-2.00 and OR, 0.78; 
95% CI, 0.35-1.72, respectively) . Recently Duan et. al. found regular use of aspirin 
and non-aspirin NSAIDs was associated with reduced relative risk of AC (OR, 0.60; 
95% confidence interval, 0.38-0.95; P(trend) = 0.04)132. In аdditiоn, in vitrо ѕtudiеѕ 
аnd аnimаl ѕtudiеѕ hаvе bееn publiѕhеd which ѕuppоrt thе pоѕѕiblе chеmоprеvеntivе 
еffеct оf ѕеlеctivе CОX-2 inhibitоrѕ in Bаrrеtt’ѕ еpithеlium. Buttаr еt аl. dеmоnѕtrаtеd 
in primаry culturеd еndоѕcоpic biоpѕy ѕpеcimеnѕ frоm pаtiеntѕ with Bаrrеtt’ѕ 
оеѕоphаguѕ thаt ѕеlеctivе CОX-2 inhibitоrѕ ѕignificаntly dеcrеаѕеd CОX-2 аctivity 
аnd dеcrеаѕеd prоlifеrаtiоn оf еpithеliаl cеllѕ by 55% (95% CI 47.1–63.8)133. Thе 
ѕаmе invеѕtigаtоrѕ аlѕо fоund in а rаt mоdеl thаt twо diffеrеnt ѕеlеctivе CОX-2 
inhibitоrѕ rеducеd thе rеlаtivе riѕk оf dеvеlоping оеѕоphаgеаl cаncеr by 55% (95% CI 
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43–66, P = 0.008) аnd by 79% (95% CI 68–87, P = 0.001) аftеr 
оеѕоphаgоjеjunоѕtоmy, whеn cоmpаrеd with cоntrоlѕ. Hоwеvеr, thе prеvаlеncе оf а 
Bаrrеtt’ѕ оеѕоphаguѕ wаѕ nоt ѕignificаntly diffеrеnt bеtwееn thе grоupѕ (P = 0.98). 
Kаur еt аl. indirеctly dеmоnѕtrаtеd thе pоѕѕiblе chеmоprеvеntivе еffеct оf ѕеlеctivе 
CОX-2 inhibitоrѕ in vivо as well134. In this study, biоpѕy ѕpеcimеnѕ оf humаn Bаrrеtt’ѕ 
еpithеlium wеrе cоmpаrеd with biоpѕy ѕpеcimеnѕ оbtаinеd аftеr 10 dаyѕ оf thеrаpy 
with rоfеcоxib 25 mg оrаlly dаily. Аftеr rоfеcоxib thеrаpy, thе CОX-2 еxprеѕѕiоn 
dеcrеаѕеd by 77% (P =0.005), thе PGЕ2 cоntеnt dеcrеаѕеd by 59% (P =0.005), аnd 
thе prоlifеrаting cеll nuclеаr аntigеn (PCNА) еxprеѕѕiоn dеcrеаѕеd by 62.5% (P 
=0.005). Further evideice of COX-2 inhibitors chemopreventive properties is 
presented in the following chapter. 
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10.2. Evidence against chemoprevention:  
Еvidеncе dеmоnѕtrаting thе оvеrеxprеѕѕiоn оf CОX-2 аnd PG, highlightеd thе 
pоtеntiаl оf NЅАIDѕ аѕ chеmоprеvеntаtivе аgеntѕ, аnd may have lеd tо thе 
dеvеlоpmеnt оf mоrе ѕеlеctivе CОX-2 inhibitоrѕ. Hоwеvеr, thе mеchаniѕmѕ by which 
thеѕе CОX-2 inhibitоrѕ еxеrt thеir аntinеоplаѕtic еffеctѕ rеmаin cоntrоvеrѕiаl. 
Аpоptоtic аnd/оr аnti-prоlifеrаtivе еffеctѕ hаvе bееn rеpоrtеd in ѕеvеrаl cеll linеѕ 
including lung , prоѕtаtе  аnd cоlоn . In оеѕоphаgеаl cаncеr cеllѕ, bоth grоwth аrrеѕt 
аnd аpоptоѕiѕ hаvе bееn rеpоrtеd tо bе inducеd by CОX-2 inhibitоrѕ. A study by 
Bardou et al failed to demonstrate a lasting effect of chronic ingestion of NSAIDs and 
cyclooxygenase-2 inhibitors on OC135. Thе CОX-2 dеpеndеnt аnd indеpеndеnt 
mеchаniѕmѕ оf thеѕе inhibitоrѕ nееd tо bе еѕtаbliѕhеd in оrdеr tо аchiеvе ѕаfе аnd 
еffеctivе dеѕign оf chеmо-thеrаpеutic аnd chеmо-prеvеntаtivе prоtоcоlѕ. However 
this case-control study did not differenciate between the histological types of OC. 
They also could not account for over the counter medication use i.e Aspirin, and 
NSAIDs. Rеcеnt review hаvе аѕѕеѕѕеd thе ѕаfеty оf ѕеlеctivе CОX-2 inhibitоrѕ аnd 
whilе gаѕtric tоxicity iѕ rеducеd, ѕоmе аgеntѕ hаvе аn incrеаѕеd riѕk оf 
cаrdiоvаѕculаr cоmplicаtiоnѕ136. A recent retrospective analysis of the large UK 
National Barrett's Oesophagus Registry database concluded no difference in risk of 
development of dysplasia or adenocarcinoma was observed between patients taking 
aspirin and those not taking aspirin (hazard ratio 1.092, 95% confidence interval 
0.358-3.335, P = 0.877)137. This study did not examine any relation between NSAIDs 
use and risk of OC.   
Furthermore, a randomized controlled trial by Heath et. al. found administration of 200 
mg of celecoxib twice daily for 48 weeks of treatment does not appear to prevent 
progression of  Barrett's dysplasia to cancer138.  However in this study, few patients 
were not assigned randomly. They also found treatment with celecoxib for 24 weeks 
compared with placebo did not change the levels of COX-2 mRNA, regardless of 
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grade. This could be due to the fact they used only one dose of Celecoxib i.e: 200mg. 
Increasing dose to 300mg or 400mg amy have given more information. 
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10.3. Evidence of  association of LOS relaxation with OC: 
The association of chronic reflux with the development of oesophageal AC suggests 
that drugs known to decrease the pressure of the lower oesophageal sphincter (and 
hence predispose to reflux) may be a risk factor for Barrett's esophagus and possibly 
AC. However, the strength of this association remains uncertain. In a case control 
study involving 189 patients with newly diagnosed oesophageal carcinoma were 
compared to 262 patients with adenocarcinoma of the gastric cardia, 167 patients 
with oesophageal squamous cell carcinoma, and 820 population-based controls139. In 
this study, past use of drugs known to relax the LOS (such as nitroglycerin, 
anticholinergics, beta adrenergic agonists, aminophylline, and benzodiazepines) was 
positively associated with the risk of oesophageal adenocarcinoma (Odds ratio 3.8 
(95 percent CI, 2.2 to 6.4) for use >five years). Assuming a causal relationship, it was 
estimated that approximately 10 percent of oesophageal adenocarcinomas occurring 
in men older than age 60 may be attributable to intake of these drugs. By contrast, in 
another case control study, an association was detected only between asthma 
medications (xanthines and beta agonists and not nitrates, calcium channel blockers 
or benzodiazepines) and Barrett's esophagus among persons younger than age 70140. 
Lui and collegues studied the role of beta-adrenergic signaling in the regulation of 
growth of an oesophageal squamous-cell carcinoma cell line HKESC-1141. They 
concluded that epinephrine stimulates oesophageal squamous-cell carcinoma cell 
proliferation via beta-adrenoceptor-dependent transactivation of ERK/COX-2 
pathway.  
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62, 63,10.4. Materials and Methods: Case-Contorl Study 
I. Case Identification  
The study population lived in Norfolk and presented to one of the three hospitals in 
the region: The Norfolk and Norwich University Hospital NHS Trust; Norwich, The 
Queen Elizabeth II Hospital; King’s Lynn and the James Paget Hospital; Great 
Yarmouth which cover the county. The population of Norfolk was approximately 
824,200 in mid-2005. Permission was sought from clinicians in each hospital to 
review patient notes. The International Code of Diseases (ICD), version 10, was used 
to identify case notes of 411 primary malignant neoplasms of the oesophagus or 
cardia diagnosed between 1999 and 2004. These codes were: C15.0-C15.5 for 
cervical oesophagus, thoracic oesophagus, abdominal oesophagus, upper, middle 
and lower part of oesophagus, C15.8 for overlapping lesions of the oesophagus and 
C16.0 for lesions of the cardia. These neoplasms were divided into squamous and 
adenocarcinoma. The study included patients who had been exposed to NSAIDs and 
LOS relaxing drugs for a minimum period of 4 weeks in the last 10 years. Exposure 
of these patients to NSAIDs was for analgesia, arthritis, anti-platelet action, and LOS 
relaxing drugs for asthma, chronic obstructive airway disease, hypertension, 
ischemic heart disease and cerebro-vascular disease. The case notes were reviewed 
to confirm the diagnosis.   
The study was approved by the Norfolk Research Ethics Committee in June 2004. 
Protocol of case control study attached as Appendix 1.  
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II. Control Identification 
Patients who had undergone a minor day case procedure for non-melanotic skin 
tumours, and were under the care of dermatologists and plastic surgeons, formed the 
control group. They were identified as per the ICD 10 criteria using the code C44. 
This group of patients was selected because their use of NSAIDs was similar to that 
in the general population. Any potential control with a past history of oesophageal 
cancer was excluded. Data were collected on all drugs with respect to their type, 
dosage and frequency of use. Data on potential confounding factors such as 
smoking and alcohol consumption were also collected. 
 
III. Data Collection and analysis  
Data was collected over a period of 2 years during the period from July 2004 to June 
2006. Data was collected by the principal investigator and checked by the Clinical 
and Non-clinical Supervisors 
Demographic and clinical data on drugs, illnesses and surgical management for each 
proven case were collected on a standard data collection sheet (Appendix 2) and 
anonymised. The data on drug type, frequency of administration, dosage and any 
associated illnesses were ascertained from the general practitioner referral letter, 
medical admission notes and nursing records. Data for controls were obtained from 
the general practitioner’s referral letters and hospital medical and nursing records. 
Each case was matched for exact age, sex and year of hospital admission with four 
controls. A total of 411 cases were matched with 1644 controls. The Odds ratios were 
calculated using conditional logistic regression with 95% confidence interval. NSAIDs 
use was divided into the following categories: Aspirin, other NSAIDs and specific 
Coxibs, LOS relaxing drugs were divided into calcium channel blockers, 
bronchodilators and Theophylline. The data were adjusted for the confounding effects 
of smoking and alcohol. STATA SE 8.3 software was used to perform the analysis. 
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10.5.Results:  
Demographic details of cases, control, case tumour characteristics are presented in 
Tables 7 and 8. Males dominated the study with the gender ratio being 3.2:1 (M:F). 
The mean age of cases was 71 years and controls 70 years. The most common site 
of the tumour was the lower third of the oesophagus. 
I. Smoking, alcohol consumption and OC 
A history of tobacco smoking (past or present) was found in 79% of cases as 
compared to 28% controls.  Seventy one percent of controls never smoked. Data on 
tobacco smoking was unavailable in 2% of the cases and 1% of the controls. 
Smoking was 3 times more common in cases with oesophageal cancer as compared 
to the controls. Alcohol consumption was virtually identical in both the groups (Table 
9).  
II. NSAIDs and OC   
Following adjustment of smoking and alcohol consumption, intake of NSAIDs was 
lower in cases of OC as compared to the controls, and exposure to any dose of 
NSAIDs was associated with a signicicant reduction in risk of OC by 60-70%. 
Amongst the medications, consumption of low dose aspirin (75mg) and other 
NSAIDs predominated in both cases and controls. The data were therefore sub- 
divided into low-dose and high-dose NSAIDs, using the minimum daily dose and 
frequency of consumption of NSAIDs while performing the analysis. Low-dose aspirin 
appeared to be as effective as high-dose (OR 0.33, CI: 0.23-0.47). There was 
insufficient data regarding exposure to low-dose Coxibs (n=10), for us to estimate the 
risk. 
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III. NSAIDs and  OAC 
Aspirin and other NSAIDs were more protective than specific Coxibs. As there is an 
overlap between the CI of OAC and  SCC, it was not possible to be certain whether 
NSAIDs were more beneficial to patients with OAC or SCC. 
 
IV. NSAIDs and SCC 
There was a negative association between exposure to aspirin (OR:0.50, CI: 0.25-
0.97) and other NSAIDs (OR: 0.36, CI: 0.16-0.81) and SCC of the oesophagus 
(Table 9).  The reduction in risk of SCC was approximately 50% for Aspirin and 65% 
for other NSAIDs. In this study, no patient with SCC was consuming Coxibs; hence it 
was not possible for us to evaluate any correlation here. 
 
V. LOS relaxing drugs and OC 
Statistically significant positive associations were observed between the risk of OC 
and exposure to several different drugs that are known to relax the lower 
oesophageal sphincter. Exposure to these drugs at any level was associated with an 
odds ratio of between 1.9 and 3.2 (95% CI 1.2 - 5.1) for OC. Exposure to any 
formulation of CCB, whether short or long acting, was also associated with an odds 
ratio of 2 to 3 (95% CI: 1.2 - 5.1). 
 
VI. LOS relaxing drugs and OAC 
A statistically significant association between the use of drugs which relax the LOS 
and OAC was observed.  Among cases with OAC, 15% had an exposure to a CCB 
and 22% cases were on anti-asthma medication (Table 9). Cases with OAC were 2-3 
times more frequently exposed to LOS relaxing drugs as compared to the controls.  
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VII. LOS relaxing drugs and SCC 
Only weak associations between bronchodilators, CCBs and SCC of oesophagus 
were observed (Table 9). As only 4 patients with SCC were exposed to Theophylline, 
no association between Theophylline and SCC could be calculated. 
 
VIII. Data unadjusted for smoking and alcohol 
Table 10 & 11 show the data unadjusted for smoking and alcohol. The protective 
effect of the NSAIDs and the risk with CCBs is reduced when unadjusted for smoking 
and alcohol. 
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            Cases         Controls 
Patient Numbers 411 1644 
Males 285 (70%) 1141 (70%) 
Females 126 (30%) 503 (30%) 
Mean Age (years) 71 (40-93) 70 (41-94) 
Age Range   
41-50 years 15 (3%) 60 (3%) 
51-60 years 65 (16%) 260 (16%) 
61-70 years 102 (25%) 408 (25%) 
71-80 years 148 (36%) 592 (36%) 
81-90 years 78 (19%) 312 (19%) 
91- 94 years 03 (1%) 12 (1%) 
 
 
Table 7: Demographics of patients.  
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Tumour Site      Upper 1/3rd 
                         Mid 1/3rd  
                         Lower 1/3rd  
11 (3%) 
41 (10%) 
359 (87%) 
Tumour type      Adeno Ca 
                          Squamous Ca 
318 (77%) 
93 (23%) 
Degree of differentiation 
                        Mild 
                        Moderate 
                        Poor 
 
60 (15%) 
224 (54%) 
127 (31%) 
 
 
Table 8: Oesophageal tumour distribution and histology 
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 Cases n=411 Controls n=1644 Odds Ratio
+
 Confidence Interval
+
 
Smoking: Never 
                Ever 
79 (19%) 
323 (79%) 
1174 (71%) 
398 (24%) 
- 
3.18 
- 
2.75-3.68 
Alcohol : Never 
               Ever 
143 (35%) 
264 (64%) 
514 (31%) 
1099 (67%) 
- 
0.90 
- 
0.80-1.01 
Oesophageal Cancer     
 Aspirin  
        Low Dose Aspirin  
        High Dose Aspirin  
93 (22%) 
56 (14%) 
37 (8%) 
524 (32%) 
421 (26%) 
103 (6%) 
0.38 
0.43 
0.33 
0.27-0.54 
0.23-0.47 
0.15-0.98 
Other NSAIDs : 
        Low Dose  other NSAIDs 
        High Dose other NSAIDs 
79 (19%) 
23 (6%) 
56 (13%) 
575 (35%) 
8 (0.5%) 
567 (34%) 
0.29 
0.44 
0.17 
0.19-0.41 
0.26-0.94 
0.10-0.27 
Coxibs 55 (12%) 135 (8%) 0.35 0.16-0.78 
CCBs:  
        Short Acting CCBs 
        Long Acting CCBs 
Inhaled Bronchodilators 
Theophylline 
78 (19%) 
11 (3%) 
67 (16%) 
86 (21%) 
27 (7%) 
112 (7%) 
26 (2%) 
86 (5%) 
108 (7%) 
18 (1%) 
2.41 
2.08 
2.90 
3.21 
1.92 
1.22-5.01 
1.22-5.13 
1.84-4.73 
2.24-4.71 
1.36-5.10 
Oesophageal Adenocarcinoma     
Aspirin 
Other NSAIDs 
Coxibs 
CCBs 
Inhaled Bronchodilators 
Theophylline 
62 (15%) 
54 (13%) 
55 (13%) 
60 (15%) 
65 (16%) 
23 (6%) 
345 (21%) 
391 (24%) 
135 (8%) 
86 (5%) 
82 (5%) 
15 (1%) 
0.35 
0.25 
0.46 
2.91 
3.64 
2.13 
0.24-0.51 
0.16-0.40 
0.20-0.94 
2.12-4.14 
2.67-5.13 
1.36-5.12 
Oesophageal Squamous Cell Cancer     
Aspirin 
Other NSAIDs 
Coxibs 
CCBs 
Inhaled Bronchodilators 
Theophylline 
31 (7%) 
25 (6%) 
0 
18 (4.4%) 
20 (5%) 
4 (1%) 
179 (11%) 
184 (11%) 
0 
26 (2%) 
26 (2%) 
3 (0.2%) 
0.50 
0.36 
- 
1.45 
1.76 
- 
0.25-0.97 
0.16-0.81 
- 
1.22-5.13 
1.53-5.16 
- 
+ Conditional logistic regression model, adjusting for cigarette smoking status (ever, never) and alcohol consumption (ever, never) 
 
Table 9: Relationship between NSAIDs, Drugs which relax the 
LOS and Oesophageal Cancer adjusted for Smoking and 
Alcohol consumption 
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 Cases n=411 Controls n=1644 Odds Ratio
+
 Confidence Interval
+
 
Oesophageal Cancer     
 Aspirin  
        Low Dose Aspirin  
        High Dose Aspirin  
93 (22%) 
56 (14%) 
37 (8%) 
524 (32%) 
421 (26%) 
103 (6%) 
0.14 
0.10 
0.29 
0.11-0.19 
0.09-0.15 
0.19-0.44 
Other NSAIDs : 
        Low Dose  other NSAIDs 
        High Dose other NSAIDs 
79 (19%) 
23 (6%) 
56 (13%) 
575 (35%) 
8 (0.5%) 
567 (34%) 
0.11 
0.02 
0.08 
0.08-0.15 
0.01-0.05 
0.06-0.11 
Coxibs 55 (12%) 135 (8%) 0.33 0.23-0.47 
CCBs:  
        Short Acting CCBs 
        Long Acting CCBs 
Inhaled Bronchodilators 
Theophylline 
78 (19%) 
11 (3%) 
67 (16%) 
86 (21%) 
27 (7%) 
112 (7%) 
26 (2%) 
86 (5%) 
108 (7%) 
18 (1%) 
5.70 
5.64 
6.72 
6.18 
16.86 
4.50-7.23 
2.88-11.04 
5.13-8.80 
4.90-7.80 
9.61-29.60 
Oesophageal Adenocarcinoma     
Aspirin 
Other NSAIDs 
Coxibs 
CCBs 
Inhaled Bronchodilators 
Theophylline 
62 (15%) 
54 (13%) 
55 (13%) 
60 (15%) 
65 (16%) 
23 (6%) 
345 (21%) 
391 (24%) 
135 (8%) 
86 (5%) 
82 (5%) 
15 (1%) 
0.14 
0.11 
0.33 
6.32 
6.91 
8.30 
0.11-0.20 
0.08-0.15 
0.23-0.47 
4.78-8.36 
5.25-9.11 
4.49-15.37 
Oesophageal Squamous Cell Cancer     
Aspirin 
Other NSAIDs 
Coxibs 
CCBs 
Inhaled Bronchodilators 
Theophylline 
31 (7%) 
25 (6%) 
0 
18 (4.4%) 
20 (5%) 
4 (1%) 
179 (11%) 
184 (11%) 
0 
26 (2%) 
26 (2%) 
3 (0.2%) 
0.14 
0.11 
- 
8.56 
9.32 
18.91 
0.09-0.21 
0.07-0.17 
- 
4.87-15.05 
5.40-16.10 
4.30-83.09 
 
 
Table 10: Relationship between Smoking unadjusted, NSAIDs 
and Drugs which relax the LOS and Oesophageal Cancer 
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 Cases n=411 Controls n=1644 Odds Ratio
+
 Confidence Interval
+
 
Oesophageal Cancer     
 Aspirin  
        Low Dose Aspirin  
        High Dose Aspirin  
93 (22%) 
56 (14%) 
37 (8%) 
524 (32%) 
421 (26%) 
103 (6%) 
0.04 
0.03 
0.08 
0.03-0.05 
0.02-0.04 
0.05-0.12 
Other NSAIDs : 
        Low Dose  other NSAIDs 
        High Dose other NSAIDs 
79 (19%) 
23 (6%) 
56 (13%) 
575 (35%) 
8 (0.5%) 
567 (34%) 
0.03 
0.69 
0.02 
0.02-0.04 
0.30-1.56(p=0.37) 
0.01-0.03 
Coxibs 55 (12%) 135 (8%) 0.10 0.07-0.14 
CCBs:  
        Short Acting CCBs 
        Long Acting CCBs 
Inhaled Bronchodilators 
Theophylline 
78 (19%) 
11 (3%) 
67 (16%) 
86 (21%) 
27 (7%) 
112 (7%) 
26 (2%) 
86 (5%) 
108 (7%) 
18 (1%) 
2.47 
1.73 
2.79 
2.74 
5.76 
4.50-7.23 
0.87-3.46(p=0.12) 
2.08-3.75 
2.12-3.55 
3.22-10.30 
Oesophageal Adenocarcinoma     
Aspirin 
Other NSAIDs 
Coxibs 
CCBs 
Inhaled Bronchodilators 
Theophylline 
62 (15%) 
54 (13%) 
55 (13%) 
60 (15%) 
65 (16%) 
23 (6%) 
345 (21%) 
391 (24%) 
135 (8%) 
86 (5%) 
82 (5%) 
15 (1%) 
0.04 
0.03 
0.10 
2.55 
2.84 
5.95 
0.03-0.06 
0.02-0.04 
0.07-0.14 
1.88-3.46 
2.10-3.85 
3.15-11.26 
Oesophageal Squamous Cell Cancer     
Aspirin 
Other NSAIDs 
Coxibs 
CCBs 
Inhaled Bronchodilators 
Theophylline 
31 (7%) 
25 (6%) 
0 
18 (4.4%) 
20 (5%) 
4 (1%) 
179 (11%) 
184 (11%) 
0 
26 (2%) 
26 (2%) 
3 (0.2%) 
0.04 
0.03 
- 
2.76 
3.04 
5.48 
0.02-0.06 
0.02-0.05 
- 
1.54-4.97 
1.72-5.38 
1.23-24.35(p=0.2) 
 
 
Table 11: Relationship between Alcohol unadjusted, NSAIDs 
and Drugs which relax the LOS and Oesophageal Cancer 
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10.6. Discussion: 
In this case-control study, examining the association between oesophageal cancer 
and exposure to NSAIDs, Negative associations between both AC and SCC and use 
of NSAIDs, and observed a positive association with drugs that relax the LOS were 
observed.  In the cases, only 3.5% patients with OC were less then 50 years of age, 
and, as has been observed by others, male cases considerably outnumbered 
females (Table 7). The fact that the mean age of our cases with OC was 71 years is 
also consistent with previous observations suggesting that the development of OC is 
strongly related to age.  An important issue with any study of this type is the choice of 
hospital-based controls, who may not be truly representative of the general 
population from which the cases are derived. In the present study, I chose patients 
with non-melanotic skin tumors as the control group, but cannot entirely exclude the 
possibility that risk-factors related to non-melanotic skin cancer might lead to 
unidentified risk-associations. 
In previous epidemiological studies it has been established that a combination of 
smoking and alcohol consumption are strong risk factors for OC. Individually, smoking 
is a weak risk factor and alcohol intake may not be a risk factor for AC142,143. In the 
present study an association between smoking and OC was observed. The 
consumption of alcohol was however similar in cases and controls. The associations 
between medication and OC were observed following adjustment for smoking and 
alcohol consumption. However, when the data is unadjusted for smoking and alcohol, 
the protective effect is reduced for both smoking and alcohol. Alcohol unadjusted is 
weakly associated with the risk of OC in presence of NSAIDs and smokling slightly 
more. Unadjusted data may also be influenced by other risk factors like obesity, 
GORD, genetic compositions and dietary factors. I am unable to reproduce any data 
with respect to other risk factors as they were not part of the study. 
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These results are also consistent with the prospective data of Vaughan et al.  which 
examined the effects of NSAIDs on the incidence of OAC144. They observed a 70 % 
lower incidence of OAC amongst current users of NSAIDs, a protective effect that 
was reduced to 30% amongst former users of NSAIDs.  My results are also in general 
agreement with a meta-analysis by Corley et.al145, but they tend to contradict the 
suggestion of Bardou et.al146 that aspirin may not be as beneficial as Coxibs.  In the 
current study, odds-ratios for differences in dosages of Coxibs were not calculated, as 
exposure was only recorded for a small number of cases. Since no case with SCC 
was exposed to Coxibs, no association with SCC could be determined.  
One potentially important limitation of the study design which needs to be borne in 
mind relates to the accuracy with which exposure to drugs has been determined.  For 
example there is some risk of differentiation bias, in that the registration of medical 
details from cancer patients hospitalised due to a malignant disease may have 
differed from that of controls, who would have undergone mostly day-procedures for a 
relatively benign form of metaplastic disease. This risk was minimised by verifying 
that the general practitioner's referral letters contained a list of current and former 
medications used by the patients that were consistent with nursing records and the 
inpatient records.  
Since this is a case control study, no assessment could be made of any relationship 
between the time of exposure to the drugs and the disease. However the data were 
drawn only from patients with a recorded minimum of four weeks exposure to the 
drugs in the last ten years.   Finally it should be noted that the study design did not 
enable us to account for the effects of any over-the-counter purchase of aspirin or 
other NSAIDs .   
The mechanisms by which NSAIDs and Coxibs protect against oesophageal 
neoplasias are not clearly established, but plausible possibilities include both 
suppression of pro-inflammatory mechanisms mediated via the cyclo-oxygenase 
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pathway, and induction of apoptosis, leading to deletion of precancerous cells53,147. 
Recent studies indicate that in addition to the cyclo-oxygenase pathway, induction of 
the lipo-oxygenase pathway of arachidonic acid metabolism may be implicated in the 
development of oesophageal cancer148,149. In the present study the greatest negative 
association of OAC was with other NSAIDs compared to specific Coxibs, implying 
that leucotrienes formed by lipo-oxygenase activity may play a role in the 
development of OAC. Negative association between exposure to NSAIDs and the 
risk of both histological sub-types of oesophageal cancer were observed.  Assuming 
that inhibition of cyclo-oxygenase activity is the main mechanism of 
chemoprevention, this observation is consistent with the fact that there is over-
expression of COX-2 enzyme in both histological sub-types of this disease150. 
However the negative association with NSAIDs was evidently stronger for 
adenocarcinoma as compared to squamous carcinoma.  
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11.0: Development of a food frequency questionnaire for the 
assessment of quercetin and naringenin intake 
11.1: Introduction: Over the past few decades conflicting principles of healthy 
eating have been proposed, generating diverse opinions on what constitutes healthy 
food choices. Some recommend the exclusion of particular foods, while others 
profess that the same foods should occupy the central focus of the diet. There is 
confusion in the general population, including the medical profession, as to which 
dietary recommendations to follow, and which dietary components may be most 
important. This confusion has consequences. Clinicians continue to be the most 
respected source of lifestyle modification information and are exposed to 60 to 70 
percent of adult population each year151,152. As an example, a study of clinician 
attitudes highlights these concerns in the delivery of nutrition advice to their patients 
150. Nearly all clinicians were aware of the obesity epidemic and 60 percent of them 
felt capable of assuming a major role in obesity control, but only 36 percent agreed 
that they had effective weight-management practices. Clinicians use several 
strategies, but there are barriers to nutritional counseling which include skepticism 
about the effectiveness of nutritional interventions, concerns about patient response 
and compliance, lack of specific knowledge and training a67bout nutrition as it relates 
to disease, and the perceived unpalatability of nutritional changes154-157. Clinicians are 
able to identify patients at risk, but encounter time constraints, lack of specialty clinics, 
absence of guidelines, and an inadequate number of dietitians153. In addition to 
appropriate training, physicians need effective nutritional tools and information that 
can be used in the clinical setting158. 
Dietary choice may reverse or lessen the disease burden of some common risk 
factors for the main contributors to morbidity and mortality, including coronary heart 
disease, diabetes, some cancers, and stroke159. The dissemination of accurate 
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dietary information within a medical setting has become an increasing priority to the 
clinician and patient. Many people believe that a comprehensive plan of complete 
dietary change is necessary to accomplish goals; however, this is not always the 
case. Indeed, sometimes simple changes in one area of the diet may make beneficial 
impact to other areas of the diet160. The balance of protective foods is just as 
important as the avoidance of foods containing excess calories, sugars, saturated or 
trans fat. Making simple recommendations directed at modifying appropriate risk 
factors for chronic disease, and providing flexibility within the plan can be more 
effective over the long term161. The goal of nutrition assessment is to identify 
appropriate and actionable areas of change in the dietary lifestyle. 
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11.2: Food Frequency Questionnaires 
A food frequency questionnaire measures habitual diet over a period of time e.g. over 
the preceding year. They describe one’s usual frequency of food consumption rather 
than specific meals162,163. A comprehensive assessment of diet is necessary which 
allows a calculation of macro & micro nutrients in individuals. Levels of intake can 
then be divided into categories such as high, medium and low intake. A number of 
factors affect the accuracy & compliance of a food frequency questionnaire namely 
length, number of food items, frequency of intake and portion size. Filling in a lengthy 
FFQ can lead to fatigue & boredom thus impairing concentration & accuracy. This is 
true even for a highly motivated cohort as demonstrated by Willett in the United 
States of America cohort study which studied US nurses164. 
In a FFQ food list should be comprehensive, include all foods which contribute to the 
nutrient of interest and should also be able to detect between person variations in 
intake. The foods which contribute most to between person variation, and are 
therefore the most discriminatory can be calculated statistically by stepwise 
regression. This process may lead to fewer questions in the FFQ, but which still 
discriminate between individual’s intakes165. As intake of food is seasonal, food 
frequencies are usually described by subjects referring to their diet over the entire 
previous year. A standard approach is to give subjects a choice of frequency options 
ranging from never to intake of many times/day e.g. 6 times/day. Defining the options 
increases clarity and reduces errors compared with open-ended responses where 
subjects self- report their frequency intake166. 
Controversy exists over the inclusion of portion sizes in FFQ's, which can be achieved 
by giving descriptive examples or including photographs of different portion sizes86. 
Food items with natural units may be interpreted correctly e.g. a glass of milk, 
however, portion sizes with-out natural units e.g. a portion of vegetables can be 
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difficult to describe by subjects167,168. Providing ranges of serving sizes e.g. ¼  cup or 
½ cup improves clarity as compared to small, medium & large portions169. Existing 
FFQ's can be used to measure individual diets and extra questions added if particular 
nutrients are required to be studied. Borrud et al found that although the frequency 
distributions of food used by ethnic subgroups differ, a comprehensive FFQ may 
function well in a diverse population170.         
Also it is widely recognised that self-reporting of individual food items leads to a 
measurement errors, and FFQs are probably less reliable than other dietary recall 
methods. For example Michels et al used both a FFQ and a 7-day diet diary to 
correlate fruit and vegetable intake with plasma vitamin C levels171. They found similar 
associations of relative intake with plasma vitamin C, but absolute estimation differed. 
Day et al found FFQ to have a higher regression dilution as compared to 7-day 
diary172. However they examined only absolute rather then energy-adjusted intakes.  
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11.3. Rationale for using urinary excretion of flavonoids to validate 
the FFQ: 
High intake of fruits and vegetables has been shown to protect against development 
of many non-communicable diseases like several types of cancers173. Accurate 
estimation of fruit and vegetable intake is critical to further study the association 
between intake and development of chronic disease. Food diaries, food frequency 
questionnaires, and dietary recalls represent traditional methods for dietary 
assessment. All of these methods are associated with large random and systematic 
errors174-178. Blood and urine biomarkers for intake of foods may offer a more 
objective, universal, and physiologically relevant method for measuring intake. 
However, a thorough validation of the suggested biomarkers represents a critical and 
often underrated step in the development and maturation of new biomarkers. Due to 
large cultural and geographic variation in eating patterns, the validation of biomarkers 
for food items will have to include several controlled studies testing a large variety of 
eating patterns.  
Several substances found in fruits and vegetables may be potential biomarkers, and 
serum concentrations of carotenoids and vitamin C have received most attention179-
187. However, these biomarkers have several limitations; the absorption of carotenoids 
is subject to high inter-individual variation188,189 and is affected by factors such as 
gender, body mass index, physical activity and amount of fat in the diet190-194. 
Moreover, plasma concentration of vitamin C has been shown to be affected by 
smoking and oxidative status195. New candidate biomarkers are the flavonoids that 
are found ubiquitously in most fruits and vegetables. A recent parallel feeding study 
has demonstrated a correlation between total urinary excretion of flavonoids and the 
intake of fruits, berries, and vegetables196. Beyond this study, the literature about 
flavonoids as biomarker of fruit and vegetable intake is scarce. Also a Norwegian 
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study indicates that urinary excretion of dietary flavonoids may be used to assess 
changes of mixed fruit and vegetable intake197. 
Another study from Denmark concluded that the habitual intake of fruits and 
vegetables, determined by 3-day dietary records, correlated significantly with the total 
excretion of urinary flavonoids, with a coefficient of correlation of 0.35, P < 0.005 (n = 
94)198. In addition, highly significant differences in the urinary excretion of different 
flavonoids were observed in the human intervention study between subjects on diets 
high or low in fruits, berries, and vegetables. Also, at the individual level a significant 
positive correlation between changes in fruit and vegetable intake and changes in 
urinary flavonoid excretion was observed. Furthermore, urinary excretion of quercetin 
although small, is a constant function of quercetin intake199. 
I. Quercetin and naringenin as a biomarker of intake:  
Few studies have attempted to assess the use of plasma or urine quercetin levels as  
biomarkers of intake. Noroozi et al studied the effect of 2 high-flavonol diets on 
plasma quercetin concentrations in 10 diabetic subjects. They were supplemented at 
one of two high flavonols levels (total 77.3 or 110.4 mg/day) provided by supplements 
of 1500 ml tea daily and 400 g fried white onion in olive oil with and without tomato 
ketchup and herbs200. Fasting plasma flavonols concentrations on habitual diets 
ranged from 0 to 43.7 ng/ml mean. Regression equations were constricted: total 
flavonols intake r=0.74, P<0.001 and quercetin intake r=0.744, P<0. 001. From these 
equations, flavonol intakes from habitual diets were estimated at 17-50, mean 35 
mg/day. Of this, 91% was from quercetin.These findings indicate that plasma 
quercetin concentrations increase with increasing intake. 
Radtke et al estimated the intake of several flavonoids from 1- or 7-day dietary 
records obtained from 48 female students201. Intake data were correlated with fasting 
plasma flavonoid concentrations. For 1-day dietary records (collected on the last day 
before blood sampling), Spearman correlations were 0.42, 0.64, and 0.47 for 
  
 
81 
quercetin, hesperetin, and naringenin, respectively. For the 7-day dietary records, the 
corresponding values were 0.30, 0.32, and 0.35, respectively. These correlations are 
similar to what has been reported for many other nutrients, the plasma concentrations 
of which are used as biomarkers of intake. 
In another study, middle-aged men consumed either their habitual diets or 100 g/d of 
berries in addition to their habitual diets. In this study, plasma quercetin was 30% to 
50% higher in the subjects consuming berries, compared with the control group202. In 
a strictly controlled dietary intervention study, 77 healthy men and women consumed 
either 170 or 850 g of fruits, vegetables, and berries daily. Quercetin intake was 
calculated to be 3 and 24 mg/d on the respective diets. The mean F SD plasma 
quercetin concentration was 69.2nmol/L during the habitual diet, and it decreased to 
50% during the low-vegetable diet and increased to 125% during the high-vegetable 
diet (changes statistically significant) 203. In addition to blood samples, 24-h urine 
samples were also collected from the study and analyzed in Denmark204. Urinary 
quercetin was clearly higher after the high-vegetable diet compared with the low-
vegetable diet and decreased during the low-vegetable diet. In another study from 
Denmark, consumption of rather low amounts of quercetin in 3 increasing doses of 
fruit juice resulted in a significant increase in urinary quercetin with both dose and 
time205. The results of the 2 studies indicate that the urinary recovery of quercetin in 
24-h urine samples also respond to changes in dietary intake.  
The use of plasma flavanone levels as biomarkers of intake were investigated in 
further 2 studies. Bioavailability was studied after both single ingestion and long-term 
consumption76,85. According to the results of the first study, flavanones were clearly 
bioavailable, but the plasma half-lives were short (1-2 h). Urinary excretion appeared 
to be dependent on dose76. In the second study, 37 Finnish volunteers consumed 
their habitual diets followed by a diet containing on average 211 g of orange juice, 
one half orange, and one half mandarin per day for 5 weeks. During the habitual 
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diets, flavanones were detectable in few samples. After the consumption of citrus, 
naringenin was  detectable in 20% of the fasting plasma samples85. The results 
indicate that fasting plasma flavanone concentrations are problematic as biomarkers 
of intake. In the controlled dietary intervention study mentioned in the previous 
paragraph204, urinary flavanones clearly increased after the high-vegetable diet 
compared with the low-vegetable diet, which suggests that pooled 24-h urinary 
samples may be useful as biomarkers of flavanone intake in further studies. 
Plasma, serum or urinary quercetin appears to be a good biomarker of intake and can 
be used for this purpose in epidemiological studies. It should be noted that an 
accurate assessment of the intake of onion, qualitatively and quantitatively, the most 
important source of quercetin, is problematic, because onion is a commonly used 
hidden ingredient of many homemade and processed food. For flavanones, on the 
other hand, the situation is quite different. The errors in estimating their intake are 
probably relatively small because they are mainly obtained from citrus fruits and 
juices. Therefore, in epidemiological studies, a more sensible approach would be to 
assess their intake from food frequency questionnaires. 
II. Interindividual variation in bioavailability of quercetin and naringenin: 
Several studies indicate marked individual variation in the bioavailability of 
flavonoids75, 89,90 . Such variation is because of both physiological (differences in body 
weight, body composition, and gastric motility) and molecular factors (differences in 
the activity or synthesis of transporters or enzymes involved in biotransformation). 
Individual variation has been reported to occur for secretory transporters, such as P-
glycoprotein206,207 and Multi drug resistence proteins(MRPs)208, and biotransformation 
enzymes, such as CYP3A4209,210, Uridine diphosphate glucuronosyltransferases211, 
and sulfotransferases212. All of these proteins have been associated with flavonoids; 
quercetin interacts in vitro with P-glycoprotein213, MRP214 and MRP2215 and is a 
substrate for uridine diphosphate glucuronosyltransferases216-218 and 
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sulfotransferases. In addition, the composition and metabolic activity of the 
gastrointestinal microflora are likely determinants of the bioavailability of flavonoids 
absorbed from the distal parts of the gastrointestinal tract. 
To date, knowledge about the factors affecting the processes involved in the 
absorption and gastrointestinal metabolism of flavonoids has been rather fragmentary 
219,220. However, recent advances in molecular methods are expected to result in new 
information about the influence of environmental and genetic factors on the ctivity and 
expression of biotranformation enzymes221,222 and the composition of the microflora. 
This will almost certainly, in the near future, improve our  understanding about the 
bioavailability of specific compounds such as flavonoids. 
In this study, a FFQ was developed  to specifically measure flavonoids quercetin and 
naringenin intake by modifying an existing questionnaire developed at the Institute of 
Food Research, Norwich223. Modifying a FFQ to suit a study does not reducee its 
potential as documented in literature224,225. This existing FFQ measures the intake of 
basic macro & micro nutrients. The questionnaire was assessed to see if it can be 
shortened to increase compliance, whilst still be able to differentiate between in take. 
Secondly it was reviewed to see if portion size adds to the dietary assessment. By 
modifying a general FFQ, it is possible to assess individual diets with respect to 
particular issues, such as the intake of particular micronutrients or phytochemicals. 
Such ‘tailoring’ of an FFQ can be validated by using it to estimate intake of the target 
compound, and then determining the correlation between the data obtained and an 
objective biomarker such as urinary excretion of the compound under investigation, or 
its metabolites. The FFQ would then be used in future case-control studies to assess 
if flavonoids protect against gastro-intestinal malignancies.  
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11.4. Materials and Methods: Flavonoid Study  
I. Overview 
The study involved the recruitment of apparently healthy subjects via the Human 
Nutrition Unit (HNU) volunteer databank at the Institute of Food Research, Norwich, 
advertisement’s and email for recruitment of volunteers with in the Norwich Research 
Park (John Innes Institute, Institute of Food Research and University of East Anglia) 
and from surgical clinics at the Norfolk & Norwich University Hospital. 64 apparently 
healthy adult volunteers were recruited. The study involved assessing the dietary 
intake of the volunteers by a food frequency questionnaire, collection of up to five 24 
hour urine samples. Volunteers were not be given any dietary advice as there was no 
dietary intervention in the study. A flow chart of the overall study design is given in 
Figure 9 & 10. Flavonoid Study protocol attached as Appendix 2. A slightly modified 
version of the IFR food frequency questionnaire was used to improve compliance223.  
I as a Principal investigator was involved in the modification of the original FFQ. The 
FFQ was validated in this research and not the previous version of the FFQ. This is 
attached as Appendix 3. 
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Figure 9.  Study Design 
 
1.    RECRUITMENT 
via HNU database, NRP 
advert, N & N Clinics 
4. HNU APPOINTMENT 
 5 x 24 hr Urine Sample 
collection container 
 One FFQ 
SAMPLES 
Refer to figure 2 
 
6.  Analysis at IFR 
 
7. FLAVONOID INTAKE ASSESSMENT 
 Statistical calculation of dietary intake of Flavonoids 
 
 Food Frequency 
Questionnaire analysis  
 
 Urinary specimen 
analysis for flavonoid 
excretion 
 
2. INITIAL INTERVIEW  
 3 day consideration 
period  
3.   CONSENT &  HNU 
SCREENING 
5 Collection of Urine 
samples & completion of 
FFQ.    
 
8.  Correlation coefficient 
calculated comparing 
intake of flavonoids and 
their urinary excretion 
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Figure 10: Plan of Urine Sample collection and analysis
Collection of Samples & 
Storage 
at  IFR 
 Endpoint  
 Determination of  quercetin and 
naringenin concentrations in urine 
SAMPLES 
5 x Urinary Samples 
3 on weekdays ( Mon-Thurs)  
Two on Sunday`s 
Measuring 
Flavonoids 
 HPLC machine 
 20ml urinary 
specimen 
 Faeces 
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II. Volunteer Recruitment 
Apparently healthy male/female volunteers were recruited until 64 volunteers, 
completed the study. Experience has shown that the drop out rate for these types of 
studies is about 10%. It was envisaged that patients will be recruited onto the study at 
a rate of 4-5 per week and therefore recruitment continued for approximately 3-4 
months. If greater drop out rates occur recruitment would be reviewed. 
Advertisements were placed on: the Norwich Research Park* (University of East 
Anglia (UEA), John Innes Centre (JIC), Institute of Food Research (IFR)), and in the 
Human Nutrition Unit (HNU) news letter which is sent to all volunteers on the HNU 
volunteer database  (Annex 1). Patients with minor surgical ailments (e.g. groin 
hernia`s, cysts etc. that have no impact on dietary habit), their accompanying relatives 
or friends who attend the Norfolk & Norwich University Hospital surgical clinics, were 
also be informed of the study, and if interested were sent further information.  
Apparently healthy volunteers, who met the basic inclusion criteria, were sent a letter 
of invitation (Annex 2) to participate in the study.  This was supported by the volunteer 
information sheet (Annex 3). Included was a response slip and pre-paid envelope for 
returning the slip (Annex 4) if they were interested and wish for further information. 
The HNU databank contains names and contact details of people who have 
registered an interest in volunteering for human studies. 
Advertisements were placed around the Norwich Research Park  (UEA, JIC and IFR) 
inviting anyone who is interested in receiving information about the study to contact 
named researchers. NRP staff was also invited to participate in the study by email by 
seeking adequate permission.  Interested responders were sent the volunteer 
information sheet. This included a response slip and pre-paid envelope in which to 
return the response slip if they were further interested.  
Patients with minor surgical/medical conditions, not affecting their diet or ability to give 
up to five 24 hour urine samples, if fitting the inclusion criteria, were invited to 
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participate in the study. Healthy relatives or friends accompanying them were also 
invited to participate in the study. 
Following an expression of interest volunteers were invited to the Human Nutrition 
Unit for a preliminary interview and given further details of the study. The volunteers 
were encouraged to ask questions at this point prior to making any commitment. At 
the end of the interview all volunteers were given a minimum of 72 hours to consider 
whether they wish to participate in the study. They were also given a small sterile 
container to take away with them. If they wished to participate, this container was to 
be used for the urine sample on the morning of the clinical screening visit. If they 
decided they do not wish to take part in the study they were told to discard the 
container. During this consideration period the volunteers were not contacted. If, 
following this period of consideration, the volunteer wished to participate they were 
asked to contact HNU on telephone number 01603 255305. 
All those responding positively following this period of consideration were invited to 
attend the HNU for a clinical screening. No fasting was required. They were reminded 
to bring a midstream sample of urine from the first urine of the morning in the 
container provided at the first interview (This was not be tested until after the consent 
form has been signed). Volunteers needed to arrive within 2 hours after collection of 
the urine sample as this was a required specification for the validity of the urine 
dipstick test. 
III. Clinical screening: 
On arrival at the HNU the study scientist went through the consent form (Annex 5) 
with the volunteer and encouraged any questions they may have at this stage, 
volunteers were then asked to sign a consent form agreeing to participate in the 
study. A copy of the signed consent form was given to the volunteer to keep. A 
qualified nurse completed a basic health questionnaire (Annex 6), take and record 
blood pressure, pulse, height and weight measurements, Body Mass Index (BMI), 
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perform the urine dipstick test (Combur 9  Test®, Roche Diagnostics Ltd).The urine 
results were known immediately. If any of the results for the urine test were flagged 
the HNU protocol for abnormal urinalysis results was referred to. If the BMI is <18.5 or 
>30 the volunteer was excluded from the study. 
Volunteers who did not wish to be re-screened or who displayed screening 
parameters outside the standard reference ranges on both occasions were excluded 
from the study. 
Copies of all clinical results were be sent to the volunteer’s GP (Annex 7) and in the 
event of flagged urine results, the volunteer were informed verbally and advised to 
speak to their GP to discuss the results. Results were not discussed with the 
volunteer. 
Volunteers who meet the study criteria and whose screening results were satisfactory 
were included in the study. The GPs of those successfully recruited onto the study 
were  informed of their patient’s participation in the study by letter (Annex 8) and were 
sent copies of all clinical results. The volunteer agreed to this information being sent 
to the GP by signing the consent form.   
Once recruited onto the study, volunteers were assigned a code number with only the 
named study scientists approved by the Ethics Committee being able to link codes to 
volunteers. All personal information was kept confidential and known only to the  
Researcher’s, project leader, HNU research nurses, HNU Medical advisor and the 
volunteer’s GP. 
The inclusion and exclusion criteria were as follows:  
Basic Inclusion criteria 
 Aged 40-85 years (Malignancies more common in this age group) 
 Male or female 
 Non-smoker (Healthy volunteers with out smoking related diseases) 
 
  
 
90 
Basic Exclusion criteria 
 Pregnant and breastfeeding 
 Organ transplant recipients (on immunosuppressant’s can effect diet) 
 Long term illness requiring active treatment (e.g. Diabetes, cardiovascular 
disease, anaemia, cancer : may affect diet & participation in study) 
 Volunteers currently on antibiotics (ongoing infections can affect the diet) 
 
Screening Exclusion criteria 
 BMI < 18.5 or > 30 (exteremes of BMI may be associated with undiagnosed 
metabolic conditions) 
 Abnormal urine analysis results indicative of active illness (Refer to HNU 
protocol for abnormal Urinalysis results) 
 Results of clinical screening which are judged by the HNU Medical Advisor to 
be indicative of a health problem and could compromise the well-being of the 
volunteer if they participated, or which would affect the data. 
 Volunteers currently on antibiotics (ongoing infections can affect the diet) 
 
Once the volunteer was selected through the screening process, I gave instructions 
and equipment needed to prepare for the study. The study involved completing a 
questionnaire on diet and producing up to five 24 hr urine collections over a period of 
2 weeks including two on Sundays. 
IV. Assessment of Dietary Intake 
Diet was assessed by a food frequency questionnaire. The volunteers were asked to 
complete the questionnaire at home taking into account their diet over the period of 
the last year. The food frequency questionnaire (annex 9) focuses on habitual diet 
intake during the previous twelve months and allows an estimate to be made of the 
habitual intake of flavonoids from food sources. This questionnaire has been modified 
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from one previously used for studies at the Institute of Food Research, Norwich. The 
FFQ takes approximately 30 minutes to complete. In addition to recording the habitual 
intake of a wide range of foods and food groups, the computer software used to 
interrogate the FFQ data calculated the dietary intake of selected flavonoids e.g. 
quercetin, naringenin from the information supplied by each volunteer.  
The original questionnaire  specified 185 foods, divided into 16 major categories 
(Table 12). This questionnaire was modified as follows: For the purposes of the 
present study the categories were retained but, in order to minimise the number of 
questions and at the same time acquire sufficient information on individual fruits and 
vegetables, some foods with very similar macronutrient content, particularly in the 
meat section, were grouped together. Also, some previously grouped fruits and 
vegetables were divided because their flavonoid content was different.  Overall, this 
facilitated an overall reduction in the number of specified foods to 159, which was 
deemed to have the probable added advantage of improving compliance. Frequency 
of consumption was based on recall over the past year, and the response divided into 
six replies: more than once a day, once a day, 4-6 times a week, 1-3 times a week, 1-
3 times a month and rarely or never (Table 13). Volunteers were asked to assess 
portion size (small, medium or large) with the aid of a series of colour photographs of 
medium portions, on a standard dinner plate with cutlery alongside.  
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Meats Biscuits And Puddings 
Vegetables Breakfast Cereals 
Pasta And Rice Bread 
Cheese And Cheese Dishes Chocolate And Sweets 
Fish Alcohol And Other Beverages 
Fats Fruit; 
Dairy Products Nuts 
Eggs Other Foods 
Cakes  
 
  
Table 12: 16 major categories of the food items 
retained from the original FFQ. 
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Food category 
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A.  Meats 
Do you eat meat?  YES /NO (please delete) 
If ‘NO’ please go to section B. 
How often do you usually eat the following? 
1 Salami, Pate or similar meats see photograph 
1c 
         
2 Meat pies (e.g.pork steak & 
kidney)  
see photograph  
2a 
         
3 Sausage rolls, Cornish pasties 1 small 
 
         
4 Ham, corned beef + other cold 
meats 
see photograph 
1a 
         
5 Chicken, turkey etc. including 
minced & casseroled 
see photograph 
3b 
         
6 Lamb chops, cutlets and mince see photograph 
4b 
         
7 Leg of lamb see photograph 
3b 
         
8 Leg of pork, pork medallions, 
steaks and fillets 
see photograph 
3b  
         
9 Pork chops see photograph 
3b 
         
10 Reduced fat pork or beef  
sausages 
  1 thick 
 
         
11 Sausages, pork or beef 1 thick 
 
         
12 Beef steak - rump or sirloin see photograph 
4b 
         
13 Beef  - topside, brisket, forerib, 
mince 
see photograph 
3b 
         
14 Bacon (back, lean, meat and 
fat), grilled or fried 
1 slice 
 
         
15 Bacon, streaky, grilled or fried 1 slice 
 
         
16 Liver see photograph 
1b 
         
17 Kidney, pig, stewed and other 
offal 
see photograph 
1b  
         
18 Stew, Shepherds pie, 
casserole, curry, kebab 
see photograp 
7b 
         
 
 
V. Sample Collection 
Up to five 24 hours urinary samples were collected at the HNU, IFR, according to the  
 
 
Table 13: FFQ used in the study detailing the frequency and 
portion responses 
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V. Sample Collection  
Upto five 24 hours urinary samples were collected at the HNU, IFR, according to the  
plan in Figure 9. Ascorbic acid 99% crystalline Sigma Ultra 1gm in 2.5 litres pot was 
added to the urine collection pots as a preservative and the volunteers informed of its 
presence. These samples were stored in a cold room at temperatures +10 C to +40C 
for up to a month before being processed. 
Urine Samples & Creatnine clearance : 
Volunteers were be asked to collect up to five 24 hours urine samples. These 
samples were stored, processed and analysed at IFR. The procedure for collection of 
the urinary sample was explained to the volunteers and they had the opportunity to 
ask questions. Researchers at the Institute of Food Research have many years of 
experience in collecting urinary samples from volunteers and are able to instruct 
volunteers to collect samples in a safe and hygienic manner. Creatnine clearance was 
used as a marker of compliance by determining the amount of creatnine in the 24h 
sample using a ABX Diagnostic’s Creatnine 80 kit on a COBAS Mira Plus analyser. 
This kit uses the Jaff’e colorimeteric method for determining Creatnine in urine. ABX 
Diagnostics Human Control N was run as quality control and inter-assay variation was 
determined. 
VI. Sample Analysis 
The urinary samples were analysed by the principal investigator for the following 
flavonoids: quercetin and naringenin.  Flavonoids in the urine samples were 
enzymatically deconjugated, extracted and quantified by HPLC (High Performance 
Liquid Chomatography) according to the method of Du Pont et.al226. Sample handling 
and analysis was carried by myself as the Principal investigator. 
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VII. Method of development for extraction of Quercetin: Pilot Study 
As a part of method development, in a pilot study, a subject consumed 50gms, 
100gms and 150gms of red onions on three different days. The subject collected 24 
hr urine samples for each of those days.  These samples were then used to extract 
quercetin in its aglycone form.  
VIII. Extraction of flavonoids from Urine, including HPLC analysis: 
The process of deconjugation and extraction of flavonoids was based on a previous 
studies from IFR on flavonoid extraction226,227.   
 
Chemicals and reagents  
HPLC-grade methanol was purchased from Fisher Scientific (Loughborough, UK). 
Acetonitrile (HPLC grade), trifluoroacetic acid, b-glucuronidase (Helix pomatia type 
H5), sulfatase (H. promatia type H1), N,O-bis-(trimethylsilyl) trifluoracetamide, 
rhamnetin, naringenin, hesperetin, perillic acid, ethylbenzoic and propylbenzoic acids, 
cobalt(II) bromide and 4,7-diphenyl-1,10-phenanthroline (4,7-dpphen) were 
purchased from Sigma-Aldrich (Poole, Dorset, UK). Pelargonidin-3-glucoside and 
galangin were obtained from Extrasynthe`se (Genay, France). 
Extraction process: 
Samples were analysed by HPLC with online UV-diode array and LC-MS detectors. 
Absorbance at 270 nm was used for quantification, and tandem MS (positive-ion 
mode) to confirm the identity of the analytes. Acidified urine samples (10·0 ml) were 
incubated with 5·0 ml phosphate buffer (pH 5·0), 1·0 ml β-glucuronidase (10 000 
units) and 1·0 ml sulfatase (1000 units) at 37°C for 2 h. Then 50 μl galangin 
(0·1 mg/ml) was added as an internal standard before incubation. Flavanones in 
hydrolysed urine samples were extracted using a solid-phase extraction (SPE) 
cartridge (Varian Bond Elute C18) conditioned with methanol (5 ml) followed by water 
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(10 ml). Following application of urine or plasma, the cartridge was washed with water 
(10 ml) and flavanones eluted directly into vials with 1 % HCl in methanol (1·0 ml for 
urine) or 1 % HCl in acetonitrile (0·5 ml for plasma). Pelagonidin-3-glucoside (50 μl of 
0·1 mg/ml) was added to the SPE eluate as a volume marker immediately before 
HPLC analysis. 
Samples (1 μl) of hydrolysed urine extracts were analysed by HPLC (Agilent HP1100; 
Agilent Technologies, Waldbronn, Germany) using a Gemini C18 column 
(150 × 2·00 mm, 5 μm particle size; Phenomonex, Macclesfield, Cheshire, UK) eluted 
at 0·3 ml/min with a gradient of increasing solvent B (0·1 % trifluoroacetic acid in 
acetonitrile) from solvent A (0·1 % aqueous trifluoroacetic acid) at 30°C over 
65 minutes. The eluent was scanned over 200–600 nm by a diode array detector and 
subsequently an ESI-MS (Agilent Technologies, Waldbronn, Germany). The mass A 
spectrometer was operated in negative ionisation mode (cone voltage 22 V, source 
block temperature 120°C, desolvation temperature 300°C) with multiple reaction 
monitoring. Quantification was based on peak areas at 270 nm. Quantification of the 
flavonoids was based on standard curves (range 0·1–100 μg/ml) for quercetin and 
naringenin. Standard curves were linear with regression coefficients >0·99 as per the 
pilot study. 
IX. Identification of Quercetin and its quantitative calculations: 
Standards were used to identify (or eliminate) peaks using HPLC retention times. The 
calculations were based on the area underpeaks from HPLC analysis according to a 
standard curve (Table 14 & Figure 13). The standard curve was produced by injection 
of 6 different concentrations (0.5ng, 1ng, 5ng, 10ng, 50ng, 100ng) of authentic 
quercetin standards over the concentration range 50 to 10,000ng/ml. The slope of this 
curve was used to calculate the concentration of the post-SPE sample and from the 
total volume of urine collected over a 24 hour period, the total mass of quercetin 
excreted.      
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X. Sample Safety 
IFR has standard operating procedures for the storage of body fluids. These 
procedures were adhered to and are integral to IFRs recognition as ISO 9001:2000 
compliant and constitute part of process working to the standards of GCP. 
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Quercetin ng injected Quercetin area on HPLC 
100 2279 
50 1109 
10 219 
5 111 
1 24 
0.5 10 
Relation between quercetin injection and the peak areas on HPLC 
 
 
Table 14 
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r=0.999, p<0.0001 
Quercetin standard curve for method development 
 
Figure 11 
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11.5. Statistical Analysis 
Total food intake, total energy intake, macro & micronutrients, percentage of energy 
consumed was calculated using an in-house FFQ which was been re-designed 
around ACCESS software. The original FFQ from which the new version was derived 
has been used in previous studies at IFR223. The power of the study was been 
calculated at 80% assuming a group size of 64 to detect a correlation of 0.35 at 5% 
significance level. All data was analysed using Microsoft excel.  The primary analysis 
was to be using a Pearson's correlation coefficient to measure the strength of the 
association between dietary assessment of flavonoids and their urinary excretion, for 
both sexes combined and stratified by sex. If the distribution of the variables was 
skewed, transformed variables (such as log) was to be used. A secondary analysis 
would be linear regression, regressing estimated mean dietary flavonoid intake on 
mean urinary flavonoids, adjusting for covariates such as age, sex and BMI. Both the 
FFQ and urine results were divided into quartiles of intake/concentrations and 
compared to check that there are no gross miscalculations between methods. 
 
11.6. Ethical considerations: The project was approved by the Human 
Research & Governance Committee, Institute of Food Research, Norwich, East 
Norfolk & Waveney Research Governance Committee, Norwich Local Research 
Ethics Committee.  
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11.7. Results:   
Sixty-three volunteers were recruited, of whom fourteen were excluded due to 
various exclusion criteria including body mass index (BMI) < 18.5 or > 30, long term 
illness requiring active treatment or abnormal urine analysis indicative of active 
illness.  Amongst the 49 volunteers who participated the mean age was 60 yr (Range 
40-85). The M:F ratio was 1:1.3 and the average BMI was 26 kg/m2 (Range 19-36).  
 
I. Results of the pilot study: (Table 15 & Figure 12) 
A single volunteer was used as a pilot to determine the accuracy of the method for 
urinary excretion of quercetin. The process of deconjugation was based from previous 
IFR studies226,227. The pilot study was done to ascertain the process could be 
duplicated by me, the principal investigator. Raw red onions usually contain 
20mg/100gm of quercetin228. It was expected that ingestion of 50, 100 and 150 gms 
of red onions, therefore would yield 10, 20 and 30 mg of quercetin respectively. 
Urinary excretion of quercetin was between 0.31-0.48% in this volunteer. The 
correlation coefficient for the intake versus urinary excretion of quercetin was 0.978 
(p<0.0001). 
 
II. Estimated Nutrient intakes 
Details of average energy consumption and intake of major macro-nutrients, fibre, 
selected minerals and vitamins are given in Table 16.  
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III. Relationship between estimated flavonoid intakes and urinary excretion  
The average 24 hr ingestion of quercetin and naringenin estimated from FFQ with 
inclusion of portion size was 29 mg (SD 15.0) and 56 mg (SD 62.76). The estimated 
ingestion of quercetin (Fig 13) correlated significantly with urinary excretion (r = 0.827; 
p < 0.0001;  95% CI: 0.712 to 0.899) whereas to the relationship for naringenin (Fig 
14) was less clear cut (r = 0.251; p<0.05; 95% CI: -0.032 to 0.497).  
 
When estimates of portion size were not included, the estimated average 24 hr 
ingestion of quercetin and naringenin from FFQ were 25.9 mg (SD 11.7) and 46.64 
(SD 43.38) respectively. Exclusion of portion size reduced the correlations between 
the estimated ingestion of quercetin (r = 0.693, 95% CI: 0.533 to 0.825) and 
naringenin (r = 0.157, 95% CI: 0.54 to 0.26) and their respective urinary excretions     
( Fig 15 and 16).  The correlations between the intakes of quercetin and naringenin 
estimated from the FFQ, with and without portion size, were 0.856 (95% CI: 0.758 to 
0.917) and 0.926 (95% CI: 0.872 to 0.958) respectively. Tests of equality of the two 
correlation coefficients drawn from the two different samples indicated no statistically 
significant differences due to inclusion or exclusion of portion size for either quercetin 
(p=0.1192) or Naringenin (p=0.6378).  
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          Day 1                         Day 2                       Day 3 
Raw onions ingested 50 grams 100grams 150 grams 
Quercetin from 
onions 
10 mgs 20 mgs 30 mgs 
HPLC peaks 115 155 248 
Urine Volumes 1900 mls 1850 mls 1700 mls 
Quercetin excreted 
in 24 hr sample 
48 g/L  
(0.48%) 
62 g/L    
(0.31%) 
92 g/L 
  (0.34%) 
 
    Table 15: Details of pilot study for method development 
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r=0.978, p<0.0001 
Correlation between ingestion of quercetin and its urinary excretion in the pilot study 
 
Figure 12 
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Nutrient FFQ with portion size FFQ without portion size 
Energy 2749 Kcal 2547 Kcal 
Proteins 103 mg 95 mg 
Fats 113 mg 105 mg 
Carbohydrates 313 mg 291 mg 
Fibres 30 mg 28 mg 
Iron 18 mg 17mg 
Vitamin E 14 mg 14 mg 
Vitamin C 284 mg 255 mg 
Vitamin B1 2 mg 2 mg 
Vitamin B2 2 mg 2 mg 
Vitamin B6 3 mg 3 mg 
Vitamin B12 12 mg 11 mg 
 
Table: 16: FFQ determination of selected macro and micro 
nutrients per 24 hrs 
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r = 0.827, p<0.0001 
Correlation between FFQ estimated intake of Quercetin with portion size and its 
urinary excretion. 
 
Figure 13 
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r = 0.2515, p<0.05 
Correlation between FFQ estimated intake of Naringenin with portion size and its 
urinary excretion. 
 
Figure 14 
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r = 0.693, p<0.0001 
Correlation between FFQ estimated intake of Quercetin without portion size and its 
urinary excretion. 
 
Figure 15 
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r = 0.1573, p<0.005 
Correlation between FFQ estimated intake of Naringenin without portion size and its 
urinary excretion. 
 
Figure 16 
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11.8. Discussion:  
The primary objective of this study was to assess the ability of the FFQ to estimate 
dietary flavonoid intake. The relationship between dietary intake of quercetin and 
naringenin with their urinary excretion was examined to validate a FFQ in 49 
volunteers. A pilot study was carried out to asses the accuracy of the method for 
urinary excretion of quercetin. It confirmed that the process of extraction was accurate 
with a correlation coefficient r= 0.978 (p<0.0001) for the intake versus urinary 
excretion of quercetin. Similair process was used to extract naringenin. 
The results of the flavanoid study suggest that there is a statistically significant 
correlation between the intake of the flavonoids quercetin and naringenin as 
estimated by an FFQ and their urinary excretion over a 24h period. Young et al229 
reported that urinary excretion reflects the absorption of quercetin and, therefore is a 
good marker of its bioavailability. De Vries230 found urinary flavonoids as biomarkers 
of dietary consumption, and a Finnish study has shown that urinary flavonoids can be 
used as a biomarker of dietary fruit and vegetable intake with a correlation co-efficient 
of 0.35, p < 0.005231.  The present study suggests therefore that FFQ can be used as 
a practical tool to estimate flavonoid ingestion in epidemiological studies.  
Metabolism quercetin and naringenin occurs via a common pathway232.These 
polyphenols are absorbed from the small intestine. Quercetin is absorbed in its 
glycosated form in the stomach and in its aglycone form in the intestine233. However, 
naringenin is absorbed only in its glycosated form in the small intestine. Once 
absorbed, they are conjugated in the liver and small intestine. They are then excreted 
via the biliary or urinary route234. In our study, the average excretion of quercetin and 
naringenin was 0.20% and 1% respectively. Our results are in conjunction with 
previous studies which found, depending upon the dietary source, human 
characteristics and process of extration,  excretion of quercetin235,236  was in the 
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range of 0.20% to 0.50% and naringenin in the range of 1-30% of its dietary intake 237-
240.  
In past, investigators have used 24-hr recalls, prospective food diaries and FFQs as 
tools to measure fruit and vegetable intake241-243. 24-hr recalls are expensive, demand 
a lot of administrative time and there is a need to obtain multiple recalls. Also there is 
literacy demand in the estimation of portion size241. Food diaries are subject to 
respondent burden, literacy demands and may be over reported244. A cross-sectional 
study by Brunner et al comparing a 7 day diet diary and FFQ with serum cholesteryl 
ester fatty acid, plasma alpha-tocopherol and beta-carotene found FFQ performed 
well in comparison with the 7 day diet diary245.  
Over/under reporting of an individuals diet could be one of the other limitations of 
using a FFQ whilst estimating diet. However, a Brazilian study conducted amongst 
over weight individuals, concluded FFQ could be used in epidemiological studies to 
assess the regular food consumption of overweight individuals246. They  found a 
higher variability in the reporting of regular food consumption among obese than 
overweight individuals. Also the exclusion of foods popular to ethnic minority groups 
that are significant contributors of nutrients could not be taken into consideration. 
Although historically, FFQ are considered less sensitive to measures of absolute 
intake for specific nutrient, we modified the FFQ to overcome these limitations. Using 
a FFQ is a retrospective method that relies upon the respondent’s memory. We 
overcame this constraint by asking volunteers to complete the questionnaire at home 
taking into account their diet over the period of last year. This was done as we 
thought they would be more comfortable and undisturbed at home. Also pictures of 
portion sizes were added to the FFQ. 
Thus, FFQs gives the advantage of being cost effective and ability to assess diet over 
longer period of time247,248.  It is representative of usual intake, preferable method of 
measuring intake for nutrients with very high day-to-day variability. Questionnaire 
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processing is significantly less expensive than food records or diet recalls and can be 
easy for literate subjects to complete as a self-administered form. It is suitable for very 
large studies designed to rank individuals according to intake. 
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12.0. General Discussion: 
12.1: Case-control study: 
Currеnt еvidеncе frоm еpidеmiоlоgicаl ѕtudiеѕ ѕuggеѕtѕ thаt lоng-tеrm nоn-ѕtеrоidаl 
аnti-inflаmmаtоry drugs intаkе mаy rеducе thе riѕk оf dеvеlоping ѕеvеrаl typеѕ оf 
cаncеr, including GI mаlignаnciеѕ. Thiѕ еvidеncе iѕ pаrticulаrly ѕtriking in thе cаѕе оf 
оеѕоphаgеаl cаncеr. А rеcеnt rеviеw оf nine publiѕhеd еpidеmiоlоgic invеѕtigаtiоnѕ 
fоund thаt thе rеductiоn in rеlаtivе riѕk оf оеѕоphаgеаl cаncеr аpprоаchеѕ 73% with 
dаily intаkе оf аn NЅАID249. Ѕimilаr ѕtudiеѕ hаvе dеmоnѕtrаtеd а 40–60% dеcrеаѕе 
in thе rеlаtivе riѕk оf cоlоn cаncеr with cоntinuоuѕ uѕе оf NЅАIDѕ  аnd , аnd оthеr 
cаncеrѕ ѕuch аѕ ѕtоmаch, brеаѕt, lung аnd оvаriаn аlѕо ѕhоw riѕk rеductiоn with 
NЅАID intаkе250,251. Two studies from the UK have found significantly lower 
consumption of NSAIDs in cases of OC as compared to controls252,253. A recent 
meta-analysis showed that the protective effects of aspirin and NSAIDs may be 
dose-related254. It is not clear, however, at what dose aspirin becomes chemo-
preventive255,256. A study by Bardou et al failed to demonstrate a lasting effect of 
chronic ingestion of NSAIDs and COX-2 inhibitors on OC257. NЅАIDѕ hаvе bееn 
ѕhоwn tо inhibit tumоurigеnеѕiѕ in rоdеnt mоdеlѕ оf GI cаncеr. Thе NЅАIDs hаѕ 
bееn rеpоrtеd tо hаvе аnti-tumоur еffеctѕ in аnimаl mоdеlѕ оf оеѕоphаgеаl cаncеr  
аnd in rаt mоdеlѕ оf Bаrrеttѕ оеѕоphаguѕ, ѕеlеctivе CОX-2 inhibitоrѕ inhibitеd thе 
dеvеlоpmеnt оf аdеnоcаrcinоmа258,259. 
Another very important finding of the case-control study is the statistically significant 
positive association between OAC and exposure to drugs that cause a reduction in 
lower oesophageal sphincter tone. Previous studies have found only a weak 
association between -agonists and OAC and no association with CCBs260,261. The 
same authors also found anti-cholinergics to have the strongest association with 
OAC. Currently, -agonists and CCBs are more widely used. Overall, a higher intake 
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of these drugs was founf in our cases.  One possible explanation of our observations 
that needs to be considered is that of confounding by indication. Drugs that relax the 
lower oesophageal sphincter are frequently prescribed for asthma, which is also 
associated with GORD. Thus it is possible that gastro-oesophageal reflux is a cause 
of both OAC and asthma and that out findings reflect this association262. However, 
treatment of GORD may not always improve asthma control as other factors like food 
allergy may play a role263,264. 
In view of the increasing incidence of OAC across the western world, it is important to 
consider potential risk factors like BMI and history of GORD. A recent metanalysis 
from International BEACON Consortium found that BMI is directly associated with 
OAC and GEJ adenocarcinoma risk in both men and women and in those with and 
without GORD symptoms265. A prospective cohort study over a 10 year period 
involving 218,854 participants: 132,288 men and 86,566 women concluded overall 
obesity was associated with a higher risk of OAC and an increased risk of OAC with 
increasing abdominal obesity in people with normal BMI266. Risk fo GORD and OC 
have been discussed earlier in section 1.4. It seems that there may be a casual 
relationship between GORD and OC, however it is Barrets oesophagus which is 
moresignificantly associated with development of OC267,268. Data on BMI and GORD 
was not collected as this study was primarily done to assess  the risk of Cox-2 
inhibitors in OC. Hence the possible mechanisms of action by which certain drugs that 
might exert procarcinogenic effects on the oesophagus261,269 are considered in this 
study.  One obvious hypothesis is that both CCBs and bronchodilators cause a 
reduction in lower oesophageal sphincter tone, leading to more frequent reflux and 
prolonged exposure of the lower oesophageal mucosa to gastric, and possibly 
duodenal contents141,261.  As GORD is present in 30-89% of patients with asthma, 
treatment of this chronic condition may lead to the relaxation of the lower oesophagus 
due to the presence of 2 receptors in the LOS
270-272. Another possibility is that by 
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blocking the entry of calcium into the cells, CCBs may inhibit apoptosis, thereby 
reversing one putative protective mechanism that NSAIDs enhance273. A possible link 
with calcium metabolism at cellular level has been suggested by Fitzpatrick et al who 
found that CCBs increase the incidence of breast carcinoma in postmenopausal 
women by 2 fold (OR: 2.57, 95%CI, 1.47-4.49)274. A positive association between the 
use of CCBs and cancers in the elderly has been reported by Pahor et.al.275  
Furthermore, a Rotterdam study has implicated Verapamil, an L-type Ca2+ blocker, 
with an  increased risk of cancer in the elderly276. 
 
Thus although there is mixed evidence about the effects of coxibs and drugs which 
relax the LOS with OC, our study potentiates the theory of chemoprevention in 
oesophageal cancer, especially oesophageal adenocarcinomas. Also as I found an 
association with the drugs which relax the LOS and OC, however further studies are 
needed to rule out confounding factors like environmental, genetic and other chemical 
factors. This leads me to the second part of my thesis about validation of a FFQ 
against urinary excretion of flavonoids. This study is conceptually linked to the case-
control study as following validation of the FFQ, it may be possible to use this FFQ as 
a dietary tool in further studies to study the impact of intake of naturally occuring 
compounds with Cox-2 inhibitory and anti oxidant properties on the outcome of 
various diseases, including cancer. 
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12.2: Flavonoid Study: 
Diеtаry flаvоnоidѕ аnd оthеr pоlyphеnоlic fооd cоmpоnеntѕ hаvе оvеr mаny yеаrѕ 
bееn ѕuggеѕtеd tо hаvе prеvеntivе prоpеrtiеѕ bоth аt thе initiаtiоn аnd thе prоmоtiоn 
ѕtаgеѕ оf chеmicаlly inducеd cаrcinоgеnеѕiѕ. Аt thе cаncеr initiаtiоn ѕtаgе, mаinly in 
cеll culturе ѕtudiеѕ, pоlyphеnоlѕ hаvе clеаrly bееn ѕhоwn tо аffеct mаny оf thе 
cаrcinоgеn biоаctivаting ѕtеpѕ nеcеѕѕаry fоr thе cоvаlеnt binding оf thе cаrcinоgеn tо 
cеllulаr DNА, including thе mаjоr biоаctivаting CYP1А1 еnzymе. Whеrеаѕ ѕоmе 
pоlyphеnоlѕ hаvе bееn ѕhоwn tо аct аѕ inducеrѕ оf CYP1А1 by bеing аgоniѕtѕ оf thе 
аrylhydrоcаrbоn rеcеptоr (АhR), оthеrѕ hаvе bееn ѕhоwn tо bе inhibitоrѕ by bеing 
АhR аntаgоniѕtѕ.  Аt thе prоmоtiоn ѕtаgе, cеll culturе ѕtudiеѕ hаvе rеvеаlеd а widе 
vаriеty оf biоchеmicаl mеchаniѕmѕ fоr thе еffеctѕ оf pоlyphеnоlѕ оn humаn cаncеr 
cеllѕ. Thiѕ mоѕt rеcеntly includеѕ еffеctѕ оn VЕGF аnd HIF-1 еxprеѕѕiоn viа 
PI3K/АKT pаthwаyѕ  оr viа АRNT, inаctivаtiоn оf ЕGFR  аnd inhibitiоn оf thiоrеdоxin 
rеductаѕе, thymidylаtе ѕynthаѕе  аnd thе MDM2 оncоgеnе  аѕ wеll аѕ еffеctѕ оn 
cаncеr cеll rеѕiѕtаncе by tаrgеting thе mоlеculаr chаpеrоnе glucоѕе-rеgulаtеd 
prоtеin. 
Hоwеvеr, in vivо cаncеr chеmоprеvеntiоn ѕtudiеѕ in аnimаlѕ аnd еѕpеciаlly in 
humаnѕ, uѕing mоdеѕt, clinicаlly tоlеrаblе dоѕеѕ оf flаvоnоidѕ оr оthеr pоlyphеnоlѕ, 
hаvе bееn mоѕtly diѕаppоinting. Thiѕ cаn bе еxplаinеd by thе vеry pооr оrаl 
biоаvаilаbility оf thе pоlyphеnоlѕ, i.е. thеir inаbility tо pаѕѕ intаct thrоugh thе duаl 
intеѕtinаl/hеpаtic bаrriеr intо thе ѕyѕtеmic circulаtiоn. In humаnѕ, thiѕ lаck оf 
biоаvаilаbility аftеr оrаl dоѕеѕ hаѕ bееn ѕhоwn dirеctly fоr chryѕin, quеrcеtin, 
curcumin  аnd rеѕvеrаtrоl. Аlthоugh thе tеа flаvоnоidѕ  аnd thе iѕоflаvоnоidѕ, ѕuch аѕ 
gеniѕtеin, hаvе ѕоmе оrаl biоаvаilаbility, it iѕ ѕtill lоw. 
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I. Initial approach — Simply asking patients which dietary change(s) would improve 
their health can reduce time spent in assessment by highlighting areas the patient is 
willing to consider changing. Patients often can inform the clinician of the areas of 
weakness in their diet, and which behaviors contribute to body weight or other 
adverse health risk (such as elevated blood sugars). It is just as important to identify 
strengths in the diet (fruit, vegetables, other healthy options) in order to build on 
positive dietary foundations. The clinician may then follow up in subsequent visits to 
assess patient changes. This follow up is often important for patient motivation. 
II. 24-Hour dietary recall — A brief nutritional assessment tool commonly used is the 
24-hour dietary recall. The goal of the 24-hour dietary recall is to identify the day-to-
day pattern of eating with a minimum of reporting bias. Most people have little 
variability in dietary habits and are remarkably consistent with caloric intake and food 
choices. 
An abbreviated assessment may be performed by obtaining only the previous 
evening's intake, which can then be combined with the food frequency assessment. 
Typically, the evening is when the majority of calories are consumed. Asking what 
was consumed for the evening meal and any snacks afterward, including beverages 
may help. For diabetics, timing of intake is also important. Inquire as to portion sizes 
of meals. 
One may also to report the previous day's intake, separating meal occurrences: 
“What is the first thing you had to eat or drink yesterday?”; "Did you have anything 
else at the time?"; "What was the next thing you had to eat or drink?" Continuing 
through to snacks before bedtime and determining the time they went to bed, so as to 
determine how long after the last meal this occurred may help. This exercise can also 
elicit behaviors and lifestyle factors that underlie dietary choices. 
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People frequently will fail to report beverage consumption and most will require 
regular prompting such as "What did you have to drink with that?" Beverages and 
snacks often contribute greatly to over or under nutrition277. Combined foods such as 
cream in coffee and butter on bread need to be enquired as well. Mixed dishes such 
as casseroles may require additional prompting, and a number of other food 
responses may require follow-up questions to have a clear picture of what was eaten; 
e.g "Was there a sauce, cheese, or gravy with that?" "What type of beef?", "What 
percentage of fat in the hamburger?", "What percentage milk?". Be sure to ask about 
alcohol consumption. As far as assessing trans fatty acids (partially hydrogenated 
oils), it is important to remember that 40 percent of intake of these detrimental fats 
comes from cakes, cookies, crackers, pies and breads (processed foods)278. 
Hence there will be difficulties with accurately reporting portion sizes with 
underreporting of larger portion sizes occurring with almost mathematical 
predictability279,280. Use of comparisons such as a deck of cards (3 ounces), 1 cup of 
broccoli is about the size of a fist,1 cup of ice cream is about the size of a tennis or 
racketball may help. Thus using 24 hr dietary assessment may be time consuming, 
detailed with inter-personal differences and operator differences. 
III. Food diary — This is another option for dietary assessment. It entails asking 
people to keep a three or four-day diary that contains a complete record of foods and 
beverages consumed over those days. However, this transfers much of the time 
burden to the person investigated. It quickly highlight foods that need to be changed, 
in addition to any beneficial choices that may be continued. The diary itself may be an 
intervention: paeople may alter what they consume because they are required to write 
it down. A diary can be an excellent tool to help increase awareness of dietary habits 
and to encourage compliance with recommended dietary changes. 
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IV. Food frequency questionnaire — This is an assessment tool, which may be the 
quickest way to identify dietary patterns. Used in combination with the 24-hour recall, 
this may be one of the best way to identify protective and detrimental components of 
the patient diet. 
The food frequency questionnaire will cover typical intake over a period of time. Focus 
can be put on one or more key areas that are correlated with health concerns. Asking 
how often one consumes the food and then probing for greater detail helps. As an 
example, if the patient has a high LDL cholesterol level, we can explore sources of 
saturated fat and hydrogenated fats (trans fats), such as meats, cheese, processed 
foods, snacks, and dairy products including 2 percent milk, whole milk, and ice cream. 
Also FFQ assessments can reveal whether a person is eating a variety of fruit, 
vegetables, whole grains, and fish or not. In fact, a simple dietary recommendation of 
increasing fiber, or lowering saturated fat can also have a beneficial impact on other 
areas of the diet that are not specifically addressed281. 
However, they may not be able to give absolute nutrient values if they are 
unstructured, lengthy and do not provide details regarding specific foods282,283. A 
short FFQ may not have an appropriate response rate and good data quality, on the 
other hand clarity and ease of administration may be compensated in a lengthy 
questionnaire284.  Other factors which can affect the subjects compliance in filling a 
FFQ, and hence the accuracy of a food frequency questionnaire include the number 
of food items, the method used to estimate frequency of intake and the portion size. 
Because filling in a lengthy FFQ can lead to fatigue and boredom both concentration 
and accuracy of response can be impaired. This has been shown to be true, even for 
a highly motivated cohort, as demonstrated by Willett et al in their study of US 
nurses285.  Also, Warneke et al found a 7-item FFQ closely related to mean total fruit 
and vegetable consumption then a 31-item FFQ286.  Hence while formulating a FFQ; a 
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standard approach is to give subjects an adequate length FFW with choice of 
frequency options ranging from never to intake of many times/day. Defining the 
options increases clarity and reduces errors compared with open-ended responses 
where subject’s self- report their frequency intake287.  Another factor to be taken into 
consideration when interpreting the data. My subjects were a sub-sample of healthy 
volunteers participating in a prospective study selected based on selfreported dietary 
intake and therefore may not be representative of the general population with 
coexistent medical problems which may affect the urinary excretion of flavonoid 
metabolites. However, this is unlikely to bias the study as my objective was to validate 
the FFQ rather than estimate levels of flavanoid intake among the population.  
Controversy exists over inclusion of portion size in a FFQ. Block et al used a reduced 
dietary questionnaire and compared different portion sizes to a standard portion size. 
They found estimated values of macronutrients was reduced, however micronutrients 
were not reduced288. Correlations between the same FFQ with and without portion 
size were 0.9 for the nutrients. A Danish study compared FFQ with and without 
portion sizes with weighted diet records. Mean correlation coefficients for food groups 
and nutrients changed slightly289. Clapp et al found that replacing reported portion 
size data with standard portion size data may lead to conflicting outcomes for specific 
nutrients in research concerning the relationship between diet and disease290.  
Recently, a study from Germany concluded that inclusion of portion size may not be 
important in large epidemiological studies291. Portion size, although statistically 
unimportant in this study, correlates closely to flavonoid excretion when included. 
Hence I suggest, frequency and portion size may be included in an FFQ, as the 
correlation grows weaker if portion size is excluded (r = 0.693 & 0.157).   
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13.0. Cоncluѕiоn: 
In conclusion, the current studies add to the growing evidence that NSAIDs can play 
a protective role against both squamous and adenocarcinoma of the oesophagus. 
These data provide interesting evidence that use of CCBs and bronchodilators is 
associated with increased risk of OAC. One possible explanation for these 
observations is that the widespread use of these drugs may be partially responsible 
for the continuing increase in the incidence of OAC. This issue requires further 
investigation, both to further quantify the level of risk at the population level, and to 
explore the mechanisms involved. 
The Flavonoid study suggests a reasonable reproducibility of the flavonoids ingestion 
with their urinary validation using data from the FFQ. These findings suggest that 
FFQ can further be used as a tool to measure the impact of diet on health. 
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14.0. Future Research: 
Many cancers are preventable. Basic lifestyle changes can have a tremendous 
impact on the rates of cancer. The fact that such changes also protect against other 
chronic diseases (cardiovascular disease, stroke, and diabetes) makes the case for 
prevention even more compelling.  For several cancers, prophylactic medication can 
reduce cancer risk for high risk individuals.  
The primary effect of the nonsteroidal antiinflammatory drugs is to inhibit 
cyclooxygenase, thereby impairing the ultimate transformation of arachidonic acid to 
prostaglandins, prostacyclin, and thromboxanes. Increased expression of COX-2 
mRNA and protein has been noted in patients with hypertension, heart failure, and 
diabetic nephropathy292. Differences in a given non-selective NSAID or selective 
coxibs toxicity may in part be due to the extent to which it inhibits an isoform of 
cyclooxygenase. A presumed advantage of the coxibs was a reduction in 
gastrointestinal toxicity compared to other NSAIDs. However, an increased risk of 
ischemic cardiovascular disease has been described with rofecoxib, celecoxib, and 
valdecoxib. Not enough data are available to be certain, but a risk may also be 
present with etoricoxibs and lumiracoxibs.  Selective COX-2 inhibition is associated 
with reduced prostaglandin I2 (PGI2 or prostacyclin) production by vascular 
endothelium with little or no inhibition of potentially prothrombotic platelet 
thromboxane A2 production293. The relatively selective reduction in prostacyclin 
activity could predispose to endothelial injury294. In addition, selective COX-2 
inhibition, as well as non-selective inhibition of COX, elevates blood pressure. These 
are two of several proposed links between these agents and ischemic cardiovascular 
events. A similar increase in relative risk of myocardial infarction (RR 2.24, 95% CI 
1.24-4.02) or thrombotic cardiovascular events (RR 2.66, 95% CI 1.03-6.86) with 
rofecoxib therapy was noted in a 2004 meta-analysis and a randomized trial of 
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rofecoxib versus placebo for secondary prevention of colon cancer that was published 
after the 2004 meta-analysis295,296. The increase in cardiovascular risk may be greater 
with rofecoxib doses above 25 mg/day 297-299. 
In summary, all of the coxibs appear to have potential cardiovascular risk that may be 
dose-dependent300. The magnitude of the risk may differ between agents. As an 
example, a retrospective study suggested that concurrent therapy with low dose 
aspirin may have mitigated the risk of myocardial infarction associated with use of low 
dose rofecoxib but not for doses higher than 25 mg/day301. The issue of concomitant 
aspirin use was also addressed in the TARGET trial but the number of events was too 
small to have confidence in the results302.  
Furthermore, data from the Cancer Prevention Study II Nutrition Cohort (n = 146,000), 
with 18,000 cancers diagnosed during a ten year follow-up period, found that the 
overall cancer incidence in men was lower for those who took ≥325 mg aspirin daily 
for at least five years compared to no aspirin use; cancer incidence in women was 
lower, but the difference was not statistically significant303. In addition to colorectal 
cancer, longterm aspirin use was associated with a lower incidence of prostate cancer 
(RR 0.81, 95% CI 0.7-0.94) and a trend to lower incidence in breast cancer (RR 0.83, 
0.63-1.10). 
Several theories have been proposed for why aspirin and other NSAIDs are effective 
in reducing colorectal cancer risk, and possibly effective for other cancers. These 
medications may cause cell cycle arrest or apoptosis (programmed cell death) of 
abnormal cells. Reduced risk may also relate to irreversible inhibition of 
cyclooxygenase-2. Inhibition of this enzyme decreases the synthesis of 
prostaglandins, which may inhibit tumor growth. Finally, aspirin may influence 
intracellular signaling through inhibition of phospholipase activity. 
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Chemoprevention may be helpful in high risk patients but risks and benefits should be 
weighed carefully. Aspirin and NSAIDs may offer protection against oesophageal 
cancer, but are may not be recommended for routine use in average risk patients. 
Thus the adverse effect of Coxibs on cardiovascular disease highlights the challenge 
of balancing risks and benefits in chemoprevention for cancer. The result of our case 
control study highlights the significant links between the use of NSAIDs and drugs 
which relax the LOS. Efforts should be directed at identifying naturally occurring 
compounds with COX-2 enzyme blocking and anti oxidant properties to help reduce 
the risks posed by synthetic medications.  Deeks and colleagues report the findings of 
a systematic review and meta-analysis of randomised trials comparing celecoxib with 
a traditional NSAID or placebo304. They identified nine trials including 15172 patients 
with osteoarthritis and rheumatoid arthritis, in which celecoxib was compared with at 
least one NSAID (diclofenac, naproxen, or ibuprofen) or with a placebo (five trials). 
CLASS contributed over half of the patients analysed. They found equivalent efficacy 
between celecoxib and the comparator NSAIDs, but significantly greater tolerability, in 
terms of withdrawals from studies as a result of gastrointestinal adverse effects, with 
celecoxib and a lower incidence of upper gastrointestinal complications, including 
symptomatic ulcers, perforation and haemorrhage. These results seem also to apply 
to the subgroup of patients taking low dose aspirin as antithrombotic prophylaxis. 
However this study was not able to examine longer term sequelae, did not comment 
on deaths, and did not analyse cardiovascular events. Thus there is evidence  about 
the usefulness of Coxibs and future research should involve minimal risk of harm to 
the subjects and the amount of benefits must clearly outweighs the amount of risk 
thus making a point for evaluating a risk/benefit ratio for chemoprevention for 
individual cases. 
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Also prospective cohort studies have demonstrated only a weak association between 
fruit and vegetable intake and cancer risk305,306. In a large cohort study (n = 136,089) 
with 937 incident cases of colon cancer, no association was seen between either total 
or specific category of fruit and vegetable intake and colon cancer risk296. A pooled 
analysis of fourteen cohort studies (n >750,000), including the previous study, found 
that eating more than 800 g fruit and vegetables daily, compared to less than 200 g, 
decreased risk for distal colon cancer (RR 0.74) but not for proximal cancer307,308.  
However with regards to oesophageal cancer, Cheng & Day, in a systematic review of 
ecologic, case-control, cohort, and intervention studies in 1996 concluded that fruits 
and vegetables have a protective effect on SCC as compared to OAC309. Recently, 
Freedman and collegues also  found a significant inverse association between total 
fruit and vegetable intake and SCC risk (HR: 0.78, 95% CI: 0.67-0.91), but not OAC 
risk (0.98, 0.90-1.08)310. This may have several further implications. We may need to 
narrow down research, asking questions about specific fruits and vegetables after 
identifying the ones with high contents of anti cancer chemicals. Also formulating or 
modifying a FFQ to study dietary intake of naturally occurring cox 2 inhibitors may 
provide a better link between natural compounds and cancer. 
Hence, there is a scope for further research, especially developing coxibs with less or 
no cardiovascular side effects. There may be scope to identify more potential 
naturally occurring coxibs, validating their dietary intake with use of an appropriate 
dietary tools. This may include modifying existing applications or formation of new 
ones.  
With the evidence available from my studies, it would be possible to develop further 
studies directed towards identifying characteristics of subgroups that might most 
benefit from NSAIDs with out adverse effects. Also development of cardioprotection 
with use of NSAIDs may be another area that needs to be focused on to translate 
laboratory discoveries into clinical trials and to develop consensus protocols. Also it 
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would be worth conducting case control studies looking into effects of fruits and 
vegetables rich in cox 2 inhibitors like quercetin and antioxidants like naringenin on 
different cancers including oesophageal cancer. 
 
Finally it may also be possible to conduct prospective studies from populations using 
dietary assessment tools like FFQ may be focussed with estimation of different 
flavonoid intake, focusing on effect-modifying and confounding factors, such as 
dietary patterns and lifestyle, until further evidence is available about the role of 
flavonoids in the chemoprevention of oesophageal and other cancers. 
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16.0. Appendices: 
Appendix 1: Case Control Study Protocol 
SUMMARY: 
The incidence of oesophageal cancer is increasing and is associated with a 
poor survival rate of less than 5 % at 5 years. This has lead to increasing efforts to 
identify potential chemo-preventive agents. There is limited evidence that aspirin and 
non-steroidal anti-inflammatory drugs are protective in a dose dependent manner. 
However, there are no studies of adequate power to compare the potential protective 
affects of aspirin and cyclo-oxygenase inhibitors, specifically cyclo-oxygenase-2 drugs 
in a UK population using multiple methods for patient identification. This investigation 
will measure the incidence of oesophageal cancer in Norfolk and the data acquired 
will be used to plan future aetiological investigations. It will facilitate the calculation of 
the population size and monitoring period required for subsequent aetiological case-
control studies. Patient’s records from individuals who have been diagnosed with 
oesophageal cancer will be reviewed to determine both the frequency and the use of 
aspirin and cyclo-oxygenase inhibitor drugs, including selective COX-2 blockers. 
These data will be compared with the use of the same drugs in a control group of 
patients selected from dermatology clinics, to determine if there is a protective effect. 
Demonstration of such an effect would suggest a preventive strategy for oesophageal 
cancer in both the general population and in high risk groups. 
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 AIMS : 
 
1. To measure incidence of oesophageal cancer in Norfolk between 1st  April 
1995 and December 31st 2004. 
 
2. To determine if aspirin and cyclo-oxygenase-2 inhibitor drugs protect against 
the development of oesophageal cancer in a case-control study. 
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INTRODUCTION : 
Great Britain has one of the highest incidences of oesophageal cancer in 
Europe, with approximately 7,000 new cases been diagnosed annually (1). The overall 
incidence is rising with a two fold increase in Scotland in the last 8 years rising from 
8/100,000 cases/year to 15/100,000 cases/year(2),. The disease is commoner in men 
than women and incidence increases with age. Furthermore, the highest incidence of 
oesophageal cancer in the world in women is in United Kingdom(3). The prognosis for 
patients with oesophageal cancer is poor with an overall 5 year survival of less then 
5%, primarily because most patients present with advanced disease. 
Clinical and epidemiological studies have reported a change in the  two main 
histological types of oesophageal cancer i.e. squamous cell carcinoma and 
adenocarcinoma(4). Thirty years ago squamous cell cancer was commoner then 
adenocarcinoma but now this trend is reversed(5). Also a greater number of gastric 
tumours are being diagnosed at the cardia and gastro-oesophageal junction 
compared to the distal stomach(6). The reasons for these shifts in anatomical and 
histological pattern are currently unknown. 
The well demonstrated risk factors for squamous cell cancer are tobacco and 
alcohol, each increasing the risk by 2-3 fold(7). In the case of adenocarcinoma noted 
factors are obesity, a history of gastro oesophageal reflux disease and dietary 
deficiencies such as lack of fruits and vegetables are potential risk factors. Barrett’s 
oesophagus is a recognised pre-malignant condition for adenocarcinoma, increasing 
the risk by 50 times(8,9).   
Potential protective factors for oesophageal cancer are both aspirin and 
nonsteroidal anti-inflammatory drugs (NSAIDs) with two studies from the UK showing 
a protective effect of 40 %( 7, 11). However, these studies had several limitations 
including being restricted only to women, small patient numbers and lack of 
differentiation between aspirin and selective cyclo-oxygenase-2 and all COX 
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inhibitors. NSAIDs are currently classed as either COX enzyme inhibitors which block 
both the COX I & 2 subtypes of enzymes or COX 2 inhibitors which are specific for 
this form of the enzyme. Furthermore, the potential effects of selective cyclo-
oxygenase-2 inhibitors were not investigated in the two studies cited above (7,10).  
The potential protective effects of NSAIDs are supported by plausible biological 
mechanisms. The cyclo-oxygenase 2 enzyme is over expressed in oesophageal 
cancer tissue and Barrett’s oesophagus, leading to an excess production of 
prostaglandins(9). This over expression firstly prevents apoptosis, the process of 
programmed cell death and secondly induces angiogenesis, both of which promote 
neoplastic changes. COX-2 inhibitors have been shown to reduce cellular proliferation 
in Barrett’s cell lines(11) and can reduce the risk of oesophageal adenocarcinoma 
induced by reflux in a rat model(10). Furthermore, NSAIDs decrease the risk of 
development of Barrett’s oesophagus by reducing the inflammatory response 
associated with intestinal metaplasia(12). Finally cyclo-oxygenase-2 selective inhibitors 
suppress mitogen or growth factor induced prostaglandin production and inflammation 
thus reducing cellular proliferation and oxidative damage from free radicals (13). The 
potential protective effect of NSAIDs are thus mediated by the promotion of apoptosis 
via a reduction in PGE2 production and elevation of arachdonic acid levels(14) . 
The incidence and case-control studies proposed here will have several 
advantages over previous work. Firstly multiple databases will be used to identify 
patients with oesophageal cancer, including pathology records, discharge data and 
endoscopy databases. The case control study has been designed to achieve 
adequate power, include both men and women and to also specifically investigate 
selective cyclo-oxygenase-2 inhibitors. Demonstrating a positive association between 
the use of NSAIDs and a reduced rate of oesophageal cancer would suggest a 
preventive strategy for managing the progression of Barrett’s oesophagus to cancer 
and help to evaluate the mechanism of carcinogenesis. The incidence study will 
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generate invaluable data for planning future case-control studies to investigate the 
effect of diet in the aetiology of oesophageal cancer. 
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METHODS:  
 
A) An incidence study of oesophageal cancer in Norfolk and a cross - 
    sectional analysis of aspirin and NSAID use in patients. 
 
i. Disease definition: All primary malignant neoplasm’s of the oesophagus 
and cardia diagnosed between 1st April 1995 and 31st  December 2004 will 
be included using the International Classification of Diseases -10 codes. 
These codes are : 
 C15.0 : Cervical part of oesophagus 
 C15.1 : Thoracic part of oesophagus 
 C15.2 : Abdominal part of oesophagus 
 C15.3 : Upper part of oesophagus 
 C15.4 : Middle part of oesophagus 
 C15.5 : Lower part of oesophagus 
 C15.8 : Overlapping lesion of oesophagus 
 C16.0 : Cardia : 
 Cardiac orifice 
 Cardio-oesophageal junction 
 Gastro-oesophageal junction 
 Oesophagus and stomach 
            These neoplasm’s will be divided into squamous cell carcinoma and  
            adenocarcinoma and include patients who have received either  
            surgical or palliative treatment. 
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ii.  Patient identification: The data will be collected by a retrospective review 
of hospital notes of patients identified from pathology databases, 
endoscopy databases and hospital discharge records. The use of these 
multiple sources will improve the inclusion rate of appropriate patients. 
Information will be collected regarding the site of tumour, histology, 
treatment, outcomes and use of medication.  
iii. Study population: The study population will comprise both men and 
women in the postal region of Norfolk. Details of the structure of this 
population approximately 500,000 people will be obtained from the 2001 
census. Patients living in this region may present to one of the three 
hospitals: The Norfolk & Norwich University Hospital NHS Trust; Norwich; 
The Queen Elizabeth II Hospital, King’s Lynn and The James Paget 
Hospital, Great Yarmouth. Clinicians in each hospital will be approached for 
permission to review patient notes. 
iv.  Data collection: Demographic and clinical data on drugs, illnesses and 
surgical management for each proven case will be collected on a standard 
data collection form (Appendix - 1) and anonymised. The data on drug type, 
frequency of administration and dosage and the illnesses will be 
ascertained from the general practitioner referral letter, medical admission 
notes and nursing records. Drugs use will be subdivided into regular (daily) 
use and non-regular (less than daily) use. Data on the consumption of 
alcohol, smoking, past history of Barrett`s will be collected. 
The incidence study will also allow us to describe the surgical 
management of the patients. These data will include the clinical 
presentation of the patient, type of surgical management, the ASA 
anaesthetic grading of the patient’s fitness for surgery and outcome. The 
aim of collecting these data will be to identify what is current practice in the 
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surgical management of oesophageal cancer, including the outcome of the 
different types of surgical procedures. The study does not aim to examine 
or judge the management of individual cases but to identify trends in clinical 
management and patient outcomes. All patient and hospital information will 
be anonymised and kept strictly confidential. 
v. Analysis: The mean crude incidence per 100 000 per annum in Norfolk will 
be calculated with 95% confidence intervals. A gender adjusted rate will be 
computed correcting for differences in age structures between men and 
women. By using population data from the 2001 census, age and sex 
specific case fatality rates will be calculated as well as the total number of 
expected cases in the UK based on the incidence rate in Norfolk. 
vi. Approach :  Permission will be requested  from all Consultants who have 
treated patients in the study, Hospital Research & Development Committee 
and relevant Ethics Committee to review the medical notes.  
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B ) A Case control study to determine if aspirin and cyclo-oxygenase 
inhibitors including specific COX-2 inhibitors  protect against the 
development of oesophageal cancer.   
 
i. Subject recruitment: Cases will be identified and confirmed by the methods 
described in the incidence study above. Cases in which there is either no histological 
confirmation of cancer or in which a diagnosis is suspected but there are no 
confirmatory investigations will be excluded. The number of such patients should be 
small.  Dermatology patients will form the control group with 4 controls matched to 
each case for gender, age (+/-1year) and year of diagnosis. Data will be collected on 
controls by reviewing the notes of the dermatology patients, under the care of 
dermatologists and plastic surgeons, who have undergone a minor day case 
procedure for non-melanotic skin tumours. Patients with non-melanotic skin tumours 
will be identified as per the ICD 10 criteria. This control group has been selected as 
their use of NSAIDs should be similar to that in the general population. Any control 
who has a past history of oesophageal cancer will be excluded. Data will be collected 
on the dosage & frequency of use of NSAIDs and potential confounding factors 
including smoking and alcohol (Appendix - 2). This information will be obtained from 
the general practitioner’s referral letters and hospital medical and nursing records. 
 
ii. Analysis: Crude odds ratios will be calculated using conditional logistic regression 
and adjusted for the effects of smoking and alcohol. Power calculations show that 411 
cases are required matched with 4 controls per case to show a protective effect of 
NSAIDs of 0.5 with 80 % power at a 5 % significance level. 
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Data Collection Sheet A: (Case Group)               Appendix-1              
 
 
 
 
Dermographic Data :  
 
 
Code : 
 
 
 
1. Name 
 
2. Date of Birth  
 
3. Age on admission 
 
4. Hospital No. 
 
5. Study Identifier  
 
6. Postcode   (e.g. NR=1) 
 
7. Hospital  
            (Norwich=1; Gr Yarmouth=2; Kings 
Lynn=3) 
 
8. Gender  (Male=1; Female=2) 
 
9. Ethnic Group  
            (Caucasian=1; Asian=2; Afro-
Caribbean=3;  
                Other=4) 
_______________________________________ 
 
Risk Factors 
 
1. Smoking 
(No=0;  Ex smoker=1;  Current smoker=2) 
 
2. Number of cigarettes/day 
                    
3. Alcohol  
(No=0;  Ex alcohol=1;  Current alcohol=2) 
 
4. Amount of alcohol (units/week) 
 
5. Known Barrett’s 
            (No=0;  Yes=1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
 
 
Patient Label 
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6. Length of Barrett’s 
(0-3cms=1;  >3cms=2) 
 
7. Actual length in cms  
 
8. Previous endoscopic  histology 
(Normal=0;  Mild Dysplasia=1; Moderate 
Dysplasia=2; Severe Dysplasia=3) 
 
9. Time between diagnosis of dysplasia and 
diagnosis of cancer 
 
10. Time between first diagnosis of Barrett’s 
and cancer diagnosis in years. 
_______________________________________ 
 
Previous Investigations: 
 
1. Have had previous Endoscopy  
(No=0;  Yes=1) 
 
2. If Yes, Date : dd/mm/yyyy 
 
3. Macroscopic findings of last endoscopy 
(Normal=0;Barrett`s=1;Achalasia=2) 
                
4. Time between last gastroscopy and 
diagnosis of cancer 
 
Current Investigations: 
 
1. Tumour Site (From mouth in cms) 
 
2. Present histology 
              (Adenoca=1,Squamous=2) 
 
3. Degree of differentiation 
               (Mild=1;  moderate=2;  severe=3) 
 
4. Radiological Investigation 
(CT=1;  Barium=2; EUS=3) 
 
5. Disease code ( ICD ) 
            (C15.0=1;15.1=2;15.2=3;15.3=4;15.4=5;      
             15.5=6, C16.0=7) 
 
6. Preoperative Staging 
T1= 1, T2= 2,T3= 3, T4= 4 
N1= 1, N2= 2, N3= 3, N4= 4 
            M0= 1, M1= 1 
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Treatment 
 
1. ASA Grading 
( I=1, II= 2, III= 3, IV= 4) 
2. Treatment 
(Surgery=1;  Palliation=2) 
 
3. Surgery 
(Ivor-Levis=1; Trans-hiatial=2; Lt Thoraco-
abd; Other=3) 
 
4. Histological Staging  
T1= 1, T2= 2, T3= 3, T4= 4 
N1= 1, N2= 2, N3= 3, N4= 4 
            M0= 1, M1= 1 
 
 
Prognosis 
 
1. 30 Day Mortality 
( Alive= 1, Dead= 2) 
 
2. Cause of Death ( 30 day period ) 
( Anastomotic leak= 1, DVT/PE= 2, MI= 3, 
Stroke= 4, Resp infection= 5, Aspiration=6, 
Other= 7) 
 
3. Length of hospital stay in days 
 
4. Five year survival post diagnosis 
(Not relevant= 0, No= 1, Yes= 2) 
  
5. Five year survival in years 
 
6. Patient Died  
            (Due to Ca=1; Not due to Ca=2.; 
Survived=3) 
 
7. Cause of Death 
       ( Recurrence= 1, Other=2) 
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Drug History 
 
Drugs on Admission             Dose      Frequency 
 (No=1; Yes=2) 
 
i. Aspirin 
 
ii. Steroids 
 
iii. All NSAIDs  
                   (Excluding aspirin) 
 
iv. COX-2 specific inhibitors 
(No=1, Yes=2) 
 
v. Ca++ channel blockers 
(Any= 1, Short acting= 2, 
 Long acting=3) 
 
vi. Salbutamol 
 
vii. Theophylline 
 
    
Other illnesses on admission  
 
(No=1; Yes=2) 
 
i. Rheumatological 
 
ii. Orthopaedic 
 
iii. Other malignancy 
 
iv. Gastrointestinal 
 
v. Cardiac 
 
vi. Respiratory 
 
vii. Endocrine 
 
viii. Renal 
 
ix. Neurological 
 
x. Psychiatric 
 
xi. Renal 
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Data Collection Sheet B: (Control Group)                           Appendix-2              
 
 
 
 
 
Dermographic Data :  
 
 
Code:  
 
 
 
 
1. Name 
 
2. Date of Birth  
 
3. Age on admission 
 
4. Hospital No. 
 
5. Study Identifier  
 
6. Postcode   (e.g. NR=1) 
 
7. Hospital  
            (Norwich=1; Gr Yarmouth=2; King’s 
Lynn=3) 
 
8. Gender  (Male=1; Female=2) 
 
9. Ethnic Group  
            (Caucasian=1; Asian=2; Afro-
Caribbean=3;  
              Other=4) 
 
_______________________________________ 
 
Risk Factors 
 
1. Smoking 
(No=0;  Ex smoker=1;  Current smoker=2) 
 
2. Number of cigarettes/day 
                    
3. Alcohol  
(No=0;  Ex alcohol=1;  Current alcohol=2) 
 
4. Amount of alcohol (units/week) 
 
5. Known Barrett’s 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
 
 
 
Patient Label 
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            (No=0;  Yes=1) 
 
6. Length of Barrett’s 
(0-3cms=1;  >3cms=2) 
 
7. Actual length in cms  
 
8. Endoscopic  histology 
(Normal=0;  Mild Dysplasia=1; Moderate 
Dysplasia=2; Severe Dysplasia=3) 
 
_________________________________ 
 
Previous Investigations: 
 
1. Have had previous Endoscopy  
(No=0;  Yes=1) 
 
2. If Yes, Date : dd/mm/yyyy 
 
3. Macroscopic findings of endoscopy 
(Normal=0;Barrett`s=1;Achalasia=2) 
 
4. Time between endoscopy & diagnosis of 
skin tumours. 
                
 
Current Investigations: 
 
1. Diagnosis  
(BCC=1; SCC=2) 
 
2. Disease code ( ICD ) 
            (C44.0=1;44.1=2; C44.2=3; C44.3=4;  
             C44.4=5; C44.5=6; C 44.6=7; C44.7=8  
             C44.8=9;C44.9=10) 
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Drug History 
 
Drugs on Admission           Y/N   Dose    
 Frequency 
 (No=1; Yes=2) 
 
i. Aspirin 
 
ii. Steroids 
 
iii. All NSAIDs  
            (Excluding aspirin) 
 
iv. COX-2 specific inhibitors 
            (Rofecoxib=1, Celecoxib=2) 
 
v. Ca++ channel blockers 
            (Any= 1, Short acting= 2, 
            Long acting=3) 
 
vi. Salbutamol 
 
vii. Theophylline 
 
Other illnesses on admission  
 
(No=1; Yes=2) 
 
i. Rheumatological 
 
ii. Orthopaedic 
 
iii. Other malignancy 
 
iv. Gastrointestinal 
 
v. Cardiac 
 
vi. Respiratory 
 
vii. Endocrine 
 
viii. Renal 
 
ix. Neurological 
 
x. Psychiatric 
 
xi. Renal 
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Appendix 2: Flavonoid Study Protocol: 
SUMMARY: 
 Dietary flavonoids may protect against the development of cancers of the 
gastro-intestinal tract. There is epidemiological evidence that antioxidants have a 
protective effect of up to 40-50 % against oesophageal cancer. Flavonoids are found 
ubiquitously in the diet and have potential anticarcinogenic properties including 
antioxidant, cyclo-oxygenase & lipo-oxygenase enzyme inhibiting action. They are 
present mainly in citrus fruits, vegetables, tea, and wine. Quercetin is the most 
commonly studied flavonoid and is easily detectable in the urine up to 24 hrs after 
ingestion.  Food frequency questionnaires (FFQ) are used to measure habitual diet 
over a specified time period. However, currently there are limited studies, which have 
correlated a FFQ on fruits and vegetable intake against urinary flavonoids. A suitable 
FFQ for total dietary flavonoid intake as measured against urinary markers in a United 
Kingdom population is required. In this study, subjects will complete one  FFQ`s and 
provide up to five 24 hour urinary samples to measure the flavonoid excretion for 
which a correlation coefficient will be calculated for dietary intake against urinary 
excretion. This exercise will be repeated at an interval of 3-4 months to check its 
reproducibility. This FFQ could then be used in case-control studies investigating if 
dietary flavonoids protect against cancer such as oesophageal cancer. 
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AIM:  
 To correlate a food frequency questionnaire measuring flavonoid intake against 
the urinary excretion of these compounds.  As previous work from animal models and 
cellular studies has shown that flavonoids may protect against development of 
oesophageal cancer, this particular tumour will be discussed in detail.  The aim would 
be to use such a FFQ in a case-control study investigating if flavonoids protect 
against the development of oesophageal cancer.  
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INTRODUCTION: 
OESOPHAGEAL CANCER:  
i) Epidemiology: Oesophageal cancer is the 9th commonest cancer in adults in the 
United Kingdom and the 5th most common cause of death from cancer. The UK has 
the highest incidence of oesophageal cancer in women in the world and it is rising. 
The neoplasm is commonest above the age of 50 years with a Male: Female ratio of 
4:3. Furthermore the incidence of oesophageal cancer is higher in whites than in 
blacks with a ratio of approximately 5:1 ratio.  
ii) Clinical Aspect: There are two histological types of oesophageal cancers, namely 
adenocarcinoma and squamous cell carcinoma. During the last century there were 
changes over time in the histological type & tumour site. Before the mid 70’s 
adenocarcinoma accounted for less than 5 % of oesophageal cancer, but by the 
1990’s it has increased to greater than 25 % in several countries including the USA, 
Australia and Sweden. In the 1990’s adenocarcinoma changed from being a rare 
neoplasm to becoming more common than squamous carcinoma of the oesophagus 
in the USA. The overall survival of patients with oesophageal cancer is only 5 % in the 
UK, with only a worse prognosis in those with lung and pancreatic cancer. 
iii) Risk Factors: Major risk factors for squamous cell carcinoma of the oesophageal 
cancer are tobacco & alcohol, others include exposure to hot beverages & dietary 
deficiencies. For adenocarcinoma, obesity, smoking, diet lacking in fruits & 
vegetables have been identified. The risk of adenocarcinoma of the oesophagus and 
gastric cardia persists, however for nearly 30 years after cessation of smoking. A 
Barrett’s segment of greater than 3 cms, increases the risk of oesophageal cancer in 
the normal population by 30-125 times. Also the presence of a high grade dysplasia, 
large hiatus hernia and Barrett’s ulcer are recognised precursors for the development 
of oesophageal cancer.   
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iv) Mechanism of Carcinogenesis: All the above risk factors lead to metaplastic 
changes in the oesophageal mucosa by a synergistic action of acid, pepsin and 
development of gastro-oesophageal reflux. Although the oesophagus-metaplasia-
dysplasia-carcinoma sequence is clear, molecular mechanisms leading to the genetic 
changes & adenocarcinoma are poorly defined. In oesophageal cancer & Barrett’s 
oesophagus, oxidative stress may induce malignant transformation of cells.  
 
Figure 1 
 
 
Oxidative Stress (OS) is a harmful condition that occurs when there is excess 
of free radicals, a decrease in antioxidant levels, or both. Oxidative stress may 
possibly be because of excess free radicals which are increased in reflux disease. 
Oxidative stress has been suggested as being the driving force for the development 
of adenocarcinoma. Reactive oxygen species (ROS), such as free radicals and 
peroxides, are a class of molecules that are derived from the metabolism of oxygen 
and exist inherently in all aerobic organisms. There are many different sources by 
which the reactive oxygen species are generated. Most reactive oxygen species 
come from endogenous sources as by-products of normal metabolic reactions28. 
These include energy generation from mitochondria or the detoxification reactions 
involving the liver cytochrome P-450 enzyme system. Exogenous production of ROS 
may follow exposure to cigarette smoke, environmental pollutants such as emission 
from automobiles and industries, alcohol excess, asbestos, ionizing radiation, and 
bacterial, fungal or viral infections. 
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MECHANISM OF ROS INDUCED DAMAGE 
 
FIGURE 2:Production of ROS 
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 Free radicals such as superoxide and hydroxyl radicals can cause injury to 
cells by damaging proteins, cell membranes or DNA. Deficiency in antioxidant 
defence mechanisms further amplifies oxidative stress and tissue injury.  Oxidative 
stress induces the formation of high levels of DNA adducts which have been 
discovered in Barrett’s epithelium. These DNA adducts can interfere with DNA 
replication and therefore initiate mutagenic & carcinogenic processes by producing 
mispaired DNA sequences.  
  Recently anti-oxidants have been shown to be inversely associated with risk 
factors for oesophageal cancer. Examples of antioxidants are ascorbic acid, beta-
carotene & alpha-tocopherol. In rats, reflux-related oesophageal mucosal damage 
and lipid peroxidation may be reduced by antioxidants. A Swedish case-control study 
found an epidemiological association of higher intake of antioxidants and decreased 
risk for oesophageal cancer. They studied intakes of Vitamin C, beta-carotene and 
alpha-tocopherol in a nationwide population- based, case-control study and found that 
subjects with high intake of these antioxidants showed a 40-50 % decreased risk of 
both histological types of oesophageal cancer as compared to subjects with a low 
intake. Mechanism of action of flavonoids, which have antioxidant properties, will be 
discussed in the following section. 
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FLAVONOIDS:  
Introduction : Flavonoids, previously known as “Vitamin P”, are water soluble plant 
pigments. They are polyphenolic compounds found in abundance in the human diet. 
There are more than 4000 naturally occurring flavonoid compounds with 3 major 
subclasses namely, Flavonols, Flavones & Flavanols. Major flavonols are quercetin, 
kaempferol, myricetin and isorhamnetin and are found for example in onions, broccoli 
and lettuce. The most abundant flavones are luteolin and apigenin and are found in 
celery, sweet pepper and citrus fruit. The principle flavanols are catechin, epicatechin, 
gallocatechin, epigallocatechin & gallic acid esters found in citrus fruits, chocolates, 
tea and wine. The presence of flavonoids in plants depends on several factors 
including the degree of ripeness, variety, processing and storage.  
 Previous case-control studies have shown that a high intake of fruits 
and vegetables protect against several cancers including oesophageal cancer, which 
may be due to their high flavonoid content. 
Mechanism of Action: There are several plausible biological mechanisms for the 
protective effects of flavonoids as they posses antioxidant, antiplatelet, anti-
inflammatory, anti-artherogenic, immunomodulator and anti-carcinogenic activities. 
There is some evidence that they also exhibit cycloxygenase & lipoxygenase enzyme 
inhibitor properties. Cyclo-oxyxygenase enzyme is found in high concentration in 
neoplastic tissue and recent evidence suggests that cycloxygenase inhibitor drugs, 
namely NSAID’s may reduce the incidence of oesophageal cancer by 40%. 
Flavonoids have antioxidant properties, including preventing the degradation of 
Vitamin E, scavenging reactive nitrogen species and ROS, chelating metallic ions like 
Fe3+,Cu2+ involved in free radical production. These properties reduce oxidative stress 
and a number of other of biological functions which may protect against cancer and 
other diseases. 
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Epidemiological Studies: Previous epidemiological studies have found that people 
with a high intake of food containing quercetin and other flavonoids tend to have a 
lower incidence of lung cancer. Preliminary studies from the Mayo clinic suggest that 
they may help prevent or treat prostate cancer by blocking male hormones. In vitro 
studies have found that flavonoids inhibit breast cancer cell proliferation, delay 
mammary tumorigenesis and have anti proliferative properties towards human colon 
cancer cells. However no epidemiological studies have specifically assessed whether 
dietary flavonoids reduce the risk of oesophageal cancer.  
Metabolism: Flavonol glycosides can be absorbed as intact molecules and absorption 
varies according to food source. High performance liquid chromatography can 
achieve a detection limit of about 50ng/ml plasma. In humans only, data on the 
bioavailability of flavonols are available. Quercetin reaches a peak in the plasma 20 
minutes after absorption (range 0.5-9 hours).  Urinary elimination of quercetin is slow 
and may take up to 24hrs. However flavanols are rapidly excreted, with elimination 
half lives of only 1-6hrs. 
 A Finnish study has shown that urinary flavonoids can be used as a  biomarker 
of dietary fruit and vegetable intake with a correlation co-efficient of 0.35, p < 0.005. 
However, this questionnaire could not be used to estimate  the total dietary intake of 
flavonoid.  Research is therefore needed to correlate a food frequency questionnaire 
which measures dietary intake of flavonoids against a urinary biomarker.  
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FOOD FREQUENCY QUESTIONNAIRES:    
A food frequency questionnaire (FFQ’s) measures habitual diet over a period 
of time e.g. over the preceding year. They describe one’s usual frequency of food 
consumption rather than specific meals. A comprehensive assessment of diet is 
necessary which allows a calculation of macro & micro nutrients in individuals. Levels 
of intake can then be divided into categories such as high, medium and low intake. A 
number of factors affect the accuracy & compliance of a food frequency questionnaire 
namely length, number of food items, frequency of intake and portion size. Filling in a 
lengthy FFQ can lead to fatigue & boredom thus impairing concentration & accuracy. 
This is true even for a highly motivated cohort as demonstrated by Willett in the 
United States of America cohort study which studied US nurses. 
 In a FFQ food list should be comprehensive, include all foods which contribute 
to the nutrient of interest and should also be able to detect between person variations 
in intake. The foods which contribute most to between person variation, and are 
therefore the most discriminatory can be calculated statistically by stepwise 
regression. This process may lead to fewer questions in the FFQ, but which still 
discriminate between individual’s intakes. As intake of food is seasonal, food 
frequencies are usually described by subjects referring to their diet over the entire 
previous year. A standard approach is to give subjects a choice of frequency options 
ranging from never to intake of many times/day e.g. 6 times/day. Defining the options 
increases clarity and reduces errors compared with open-ended responses where 
subjects self- report their frequency intake. 
 Controversy exists over the inclusion of portion sizes in FFQ's, which can be 
achieved by giving descriptive examples or including photographs of different portion 
sizes63. Food items with natural units may be interpreted correctly e.g. a glass of milk, 
however, portion sizes with-out natural units e.g. a portion of vegetables can be 
difficult to describe by subjects. Providing ranges of serving sizes e.g. ¼  cup or ½ 
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cup improves clarity as compared to small, medium & large portions63. Existing FFQ's 
can be used to measure individual diets and extra questions added if particular 
nutrients are required to be studied. Borrud found that although the frequency 
distributions of food used by ethnic subgroups differ, a comprehensive FFQ may 
function well in a diverse population.         
In this study, we aim to develop a FFQ to specifically measure flavonoid intake 
by modifying an existing questionnaire developed at the Institute of Food Research, 
Norwich. This existing FFQ measures the intake of basic macro & micro nutrients. 
The questionnaire will be assessed to see if it can be shortened to increase 
compliance, whilst still be able to differentiate between in take. Secondly it will be 
reviewed to see if portion size adds to the dietary assessment. This modified FFQ will 
then be correlated against urinary flavonoids, which are a biomarker of dietary intake. 
The FFQ will then be used in future case-control studies to assess if flavonoids 
protect against gastro-intestinal malignancies. 
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Objectives  
 To asses whether the dietary intake of flavonoids correlates with their urinary 
excretion. 
 
Hypothesis  
 Dietary intake of flavonoids may prevent against malignancies such as 
oesophageal cancer.  Once a food frequency questionnaire is correlated against the 
urinary biomarkers, it will then be used to study whether a higher intake of flavonoids, 
as recorded by FFQ, protects against oesophageal cancer.  
 
STUDY DESIGN 
 
Overview 
The study involves the recruitment of apparently healthy subjects via the HNU 
volunteer databank at the Institute of Food Research, Norwich, advertisement’s and 
email for recruitment of volunteers with in the Norwich Research Park (John Innes 
Institute, Institute of Food Research and University of East Anglia) and from surgical 
clinics at the Norfolk & Norwich University Hospital. 64 apparently healthy adult 
volunteers will be recruited. The study involves assessing the dietary intake of the 
volunteers by a food frequency questionnaire, collection of up to five 24 hour urine 
samples and a repeat of the whole exercise 3-4 months later to check the 
reproducibility of the results Volunteers will not be given any dietary advice as there is 
no dietary intervention in the study. A flow chart of the overall study design is given in 
Figure 1 & 2 
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Figure 1.  Study Design 
 
1.    RECRUITMENT 
via HNU database, NRP 
advert, N & N Clinics 
4. HNU APPOINTMENT 
 5 x 24 hr Urine Sample 
collection container 
 One FFQ 
SAMPLES 
Refer to figure 2 
 
6.  Analysis at IFR 
 
7. FLAVONOID INTAKE ASSESSMENT 
 Statistical calculation of dietary intake of Flavonoids 
8. Correlation coefficient 
calculated comparing 
intake of flavonoids and 
their urinary excretion 
 
 
SAMPLES 
Refer to figure 2 
9. FOLLOW-UP 
Repeat steps 5 to 8,  3-4 months later 
 
 
 Food Frequency 
Questionnaire analysis  
 
 Urinary specimen 
analysis for flavonoid 
excretion 
 
2. INITIAL INTERVIEW  
 3 day consideration 
period  
3.   CONSENT &  HNU 
SCREENING 
5 Collection of Urine 
samples & completion of 
FFQ.    
  
 
188 
Figure 2: Plan of Urine Sample collection and analysis
Collection & Samples & 
Storage 
at  IFR 
 Endpoint  
 Determination of  quercetin and 
naringenin concentrations in urine 
SAMPLES 
5 x Urinary Samples 
3 on weekdays ( Mon-Thurs)  
Two on Sunday`s 
Measuring 
Flavonoids 
 HPLC machine 
 20ml urinary 
specimen 
 Faeces 
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Volunteer Recruitment 
 Apparently healthy male/female volunteers will be recruited until 64 
volunteers, have completed the study. Experience has shown that the drop out rate 
for these types of studies is about 10%. It is envisaged that patients will be recruited 
onto the study at a rate of 4-5 per week and therefore recruitment may continue for 
approximately 3-4 months. If greater drop out rates occur recruitment will be 
reviewed. 
Advertisements will be placed on: the Norwich Research Park* (University of 
East Anglia (UEA), John Innes Centre (JIC), IFR), and in the HNU news letter which 
is sent to all volunteers on the HNU volunteer database  (Annex 1). Patients with 
minor surgical ailments ( e.g. groin hernia`s, cysts etc. that have no impact on dietary 
habit ), their accompanying relatives or friends who attend the Norfolk & Norwich 
University Hospital surgical clinics, will also be informed of the study, and if interested 
will be sent further information. If insufficient numbers of volunteers are recruited from 
these areas advertisements will be placed in the local press.  
Apparently healthy volunteers, who meet the basic inclusion criteria, will be 
sent a letter of invitation (Annex 2) to participate in the study.  This will be supported 
by the volunteer information sheet (Annex 3). Included will be a response slip and 
pre-paid envelope for returning the slip (Annex 4) if they are interested and wish for 
further information. The HNU databank contains names and contact details of people 
who have registered an interest in volunteering for human studies. 
Advertisements will be placed around the Norwich Research Park  (UEA, JIC 
and IFR) inviting anyone who is interested in receiving information about the study to 
contact named researchers. NRP staff will also be invited to participate in the study by 
email by seeking adequate permission.  The researchers will send interested 
responders the volunteer information sheet. This will include a response slip and pre-
paid envelope in which to return the response slip if they are further interested.  
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Patients with minor surgical/medical conditions, not affecting their diet or ability 
to give up to five 24 hour urine samples, if fitting the inclusion criteria, will be invited to 
participate in the study. Healthy relatives or friends accompanying them will also be 
invited to participate in the study. If they show an interest to participate in the study, 
further details in the form of patient information sheet will be sent to them. 
Following an expression of interest volunteers will be invited to the Human 
Nutrition Unit (HNU) for a preliminary interview and given further details of the study. 
The volunteers will be encouraged to ask questions at this point prior to making any 
commitment. At the end of the interview all volunteers will be given a minimum of 72 
hours to consider whether they wish to participate in the study. They will also be given 
a small sterile container to take away with them. If they wish to participate, this 
container will be used for the urine sample on the morning of the clinical screening 
visit. If they decide they do not wish to take part in the study they will be told to 
discard the container. During this consideration period the volunteers will not be 
contacted. If, following this period of consideration, the volunteer still wishes to 
participate they will be asked to contact HNU on telephone number 01603 255305. 
All those responding positively following this period of consideration will be 
invited to attend the HNU for a clinical screening. No fasting will be required. They will 
be reminded to bring a midstream sample of urine from the first urine of the morning 
in the container provided at the first interview (This will not be tested until after the 
consent form has been signed). Volunteers need to arrive within 2 hours after 
collection of the urine sample as this is a required specification for the validity of the 
urine dipstick test. 
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Clinical screening: 
On arrival at the HNU the study scientist will go through the consent form 
(Annex 5) with the volunteer and encourage any questions they may have at this 
stage, volunteers will then be asked to sign a consent form agreeing to participate in 
the study. A copy of the signed consent form will be given to the volunteer to keep. A 
qualified nurse will then complete a basic health questionnaire (Annex 6), take and 
record blood pressure, pulse, height and weight measurements, Body Mass Index 
(BMI), perform the urine dipstick test (Combur 9  Test®, Roche Diagnostics Ltd).The 
urine results will be known immediately. If any of the results for the urine test are 
flagged the HNU protocol for abnormal urinalysis results will be referred to. If the BMI 
is <18.5 or >30 the volunteer will be excluded from the study. 
Volunteers who do not wish to be re-screened or who display screening parameters 
outside the standard reference ranges on both occasions will be excluded from the 
study. 
Copies of all clinical results will be sent to the volunteer’s GP (Annex 7) and in 
the event of flagged urine results, the volunteer will be informed verbally and advised 
to speak to their GP to discuss the results. Results will not be discussed with the 
volunteer. 
Volunteers who meet the study criteria and whose screening results are 
satisfactory will be included in the study. The GPs of those successfully recruited onto 
the study will be informed of their patient’s participation in the study by letter (Annex 
8) and will be sent copies of all clinical results. The volunteer will agree to this 
information being sent to the GP by signing the consent form.   
Once recruited onto the study, volunteers will be assigned a code number with 
only the named study scientists approved by the Ethics Committee being able to link 
codes to volunteers. All personal information will be kept confidential and known only 
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to the  Researcher’s, project leader, HNU research nurses, HNU Medical advisor and 
the volunteer’s GP. 
The inclusion and exclusion criteria are as follows:  
Basic Inclusion criteria 
 Aged 40-85 years 
 Male or female 
 Non-smoker 
 
Basic Exclusion criteria 
 Pregnant and breastfeeding 
 Organ transplant recipients ( on immunosuppressant’s can effect diet) 
 Long term illness requiring active treatment (e.g. Diabetes, cardiovascular 
disease, anaemia, cancer : may affect diet & participation in study) 
 Volunteers currently on antibiotics (ongoing infections can affect the diet) 
 
Screening Exclusion criteria 
 BMI < 18.5 or > 30 
 Abnormal urine analysis results indicative of active illness ( Refer to HNU 
protocol for abnormal Urinalysis results) 
 Results of clinical screening which are judged by the HNU Medical Advisor to 
be indicative of a health problem and could compromise the well-being of the 
volunteer if they participated, or which would affect the data. 
 Volunteers currently on antibiotics (ongoing infections can affect the diet) 
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Once the volunteer is selected through the screening process, the scientist will 
give instructions and equipment needed to prepare for the study. The study involves 
you completing a questionnaire on diet and producing up to five 24 hr urine 
collections over a period of 2 weeks including two on Sundays. 
The first phase of the study will be the collection of up to five 24 hour urinary 
sample’s. They will be asked to deposit the sample at the Human Nutrition Unit, IFR. 
The second phase of the study will be filling the food frequency questionnaire.  In the 
final phase the volunteers will be asked to repeat the whole exercise 3-4 months later. 
 
Assessment of Dietary Intake 
Diet will be assessed by a food frequency questionnaire. The volunteers will be 
asked to complete the questionnaire at home taking into account their diet over the 
period of the last year. The food frequency questionnaire (annex 9) focuses on 
habitual diet intake during the previous twelve months and allows an estimate to be 
made of the habitual intake of flavonoids from food sources. This questionnaire has 
been modified from one previously used for studies at the Institute of Food Research, 
Norwich. The FFQ takes approximately 30 minutes to complete. In addition to 
recording the habitual intake of a wide range of foods and food groups, the computer 
software used to interrogate the FFQ data will calculate the dietary intake of selected 
flavonoids e.g. quercetin, naringenin and catechins from the information supplied by 
each volunteer. 
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Sample Collection 
Up to five 24 hours urinary samples will be collected at the HNU, IFR, 
according to the plan in Figure 2. Ascorbic acid 99% crystalline Sigma Ultra 1gm in 
2.5 litres pot will be added to the urine collection pots as a preservative and the 
volunteers informed of its presence. These samples will be stored in a cold room at 
temperatures +10 C to +40C for up to a month before being processed. 
Urine Samples & Creatnine clearance : 
Volunteers will be asked to collect up to five 24 hours urine samples. These 
samples will be stored, processed and analysed at IFR. The procedure for collection 
of the urinary sample will be explained to the volunteers and they will have the 
opportunity to ask questions. Researchers at the Institute of Food Research have 
many years of experience in collecting urinary samples from volunteers and are able 
to instruct volunteers to collect samples in a safe and hygienic manner. Creatnine 
clearance will be used as a marker of compliance by determining the amount of 
creatnine in the 24h sample using a ABX Diagnostics` Creatnine 80 kit on a COBAS 
Mira Plus analyser. This kit uses the Jaff’e colorimeteric method for determining 
Creatnine in urine. ABX Diagnostics Human Control N will be run as quality control 
and inter-assay variation will be determined. 
 
SAMPLE ANALYSIS 
 The urinary samples will be analysed for the following flavonoids: quercetin, 
naringenin and catechins.  Flavonoids in the urine samples will be enzymatically 
deconjugated, extracted and quantified by HPLC (High Performance Liquid 
Chomatography ) according to the method of Du Pont et.al68. Briefly, urine samples 
(20ml) will be incubated with phosphate buffer (3ml, 0.1M, pH 6.2), internal standard 
(100µg), β- glucuronidase (200U) and sulphatase (20U) for 3 h at 370C.Menthol (2ml, 
containing 1mM ascorbic acid), acetic acid (200µl, 50%) and acetonitrile (to a final 
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volume of 40 ml) will be added to precipitate proteins and extract flavonoids. The 
samples will be vortex-mixed for 30s every 2min over a 10 min period, before 
centrifugation (13 600g, 10min, 40C). The supernatant will be evaporated. Evaporated 
samples will be taken up in menthol/water (300µ1; 1/1, v/v) and filtered for HPLC 
analysis. A new extraction procedure based on SPE  ( Solid Phase Extraction ) is 
being devised at IFR to replace the existing procedure68, and if proved to be more 
effective will be incorporated into the analysis protocol.  
 
Sample Safety 
 IFR has standard operating procedures for the storage of body fluids. These 
procedures will be adhered to and are integral to IFRs recognition as ISO 9001:2000 
compliant and constitute part of our process working to the standards of GCP. 
 
STATISTICAL ANALYSIS 
 
 Total food intake, total energy intake, macro & micronutrients, percentage of 
energy consumed will be calculated using an in-house FFQ which has been re-
designed around ACCESS software. The original FFQ from which the new version 
has been derived has been used in previous studies at IFR67, 69. The power of the 
study has been calculated at 80% assuming a group size of 64 to detect a correlation 
of 0.35 at 5% significance level. All data will be analysed using STATA 8.3SE.  The 
primary analysis will be using a Pearson's correlation coefficient to measure the 
strength of the association between dietary assessment of flavonoids and their urinary 
excretion, for both sexes combined and stratified by sex. If the distribution of the 
variables is skewed, transformed variables (such as log) will be used. A secondary 
analysis would be linear regression, regressing estimated mean dietary flavonoid 
intake on mean urinary flavonoids, adjusting for covariates such as age, sex and BMI. 
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Both the FFQ and urine results will be divided into quartiles of intake/concentrations 
and compared to check that there are no gross miscalculations between methods. 
All data will be analysed using STATA 8.3SE 
 ETHICAL CONSIDERATIONS: The project is being submitted to the Human 
Research & Governance Committee, Institute of Food Research, Norwich, East 
Norfolk & Waveney Research Governance Committee, Norwich Local Research 
Ethics Committee. 
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Appendix 3: Modified FFQ. 
 
 
 
 
 
 
“Correlation of dietary flavonoid intake by 
Food Frequency Questionnaire with 
measurement of urinary excretion of 
flavonoid metabolites” 
 
 
FOOD FREQUENCY QUESTIONNAIRE 
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Please 
1. Answer every question. 
2. Fill in the portion sizes for foods you eat & please note that the photos are of medium 
portion size. 
3. Tick only one box for portion size. 
4. Tick only one box for how often you eat a particular food. 
 
The research scientist will show you how to complete the questionnaire using the following example: 
 
 
 
 
Food category 
 
 
Size of medium 
portion 
Your 
portion 
size 
How often 
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D.  Cheese and cheese dishes 
How often do you usually eat the following? 
70 Reduced fat cheddar cheese see photograph  
13a 
 
 
 
√ 
     
√ 
  
 
The colour pictures at the back of the questionnaire show medium portions of various foods.  
In this example photograph 13a is used to decide on the size of the portion that is normally 
eaten. 
 
 
 
This example indicates that the portion of cheese eaten is of medium size in as shown in the 
photograph, and that cheese is eaten between one and three times a week. 
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Food category 
 
 
Size of medium 
portion 
Your 
portion 
size 
How often 
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A.  Meats 
Do you eat meat?  YES /NO (please delete) 
If ‘NO’ please go to section B. 
How often do you usually eat the following? 
1 Salami, Pate or similar meats see photograph 
1c 
         
2 Meat pies (e.g.pork steak & 
kidney)  
see photograph  
2a 
         
3 Sausage rolls, Cornish pasties 1 small 
 
         
4 Ham, corned beef + other cold 
meats 
see photograph 
1a 
         
5 Chicken, turkey etc. including 
minced & casseroled 
see photograph 
3b 
         
6 Lamb chops, cutlets and mince see photograph 
4b 
         
7 Leg of lamb see photograph 
3b 
         
8 Leg of pork, pork medallions, 
steaks and fillets 
see photograph 
3b  
         
9 Pork chops see photograph 
3b 
         
10 Reduced fat pork or beef  
sausages 
  1 thick 
 
         
11 Sausages, pork or beef 1 thick 
 
         
12 Beef steak - rump or sirloin see photograph 
4b 
         
13 Beef  - topside, brisket, forerib, 
mince 
see photograph 
3b 
         
14 Bacon (back, lean, meat and 
fat), grilled or fried 
1 slice 
 
         
15 Bacon, streaky, grilled or fried 1 slice 
 
         
16 Liver see photograph 
1b 
         
17 Kidney, pig, stewed and other 
offal 
see photograph 
1b  
         
18 Stew, Shepherds pie, 
casserole, curry, kebab 
see photograp 
7b 
         
18 Moussaka or Lasagne see photograph 
6a 
         
20 Bolognese, Chili con carne see photograph 
7b 
         
21 Burgers, plain 1 
 
         
22 Regular hamburger with bun 1 
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Food category 
 
 
Size of medium 
portion 
Your 
portion 
size 
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23 Venison, rabbit , hare or other 
game 
see photograph 
3b 
         
B.  Vegetables 
How often do you usually eat the following? 
24 Potatoes roast, fried, regular, 
chips 
see photograph 
4a 
         
25 Potatoes mashed, boiled or 
baked 
see photograph 
2b 
         
26 French fries see photograph 
10a 
         
27 Potato crisps 1 small bag 
 
         
28 Onions, leeks, spring onions see photograph 
2c 
         
29 Mushrooms, fried see photograph 
2c 
         
30 Tomatoes : fresh/tinned 1 tomato 
 
         
31 Vegetable curry or casserole see photograph 
9b 
         
32 Runner, french or broad beans see photograph 
4c 
         
33 Red kidney or butter beans see photograph 
4c 
         
34 Baked beans, canned in tomato 
sauce 
see photograph 
12b 
         
35 Sweetcorn, on the cob, boiled, 
or tinned 
1 cob 
 
         
36 Coleslaw see photograph 
14b 
         
37 Potato salad see photograph 
14b 
         
38 Lentils, chic peas etc see photograph 
7b 
         
39 Brussel sprouts or cabbage 9 sprouts or 
photograph 8c 
         
40 Cauliflower or broccoli see photograph 
8b 
         
41 Peas see photograph 
4c 
         
42 Spinach see photograph 
8c 
         
43 Swede see photograph 
9a 
         
44 Turnips, parsnips or carrots see photograph 
9a 
         
45 Vegeburger see photograph 
8a 
         
46 Lettuce see photograph 
4c 
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Food category 
 
 
Size of medium 
portion 
Your 
portion 
size 
How often 
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47 Watercress see photograph 
4c 
         
48 Beetroot see photograph 
4c 
         
49 Peppers see photograph 
4c 
         
50 Cucumber & see photograph 
4c 
         
51 celery see photograph 
4c 
         
C.  Pasta and Rice 
How often do you usually eat the following? 
52 Longgrain rice,  boiled see photograph 
5b 
         
53 Fried rice see photograph 
5b 
         
54 Spaghetti, canned in tomato 
sauce 
see photograph 
11a 
         
55 Other pasta (e.g. spaghetti, 
macaroni, pasta shells) 
see photograph 
7a 
         
D.  Cheese and cheese dishes 
How often do you usually eat the following? 
56 Reduced fat hard cheese e.g 
low fat cheddar, edam 
see photograph 
13a 
         
57 Hard cheese e.g. Cheddar, 
cheshire 
see photograph 
13a 
         
58 Soft cheese e.g. brie, 
camembert , cream cheese 
see photograph 
13c 
         
59 Veined cheese e.g. Danish 
blue, silton 
see photograph 
13a 
         
60 Cottage cheese, cheese 
spreads e.g. philadelphia 
see photograph 
13d 
         
61 Fromage frais, crème fraiche see photograph 
13d 
         
62 Cheese topped pizza see photograph 
11b 
         
63 Quiche lorraine or cheese flan see photograph 
10b 
         
64 Cheese sauce ¼ pint (125ml) 
 
         
E.  Fish 
How often do you usually eat the following? 
65 Haddock, plaice, cod or trout 
steamed 
see photograph 
12a 
         
66 Haddock, plaice or cod, fried see photograph 
12a 
         
67 Herring, mackerel or tuna see photograph          
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Food category 
 
 
Size of medium 
portion 
Your 
portion 
size 
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14c 
68 Tuna, canned in oil see photograph 
14c 
         
69 Fish cakes, fried 1 
 
         
70 Fish fingers, fried 1 
 
         
71 Shellfish 1 small jar or 20 
prawns 
         
F.  Fats 
How often do you usually eat the following? 
72 Butter (or other spread ) on 
bread, toast or sandwiches 
 
see photographs 
16c and 15 
         
73 Butter (or other spread) on 
jacket potatoes or other 
vegetables 
see photograph 
16c 
         
74 Butter (or other spread) on 
crackers or crispbread 
see photograph 
16b 
         
G.  Dairy Products 
How often do you usually eat the following? 
75 Milk on breakfast cereals see photograph 
17c 
         
76 Glass of milk see photograph 
17b 
         
77 Dried milk powder 
(e.g.Coffeemate) 
1 teaspoon 
 
         
78 Cream in drinks or soups 1 tablespoon 
 
         
79 Cream on puddings or fruit see photograph 
23b 
         
80 Cream in other recipes 1 tablespoon 
 
         
81 Whole yoghurt 1 small pot 25g 
 
         
82 Yoghurt, low fat 1 small pot 25g 
 
         
H.  Eggs 
How often do you usually eat the following? 
83 Egg, boiled, poached or raw 
(e.g. in baking) 
 1 size 3          
84 Fried or scrambled egg 1 size 3 
 
         
85 Egg, omelette 2 eggs  
size 3 
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Food category 
 
 
Size of medium 
portion 
Your 
portion 
size 
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I.  Cakes, Biscuits and Puddings 
How often do you usually eat the following? 
86 Chocolate biscuit bars e.g. KIT-
KAT, PENGUIN 
1 
 
         
87 Chocolate biscuit 1 
 
         
88 Plain or sweet biscuits 1 
 
         
89 Cream crackers, Ritz type 
biscuits, CRISPBREADS 
1          
90 Biscuits shortbread 1 
 
         
91 Chocolate/plain sponge with 
icing, cream cakes, cheese 
cake 
see photograph 
18a 
         
92 Fruitcake  see photograph 
18b 
         
93 Fruit pie or apple crumble see photograph 
19b 
         
94 Rice pudding or other milk 
pudding 
see photograph 
20 
         
95 Trifle, dairy deserts, moose etc see photograph 
20 
         
96 Ice-cream 
 
 
 
see photograph 
21 
         
97 Scones or teacakes or currant 
buns 
1 
 
         
98 Danish pastries 1 
 
         
99 Steamed pudding see photograph 
22a 
         
100 Other cakes 1 slice 
 
         
J.  Breakfast cereals 
How often do you usually eat the following? 
101 Muesli see photograph 
24 
         
102 All Bran or similar cereal see photograph 
25 
         
103 Shredded wheat, Weetabix or 
similar cereal 
1 biscuit 
 
         
104 Rice Krispies, Special K or 
similar cereal 
see photograph 
25 
         
105 Cornflakes, Sugar Puffs or 
similar cereal  
see photograph 
25 
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Food category 
 
 
Size of medium 
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portion 
size 
How often 
 
S 
 
M 
 
L 
3
 o
r 
m
o
re
 
p
e
r 
 d
a
y
 
1
 -
 2
 p
e
r 
 
d
a
y
 
4
-6
 t
im
e
s
 
p
e
r 
w
e
e
k
 
1
-3
 t
im
e
s
 
p
e
r 
w
e
e
k
 
1
-3
 t
im
e
s
 
p
e
r 
m
o
n
th
 
R
a
re
ly
 o
r 
n
e
v
e
r 
106 Porridge see photograph 
20 
         
107 Oatmeal, raw see photograph 
24 
         
K.  Bread 
How often do you usually eat the following? 
108 Bread, wholemeal, wholewheat, 
granary or soft grain  
1 medium slice 
 
         
109 Bread, white or malted 1 medium slice or 
one roll/bap 
 
         
110 Bread, white, fried 1 medium slice 
 
         
111 Naan, chapattis or pitta ½ naan or  
1 chapati/pitta 
         
112 Other breads (papudum etc.) 
 
1 
 
         
L.  Chocolate and sweets 
How often do you usually eat the following? 
113 Chocolate e.g. Mars bar 1 
 
         
114 Chocolate e.g.  Bounty bar 1 
 
         
115 Chocolate, plain 1 
 
         
116 Chocolate, milk 1 
 
         
117 Other sweets or toffees 1 
 
         
M.  Alcohol and other beverages 
How often do you usually drink the following? 
118 Beer, lager, cider (normal 
strength) 
1 pint 
 
         
119 Strong beer or lager 1 pint 
 
         
120 Wine : Red 
 
1 measure          
121 Wine : White/rose 1 measure 
 
         
122 Sherry, liqueurs and spirits 1 measure 
 
         
123 Fizzy drinks (not low calorie) 1 can or see 
photograph 17b 
         
124 
 
Fruit squashes 1 can or see 
photograph 17b 
         
125 Pure fruit juices : Citrus 1 can or see          
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 photograph 17b 
126  Pure fruit juices : Apple, pear 
etc 
 
1 can or see 
photograph 17b 
         
127 
 
Fruit Juice : Tomato 1 can or see 
photograph 17b 
         
128 
 
Tea see photograph 
17a 
         
129 
 
Coffee see photograph 
17a 
         
130 
 
Chocolate drinks see photograph 
17a 
         
N.  Fruit 
How often do you usually eat the following? 
131 Bananas 1 
 
         
132 Avocado pears ½ 
 
         
133 Olives 9 
 
         
134 Apples, pears or apricots 1 
 
         
135 Oranges, tangerines, mandrins, 
clementines : raw 
1 
 
         
136 Grapefruit or pineapple 1 or 1 slice 
 
         
137 Nectarine, peach, plum, kiwi 
fruit, grapes or melon 
1 piece, 30 grapes 
or 1 slice melon 
         
138 Strawberries or raspberries etc 9 berries 
 
         
139 
 
Black/blueberries etc 9 berries          
140 Tinned fruit see photograph 
23a 
         
141 Dried fruit 1 tablespoon 
 
         
O.  Nuts 
How often do you usually eat the following? 
142 Brazil or cashew nuts 1 small bag 
 
         
143 Peanuts and other nuts 1 small bag 
 
         
P.  Other food 
How often do you usually eat the following? 
144 Peanut butter, smooth see photograph 
16a 
         
145 Reduced calorie mayonnaise or 1 tablespoon          
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salad cream  
146 Mayonnaise or salad cream 1 tablespoon 
 
         
147 Custard see photograph 
22b 
         
148 Gravy see photograph 
2d 
         
149 Sugar,white 1 teaspoon 
 
         
150 Preserves (jam. marmalade or 
honey) 
see photograph 
16a 
         
151 Soups 1 small tin 
 
         
152 Pickles or sauces (except 
tomato or soy) 
1 teaspoon 
 
         
153 
 
Tomato sauce see photograph 
17a 
         
154 
 
Soy sauce see photograph 
17a 
         
155 Hummus see photograph 
14b 
         
156 Taramasalata see photograph 
14b 
         
157 Cod liver oil 1 capsule 
 
         
158 Bran 1 tablespoon 
 
         
159 Wheatgerm 1 tablespoon 
 
         
 
 
 
Are there other foods which you eat more than once a week ? Yes           No  
 
 
 
Food Item 
 
Usual serving size Number of times eaten each week 
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Annex 2 
DATE 
 
Dear 
 
Thank you for your interest in studies at the Institute of Food Research. 
I have sent you the details of one of the studies in progress at present, as your details on 
the volunteer database fit the criteria for this study. If you are further interested, please 
contact the Human Nutrition Unit, Institute of food Research, Norwich. 
If, however, any of your details have changed or change in the future or you would prefer to 
no longer remain on the database please could you inform the Human Nutrition Unit on; 
01603 255305. 
 
Thank you  
 
Yours sincerely 
Institute of Food Research         
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VOLUNTEER 
INFORMATION SHEET 
For 
“THE FLAVONOID STUDY” 
 
 
 
 
“Correlation of dietary flavonoid intake by Food 
Frequency Questionnaire with measurement of 
urinary excretion of flavonoid metabolites” 
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THE FLAVONOID STUDY 
Information for Volunteers: “The Flavonoid Study” 
 
You are being invited to take part in a research study. Before you decide it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. Please ask 
us any questions you may have, if there is anything contained in this information sheet that 
is not clear or if you would like more information. Take time to decide whether or not you 
wish to take part. 
Thank you for reading this. 
_____________________________________________________________________ 
What is the study called ? 
“Correlation of dietary flavonoid intake by 
Food Frequency Questionnaire with 
measurement of urinary excretion of 
flavonoid metabolites” 
 or 
 SHORT TITLE “The Flavonoid Study “. 
 
 
What is it about ? 
Studies have shown that chemicals 
present in fruits and vegetables called 
flavonoids may help prevent several 
cancers. It is known that flavonoids 
prevent the formation of chemicals 
dangerous to the body, which may lead to 
cancer. However, we currently do not 
have an accurate questionnaire which 
estimates the consumption of flavonoids 
from what you eat. The aim of this study 
is to produce a suitable Food Frequency 
questionnaire (FFQ). Further studies at a 
later date can then be carried out to find 
out whether supplementing the diet with 
these chemicals helps prevent cancer. 
 
Do I have to take part ? 
It is up to you to decide whether or not to 
take part. If you take part you are free to 
withdraw at anytime, without giving a 
reason. A decision to withdraw, or a 
decision not to take part, will not affect 
your participation in future studies. An 
expression of interest at this stage does 
not commit you to take part in the study. 
 
Why have I been chosen ? 
You have received this information about 
the study because you have responded to 
an advertisement about the study or your 
name has been given to us from the 
volunteer database held at the Institute of 
Food Research (IFR) Human Nutrition 
Unit ( (I) or you have shown interest to 
participate in the study whilst attending a 
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Norfolk & Norwich University Hospital 
surgical clinic. 
We are aiming to recruit a total of 64 
people aged 40-85 years who are 
apparently in good health.  
 
You will not be able to volunteer 
if : 
 You are a smoker 
 You are taking part in other studies 
 You have a diagnosed long term 
medical illness  
 You are pregnant or have been 
pregnant in the last 12 months or 
are breastfeeding 
 You are currently taking antibiotics 
 
If you are in any doubt about whether or 
not you are a suitable volunteer please do 
not hesitate to contact us. 
 
I have a medical condition but it 
does not affect what I do, so why 
can’t I be included? 
We know you can live a normal life with 
many medical conditions and recognise 
that you are not ill. However, these 
conditions may affect the data required for 
the study research or prevent us 
performing some study procedures 
necessary to collect the data; therefore 
we may have to exclude you from this 
particular study. 
 
 
How do I say No? 
Please feel free to say no by not 
responding to the letter we have sent you. 
Do not worry, no one will contact you and 
try to persuade you to join the study. The 
decision to participate is yours and we are 
grateful for your time. 
If you are on the volunteer database, 
saying no will not affect the likelihood of 
you being contacted for other studies. 
 
How do I say Yes? 
Anyone interested in finding out more 
about participating in the study should 
contact HNU on 01603 255305 or  
Email : satish.ranka@bbsrc.ac.uk   
 Alternatively, you can complete the 
attached response form and return it 
using the pre-paid envelope enclosed. 
 
What will happen when I have 
said yes? 
After you have contacted us to tell us you 
are interested in participating, Dr Satish 
Ranka will make an appointment for you 
to visit the Human Nutrition Unit (HNU) at 
IFR, when it is convenient for you, to 
discuss the study further.  Please ask any 
questions you may have at this or any 
stage during the study. You are free to 
withdraw from the study at any time 
without giving a reason. 
At the end of this visit you will be given a 
small container to take away with you. If 
you do decide to participate you will use 
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this container to bring a urine sample to 
the next visit to the HNU (screening visit). 
 At least 72 hours must elapse between 
your first and second visit to allow you to 
decide whether or not you wish to 
participate in the study and during this 
time we will not contact you. 
If you decide not to participate, dispose of 
the urine bottle and take no further action 
(no one will check up on you).  
If you decide you do wish to participate, 
please contact HNU, IFR to arrange an 
appointment for you, at your convenience, 
to visit the HNU for screening. 
The health screening visit will be in the 
morning and you will be asked to bring a 
mid-stream urine sample collected when 
you get up that day, in the container we 
gave you. The urine sample has to arrive 
within two hours of collection to make the 
test valid. You do not need to avoid eating 
or drinking at any time. 
All volunteers will be asked to sign a 
consent form agreeing to participate in the 
study. You will be given a copy of this to 
keep.  
A qualified research nurse will then 
complete a brief health questionnaire with 
you. You will have your height, weight and 
body mass index (BMI) measured and 
your blood pressure and pulse rate 
recorded. A dip stick test will be carried 
out on your urine. 
We are quite flexible and if you work, we 
try, where possible, to make this 
appointment at a time that suits you best.  
If you require transport, this can be 
provided to and from the HNU. 
 
What are you going to do with my 
screening urine sample? 
The urine dipstick test is a quick way to 
check that there is nothing unusual in 
your urine that might affect the study data. 
If you have any questions about the test 
please ask one of the research nurses. 
If the result of your urine is outside the 
standard reference ranges we will tell you.  
We cannot tell you what your results may 
mean as we are not medically qualified to 
do so. You should not worry if this 
happens as it may be a one-off result or it 
may be perfectly normal for you. 
Please remember these tests are 
performed to determine if you are suitable 
for the study. 
 
Are there any risks or side 
affects from participating in this 
study? 
We do not anticipate any adverse effects 
of taking part in the study. 
 
Will my GP be informed? 
Yes, it is routine practice for us to inform 
your GP that you are participating in a 
study at IFR and to forward details of your 
clinical results. This is done whether the 
results are inside or outside the standard 
reference ranges to keep your GP 
informed. 
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This is one of the things you are agreeing 
to when you sign the consent form for 
taking part in the study. If any of your 
results are outside the standard reference 
ranges, we will recommend that you 
speak to your GP about the results.  
Results outside the reference ranges are 
referred to the HNU Medical Advisor. 
Advice will be given by the Medical 
Advisor as to whether we may offer you 
the opportunity of a second screening 
appointment. If the results from the 
second test are within range you may still 
be able to participate. If not you will 
probably be excluded from the study. 
 
My screening results are ok – 
what happens next? 
Once you are selected through the 
screening process, the scientist will give 
you the instructions and equipment you 
need to participate in the study. The study 
involves you completing a questionnaire 
on your diet and producing five urine 
samples, each collected over a period of 
24 hours. Your involvement in the study 
will last for 3–4 months. If you have 
questions at any stage then you are free 
to contact the study scientists for further 
information at any time. 
 
Completing a Questionnaire on 
my diet. 
One part of the study involves us finding 
out about your diet. This will involve filling 
in a questionnaire. The questionnaire 
concentrates on the food that you eat. It 
asks you how often you eat certain foods, 
and what portion sizes you eat.. There will 
be coloured photographs of medium 
portion sizes to help you decide.  This 
questionnaire takes about 30 minutes to 
complete. 
 
How do I collect the Urinary 
samples ? 
You will be given one container at IFR, 
after the screening process. The scientist 
will give you instructions for collecting 24 
hour urine samples. Over a 2 week 
period, you will be asked to collect up to 
three 24 hour urine samples during 
weekdays (Mon-Thurs) and one 24 hour 
urine sample on two consecutive 
Sundays. You will be asked to fill in the 
dietary questionnaire when you have 
time, between these collections. Once 
you have collected the sample, you 
contact one of the members of the study 
team at the HNU to deposit it or we can 
arrange to pick the sample up. We will 
then supply the second container. Once 
you have supplied the samples and 
completed the questionnaire, you will be 
asked to repeat the whole procedure 3-4 
months later. The study does not involve 
supplying any blood samples 
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What happens to the 
questionnaire and the urine 
samples ? 
Questionnaires: The questionnaires will 
be analysed using a computer to measure 
the intake of flavonoids from your diet. 
  
Urine specimen : These will be tested 
in a special machine at IFR to determine 
the amount of flavonoid excreted in 24 
hours. 
 
If you turn to page _9_ there is a 
simple flow chart outlining what 
the study involves 
After the analysis of the questionnaire and 
the urinary sample, we will be able to 
check how accurate the questionnaire is 
in measuring flavonoid intake. 
Any sample of urine remaining after the 
information has been collected will be 
disposed off into the institute sewer 
system and the containers disinfected and 
thoroughly cleaned. 
 
What are the possible benefits of 
taking part ? 
The study will allow us to develop a 
questionnaire which will accurately 
measure flavonoids intake. We hope that 
this will be used in future work to see if 
alteration in diet may help prevent cancer. 
 
 
 Do I get paid for doing this? 
Participating in these studies is done on a 
voluntary basis, however we do recognise 
that being involved in the study can cause 
you some inconvenience and that there 
are travel costs associated with you 
visiting the HNU. 
Therefore you will receive small 
inconvenience payments for your urine 
samples and filling in the questionnaire.  
Travelling expenses will be reimbursed on 
production of a receipt for buses or trains 
and 30.5 pence/mile for travel by private 
car. If you require transport to and from 
the HNU please let us know and we will 
order a taxi and pay for it. 
Payments are liable to tax and in the case 
of IFR staff will be taxed at source. 
 
Is what you find out about me 
going to be kept safe? 
Any information relating to you will be 
held in strictest confidence. Once you are 
recruited you will be issued with a 
volunteer code number. This number will 
be used on all your samples so that no 
one else will know, or be able to work out 
that they are yours.  
Access to your records is restricted to the 
approved scientists who are running the 
study, the HNU research nurses, HNU 
Medical Advisor and your GP. 
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Will I be told my results? 
No, as a volunteer you are valuable to us 
but we are unable to tell you any of your 
results. 
Some results will be published but no 
reference is made to individuals. At the 
end of the study we will try to provide 
feedback of what we have found as a 
result of your help and what it may mean 
for the future research. 
 
Is there anything I should tell 
you? 
We do need you to tell us some things for 
your safety and for the success of the 
study. Please tell us if you have ANY 
episodes of illness even if it is just a 
headache, or if you become injured in any 
way, become pregnant. Some medication 
may affect the information we are 
collecting so you need to tell us if you 
take ANY medication, this includes 
anything you may have bought over the 
counter from the chemist e.g. 
paracetamol.  
 
What if something happens to me 
while I am on the study? 
The Institute of Food Research accepts 
responsibility for carrying out trials, and as 
such will give sympathetic consideration 
to claims from participants for harm 
suffered by them as a direct result of 
participating in the trial, with the exception 
of those claims arising out of negligence 
by the participant. Like other publicly 
funded bodies, the Institute is unable to 
insure and thus cannot offer advance 
indemnity cover for participants. Please 
note that the Institute will not fund any 
legal costs arising from any action unless 
awarded by a court.  
 
Who is funding this study? 
The research is taking place at IFR, 
Norwich. The research is being funded by 
money received by hospital Consultants 
to support medical research in Norwich. It 
is hoped that some local cancer charities 
will also offer financial support. 
 
Who has reviewed this study ? 
This study has been reviewed by the IFR 
Human Research Governance Committee 
(HRGC), East Norfolk & Waveney 
Research Governance Committee, 
Norwich and Norwich Local Research 
Ethics Committee (NLREC). 
 
What should I do now ? 
If you are interested in taking part in the 
study then please complete the reply slip 
overleaf and return it in the FREEPOST 
envelope provided (no stamp required). If 
you are not interested in taking part then 
you need do nothing, no one will contact 
you about the study. 
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Contact for further information 
 
If you would like further information about 
the study then you can contact the study 
team: 
HNU on 01603 255305 or 
Email : satish.ranka@bbsrc.ac.uk   
 
Taking part in the research is 
entirely voluntary! 
 
You will be given a copy of this 
information sheet and your 
signed consent form to keep. 
 
YOU ARE FREE NOT TO PARTICIPATE 
AND MAY WITHDRAW FROM THE 
STUDY AT ANY TIME. 
     Institute of Food Research      
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“THE FLAVONOID STUDY FLOWCHART” 
 
 
  
 
 Food Frequency 
Questionnaire analysis  
6. FLAVONOID INTAKE ASSESSMENT 
 Statistical calculation of dietary intake of Flavonoids 
2. INITIAL INTERVIEW  
 3 day consideration 
period  
3.   CONSENT & 
SCREENING 
4. Entry into study 
 5 x 24 hr Urine Sample 
collection container  
 One FFQ  
 
 Urinary specimen analysis 
for flavonoid excretion 
1.    RECRUITMENT 
into “The Flavonoid Study” 
5 Collection of Urine 
samples & completion of 
FFQ.    
 
7.  . Calculations to check 
whether the FFQ 
correlates with the urinary 
excretion  of flavonoids 
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Annex 4 
 
 
“THE FLAVONOID STUDY” 
 
 
I am interested in finding out more information about the FLAVONOID STUDY. 
 
(Please complete the personal details below) 
 
 
Name: ……………………………………………………………….. 
 
Address: ……………………………………………………………….. 
  
  ……………………………………………………………….. 
 
  ……………………………………………………………….. 
 
Date of Birth: ……………………………………………………………….. 
 
Daytime telephone no: ……………………………………………….. 
 
Evening telephone no: ……………………………………………….. 
 
Email address:  ……………………………………………….. 
 
Please return this form in the FREEPOST envelope provided to : 
 
Dr Satish Ranka  
Research Scientist 
W312 Institute of Food Research 1 
FREEPOST 
Norwich Research Park 
Colney 
NORWICH 
NR4 7BR 
 
 
 
Expressing an interest in the study does not commit to you taking part! 
     Institute of Food Research      
   Norwich Research Park, Colney, Norwich NR4 7UA, UK Tel: +44(0) 1603 255000 GTN 6626 5000 Fax: +44 (0)1603 507723 
The Flavonoid Study Version 5.0:01.2005 
 
Annex 5 
INFORMED CONSENT FORM FOR RESEARCH STUDY 
Full Study Title: Correlation of dietary flavonoid intake by Food Frequency Questionnaire 
with measurement of urinary excretion of flavonoid metabolites 
 
Have you read the Volunteer Information Sheet; Version No: 5. 0:01.2005 
Date: ………………………...………….YES/NO            
 
Do you agree that you do not fall within the basic exclusion criteria listed for this research 
study?........................YES/NO* 
*If you have answered NO to this question we are unable to accept you on this study.   
 
Have you had an opportunity to discuss this study and ask questions; including the 
exclusion criteria 
and your responsibilities as a 
volunteer?...................................................................................................................YES/N
O 
 
With whom have you discussed the information for this research study 
with?...................................................................... 
 
Have you received sufficient information about the 
study?................................................................................... ..YES/NO  
 
Have you received satisfactory answers to all your questions?    
…………………………………………………YES/NO                
 
Do you understand that you are free to withdraw from the study: 
 at any time 
 without having to give a reason for withdrawing 
 without withdrawal affecting future participation in other research 
studies………………………………YES/NO 
 
Are you aware that your personal information will be held 
confidentially?.............................................................YES/NO 
 
Do you agree to us informing your General Practitioner of your participation in this study 
and  
of all clinical 
results?....................................................................................................................................
............YES/NO* 
* If you have said NO to this question then we are unable to accept you on this study. 
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Name and address of your General Practitioner:     
 ……………………………………………………………………. 
 
…………………………………………………………………….……………………………………
………………….. 
 
Do you understand that all research is subject to Inspection and 
Audit*…………………………………………YES/NO   
*Although your records may be accessed for this purpose your personal information 
remains confidential  
 
Do you agree to take part in this 
study?..................................................................................................................YES/NO 
 
Signed:   …………………………………  Date:…………………………… 
 
(Name in BLOCK Letters:)………………………………………………….. 
 
Date of Birth:………………………………………………………………… 
 
Scientist (I confirm that the volunteer above has been given a full verbal and written 
explanation of the study) 
 
Signed:………………………………     Date:………………………………. 
 
Name in BLOCK Letters: …………………………………………………….                  
 
 
A copy of the signed consent form will be given to the volunteer to keep. 
 
NDH/Version 7/ AB/Rev. July 04 
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Annex 6                                            CONFIDENTIAL 
Volunteer Health Declaration Form 
 
Volunteer code number:…………………         Sex:…………………….. 
 
D.O.B.:…………………………………….         Age:……………………… 
 
Height:…………………………………….         Weight:………………… 
 
B.P.:………………………………………         Pulse:……………………. 
 
Urine: …………………………..                      Body Mass Index (BMI)…… 
        
Have you ever had any of the following: 
If yes give details below each relevant section. 
 
Angina/Heart disease:    Y        N                 Thrombosis:             Y       N    
……………………………………………        …………………………………… 
……………………………………………        …………………………………… 
 
High blood pressure:      Y       N                 High Cholesterol:       Y       N   
……………………………………                   ………………………………….. 
……………………………………                   ………………………………….. 
 
Chest problems:           Y         N                  Diabetes:                  Y       N 
…………………………………….                  ………………………………….. 
…………………………………….                  ………………………………….. 
 
Depression or anxiety: Y         N                  Digestive problems:  Y       N 
……………………………………                  …………………………………… 
……………………………………                  …………………………………… 
 
Skin Conditions:          Y         N                  Other: 
………………………………..                      …………………………………….   
…………………………………                    ……………………………………. 
Are you currently on any: 
 
Prescribed medication:……………….  
 
Dietary supplements:.......................... Herbal remedies:…………………… 
 
If yes give details:……………………………………………………………… 
 
Have you had a major physical injury/operation:…………………………… 
 
If yes give details:………………………………………………………….. 
…………………………………………………………………………………. 
 
Aliceon Blair/Vers.5 /Rev. March 04   Page 1 of 1
  
Volunteer No:……………………………………………………. 
 
Are you currently suffering from any illness/injuries:   Y        N 
If yes give details:……………………………………………………………. 
………………………………………………………………………………….. 
 
Are you/could you be pregnant:       Y             N        
                                                      
 
Do you/ or have you ever smoked:   Y            N                                                                
 
When did you stop smoking:…………………………………… 
                             
If yes how many per day:……………………………………….. 
 
Do you drink alcohol:                     Y               N 
 
How many units per week:………………………………………… 
 
 
Have you any known allergies:   Y               N 
Food:……………………………………………………………………. 
Other::……………………………………………………………………… 
……………………………………………………………………………… 
 
Special dietary requirements:     Y                N 
    
 
Do you agree to us, informing your General Practitioner of your participation in this study or 
of any results found:        Y               N 
 
                                                    
If you have answered NO to this question then we are unable to accept you on this study. 
 
What is the name and address of your General Practitioner? 
……………………………………………………………………………………. 
…………………………………………………………………………………… 
……………………………………………………………………………………… 
Tel. No……………………………………………. 
 
Form completed by (print):…………………Signature…………………. 
 
Date:………………………………………………… 
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Annex 7 
 
HNU/letter 
 
 
Date!! 
 
Dear Doctor ………….. 
 
Your patient, ………………………………………, has volunteered to take part in a human 
nutrition study at the Institute of Food Research entitled “ The Flavonoid Study 
 
Following consent it is our standard practice to screen the volunteers to exclude any health 
factors which may affect the study data or indicate an issue which may require further 
investigation.  We are looking for healthy people who have no chronic illness and are not 
taking any prescribed medication which may affect the study data. 
 
Some of your patient’s results fell outside the standard reference range on this occasion. 
Please find results enclosed. 
These results will/will not affect the study data. 
Your patient   will/will not be able to participate in the study. 
 
We have informed your patient that one or more of the results from their screening were 
outside these reference ranges. We have not discussed these results with them. However, 
we have asked them to speak to you as soon as convenient to discuss these results, in 
order that you may take further action/investigation if necessary.  
 
Yours sincerely 
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Annex 8 
 
Date 
 
 
Dear Doctor ………….. 
 
This is to inform you that your patient …………………………….. has consented to 
participate in a nutrition study at the Institute of Food Research. 
 
The study titled “The Flavonoid Study” as been approved by the Norwich Local Research 
Ethics Committee and the study co-ordinator Dr Satish Ranka can be contacted on 
……………………………………….. if you require further information. 
 
It is our policy to forward copies of all results (normal or abnormal) obtained during the 
study to the Volunteer’s GP.  
 
We anticipate completion of the study by ………………………………….. 
 
Yours sincerely 
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